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ABSTRACT 
Anxiety symptoms and disorders are highly prevalent mental health 
conditions that produce substantial morbidity. The increasing impact of these 
disorders underpins an urgent need for effective prevention and treatment 
strategies. There is emerging recognition that a range of potentially modifiable 
risk factors such as diet and physical activity may influence the onset and 
course of psychiatric symptoms and disorders, including anxiety.  Cigarette 
smoking is a well-recognised risk factor for a wide range of adverse health 
outcomes, including cardiovascular disease, respiratory disease and cancer. In 
addition, the relationship between increased levels of anxiety and cigarette 
smoking is gaining recognition. 
 
This research study aimed to develop a greater understanding of whether 
cigarette smoking is a plausible risk factor for the development of increased 
anxiety symptoms and disorders. The research study consisted of five separate 
sub-studies that were drawn together to inform this aim.  
 
Paper 1 reports a systematic review of the population-based epidemiological 
literature that explored the association between cigarette smoking, nicotine 
dependence and anxiety disorders. The study demonstrated consistent support 
for prior cigarette smoking, particularly with exposure in adolescence, as 
being associated with increased rates of certain anxiety disorders.  
Interpretation of these results suggested the possibility that exposure during 
critical periods of neurodevelopment (e.g. childhood and adolescence) may 
exert the most substantial deleterious effects. Paper 2 reports a comprehensive 
review of literature that has outlined the potential biological mechanisms that 
could underpin how cigarette smoke exposure may increase anxiety symptoms 
and disorders. The results elucidated numerous pathways through which 
cigarette smoke exposure may influence expression of anxiety symptoms 
including those related to control of inflammation, oxidative & nitrosative 
stress, mitochondrial functioning, neurotransmitter regulation and function, 
neurotrophins and neuroplasticity, and epigenetic effects. In addition, the 
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literature supported cigarette smoke as being noxious to neurodevelopmental 
processes, exerting changes that may subsequently increase vulnerability to 
higher levels of anxiety. 
 
The knowledge gained from Papers 1&2 was utilised to inform three separate 
epidemiological investigations. These studies examined the association 
between anxiety symptoms and disorders and exposure to cigarette smoking 
during three life stages: in utero, childhood and adolescence, and adulthood.   
 
In a nested case-control study of adult women drawn from the Geelong 
Osteoporosis Study (Paper 3), no association was discovered between having 
a diagnosed anxiety disorder (grouped disorders and panic disorder only) and 
prior history of self-reported regular smoking. However, utilising data drawn 
from the Tracing Opportunities and Problems in Childhood and Adolescence 
(TOPP) Study (Paper 4), a longitudinal cohort of children and adolescents 
from Norway, a prospective relationship between cigarette smoking at age 14 
years and early adult anxiety symptoms measured between age 18 and 19 
years (β=0.17, p<0.05) was discovered. Adolescent cigarette smoking was a 
substantial effect modifier in the association between infant internalising 
behaviours (active smokers: β=0.85, p<0.01; non-active smokers: ns), infant 
emotionality (active smokers: β=0.55, p<0.01; non-active smokers: ns) and 
subsequent expression of adult anxiety symptoms. Finally, a prospective 
investigation demonstrated an association between maternal smoking during 
pregnancy and increased offspring internalising symptoms measured at 18 
months (β=0.11, p<0.001) and 36 months (β=0.06, p<0.01) utilising data from 
The Norwegian Mother and Child Cohort Study (Paper 5).  Increased levels 
of cigarette smoking were associated with higher internalising symptoms in a 
dose-dependent fashion, and early pregnancy (<17 weeks gestation) was the 
critical period for exposure-related effects.  
 
Taken together these results provide considerable support for a model where 
cigarette smoke exposure, particularly during periods of rapid 
neurodevelopment that occur in utero and during childhood and adolescence, 
can alter the developmental trajectory of anxiety. These effects may 
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subsequently increase the likelihood of experiencing pathological levels of 
anxiety symptoms and developing anxiety disorders in individuals at risk.  
Cigarette smoking is a plausible risk factor for the development of anxiety 
symptoms and disorders. Further studies exploring the mechanisms that may 
underpin this relationship are warranted. 
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1 CHAPTER ONE: INTRODUCTION 
Anxiety and anxiety disorders represent a significant public health challenge.  
According to the National Survey of Mental Health and Wellbeing 2007, 
anxiety disorders affect approximately 14% of Australians each year 
(McEvoy, Grove, & Slade, 2011). The anxiety disorders are a heterogeneous 
group of major mental disorders that are grouped by their specific symptom 
characteristics, and in adults include panic disorder (PD), agoraphobia, 
generalised anxiety disorder (GAD), post traumatic stress disorder (PTSD), 
obsessive compulsive disorder (OCD), specific phobia and social phobia (SP) 
(American Psychiatric Association, 2013). A necessary feature of an anxiety 
disorder is that the symptoms must be accompanied by significant functional 
impairment in those affected. Worldwide, anxiety disorders are highly 
common (Baxter, Scott, Vos, & Whiteford, 2013) and result in significant 
morbidity. In the recently released Global Burden of Disease Report 2010, 
anxiety disorders as a group remained the 7th highest cause of years lived with 
disability (YLDs) globally and the 26th largest cause of global disability 
adjusted life years (DALYs) (Murray et al., 2012; Vos et al.,  2012). In 
contrast to many physical disorders such as cardiovascular disease, the anxiety 
disorders disproportionately affect individuals in the early stages of their life 
(e.g. 10-29 years) (Whiteford et al., 2013), potentially exerting a greater 
impact on functional outcomes including education and occupational 
advancement. 
 
Despite significant investment in public health interventions, cigarette 
smoking remains prevalent worldwide (Giovino et al., 2012). In the 
Australian context, even though cigarette smoking rates have declined steadily 
over preceding decades, the prevalence of daily smoking remains above 18% 
for individuals aged above 15 years (Australian Bureau of Statistics, 2009). 
The significant investment in strategies to reduce smoking rates follows the 
identification of smoking as being deleterious to health. Cigarette smoking 
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contributes to increased rates of numerous physical disorders, including 
cardiovascular disease and cancer (Boyle, 1997; Critchley & Capewell, 2003). 
Along with other “lifestyle” factors including a poor diet, lower levels of 
physical activity and excessive use of other substances including alcohol, 
cigarette smoking has been firmly established in health sciences as a 
modifiable risk factor that should be a key target of public health 
interventions. 
 
Within medicine, there is increasing recognition that the onset and course of 
psychiatric disorders may also be influenced by modifiable ‘lifestyle” factors. 
Indeed, numerous investigations have demonstrated that these factors may 
play a role in the pathogenesis of major mental disorders including 
depression, bipolar disorder and schizophrenia (Jacka, Mykletun, & Berk, 
2012; Laursen, Nordentoft, & Mortensen, 2014; Pasco et al., 2011a; Pasco et 
al., 2008; Pasco et al., 2011b). There is also emerging evidence that suggests 
these lifestyle risk factors play a role in the expression of anxiety symptoms 
and disorders. 
 
There is a long established relationship between increased anxiety symptoms 
and disorders and cigarette smoking. Numerous cross-sectional analyses of 
population-based studies have demonstrated significantly elevated rates of 
smoking in anxiety-disordered populations. For example, data from the 
National Comorbidity Survey (NCS) in the United States demonstrated rates 
of smoking in patients with SP (39.5%), Agoraphobia (38.4%), PD (35.9%), 
PTSD (45.3%), Specific Phobia (40.3%) and GAD (46%) that were 
significantly higher than in those without anxiety disorders (22.5%) (Lasser et 
al., 2000). Similarly, data drawn from the Australian National Survey of 
Mental Health and Wellbeing 2007 demonstrated significantly increased rates 
of smoking in individuals with anxiety disorders, and demonstrated that rates 
of smoking correlated with the severity of the disorder (Lawrence, Considine, 
Mitrou, & Zubrick, 2010). Smoking is so common amongst individuals with 
anxiety disorders that in population data from New Zealand, it is estimated 
that individuals with anxiety disorders consume 50% of all manufactured 
cigarettes (Tobias, Templeton, & Collings, 2008). 
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The association between cigarette smoking and anxiety symptoms and 
disorders could potentially be explained by three non-mutually exclusive 
relationships. First, smoking behaviour may increase the risk of developing 
anxiety symptoms and disorders. Second, anxiety symptoms and disorders 
may increase smoking behaviours. Third, the relationship between anxiety 
symptoms and disorders and smoking behaviours may be underpinned by a 
shared vulnerability, where an individual factor, or group of factors, serves to 
increase the likelihood of both outcomes. An example of this situation would 
include an individual being of low socioeconomic status, where this factor is 
associated with both increased rates of anxiety symptoms and disorders and 
increased smoking rates (Adler et al., 1994).  
 
Establishing that a particular exposure represents a true risk factor for the 
development of a medical disorder informs at least two different areas 
pertinent to further scientific and public health enquiry. First, if a risk factor is 
identified, it is logical that reduction of this risk factor through targeted 
individual and/or population-based interventions could reduce expression of 
the disorder. Second, the identification of a risk factor can expand our 
understanding of the pathogenesis of the disorder itself, by investigating and 
identifying the effects the risk factor exerts on physiological systems that are 
known to be relevant in mediating the disorder. Therefore, in the realm of 
anxiety symptoms and disorders, determining whether cigarette smoking is a 
risk factor for symptom and disorder onset/expression could have substantial 
public health and scientific benefits. Despite this, relatively little investigation 
has been devoted to developing an understanding of whether cigarette 
smoking itself is an independent risk factor for the development of anxiety 
symptoms and disorders. Recent evidence has shown that smoking may be a 
modifiable risk factor for major depression (Pasco et al., 2008).  Therefore, 
further understanding of how cigarette smoking may increase the risk of 
developing anxiety symptoms and disorders may lead to insights with 
significant public health and scientific implications.  
INTRODUCTION 
 4 
OVERVIEW OF THE THESIS 
This thesis by published work focuses on developing a greater understanding 
of whether cigarette smoking is a plausible risk factor for the development of 
increased anxiety symptoms and disorders. The aim is to explore this 
association through a combination of systematic review of extant 
epidemiological literature, comprehensive exploration of biological pathways 
to develop a conceptual biological model, and through primary research into 
the relationship examining exposure to cigarette smoking during three 
different life stages: adulthood, childhood & adolescence, and in utero, using 
well-characterised epidemiological cohort studies. 
 
The thesis is presented in the following fashion.  
 
Chapter 2 sets the scene to this relationship through an introductory narrative 
literature review that explores definitions, outlines the epidemiology and 
describes different theories hypothesised to explain the interaction between 
cigarette smoking and anxiety symptoms and disorders. This chapter identifies 
numerous gaps in the current literature, which subsequently inform the 
research study aims. 
 
Chapter 3 outlines the research study aim and details the five individual 
research study questions. 
 
Chapter 4 is a brief introduction to Chapters 5&6. 
 
Chapter 5 is the published version of a systematic review of population-
based, epidemiological studies that have explored the relationship between 
cigarette smoking, nicotine dependence and anxiety disorders, published in 
BMC Medicine. 
 
Chapter 6 is the published version of a comprehensive review of the human 
and animal literature that has explored biological pathways that may underpin 
a relationship between cigarette smoking and the subsequent development of 
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anxiety symptoms and disorders. This work was published in Brain & 
Behavior and includes the description of a potential neurodevelopmental 
model to understand this relationship. 
 
Chapter 7 summarises the information gained from Chapters 5&6 and 
describes how this informed the need for the subsequently described 
epidemiological studies. 
 
Chapter 8 describes a nested case-control study of the relationship between 
diagnosed anxiety disorders and prior exposure to regular cigarette smoking 
performed in the Geelong Osteoporosis Study (GOS), a well-characterised 
population-based cohort study. At time of thesis submission this study was 
submitted and under review at a high impact peer reviewed journal. 
 
Chapter 9 is the published version of a prospective observational study that 
explores the relationship between cigarette smoking in adolescence and 
subsequent early adult anxiety symptoms performed in the Tracing 
Opportunities and Problems in Childhood and Adolescence (TOPP) study. 
The results of this study were published in PloS one. 
 
Chapter 10 is the published version of a prospective observational study that 
explores the relationship between maternal smoking during pregnancy and 
offspring anxiety and depressive symptoms performed in the Norwegian 
Mother and Child Cohort (MoBa). The results of this study have been 
accepted for publication in BMC medicine. 
 
Chapters 11 & 12 summarise the main findings of the thesis, draw 
conclusions and point to future areas for research. 
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2 CHAPTER TWO: LITERATURE 
REVIEW 
WHAT IS ANXIETY AND WHAT ARE ANXIETY DISORDERS?  
Although all humans will, to some degree, have a personal understanding of 
“anxiety”, establishment of a replicable definition of anxiety that is 
meaningful across individuals and different cultures has proved somewhat 
elusive. Morissette et al. (2007) suggested that a combination of this lack of 
precise definition in concert with the diversity of language utilised to 
described anxiety (e.g. fear, dread, phobia etc.), has led to difficulty in 
conducting empirical research into the relationship between “anxiety” and 
specific environmental factors. For this reason, the current literature which 
seeks to explore these associations has often been plagued with 
inconsistencies, variance in research methodology and definitions, and 
ultimately, continuing confusion. 
 
The efforts to synthesise an understanding and differentiate anxiety from other 
states associated with general distress (e.g. depression) over the last two 
decades has, however, brought advances to the field and led to a proposed 
anxiety definition. This synthesised definition states that anxiety is “a future-
oriented state involving perceived uncontrollability and unpredictability over 
dangerous events or the person’s emotional response to those events” 
(Barlow, 2002). Such a definition distinguishes anxiety from fear or panic, 
which is “characterised by a primal alarm system activated by an immediate 
danger, which results in a prominent arousal response and behavioural action” 
(Morissette et al., 2007). There exists, however, potential for both to co-exist. 
As delineated within the Diagnostic and Statistical Manual of Mental 
Disorders 5th Edition (DSM-V) (American Psychiatric Association, 2013), 
anxiety and fear differ, with the former more associated with “muscle tension 
and vigilance in preparation for future danger and cautious or avoidant 
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behaviours”, whereas the latter is associated more with “surges of autonomic 
arousal necessary for fight or flight, thoughts of immediate danger, and escape 
behaviors” (American Psychiatric Association, 2013). 
 
Another important component of a definition for anxiety relates to the concept 
of “state” versus “trait” anxiety (Spielberger, 1966). Through the work of 
multiple scholars, trait anxiety has been defined as “an individual’s 
predisposition to respond” to perceived threat, and state anxiety defined as 
“the transitory emotion characterised by physiological arousal and 
consciously perceived feelings of apprehension, dread and tension” (Endler & 
Kocovski, 2001). Traits are classically described as being consistent, in that, 
relative to others, those with a certain trait characteristic will in general act in 
accordance with that trait. In the realm of anxiety, this suggests that those with 
a trait toward increased anxiety will, in general, tend to exhibit increased 
anxiety responses to stimuli relative to those without such a trait (Allport, 
1966). However, other theorists have postulated that trait and state anxiety are 
multidimensional constructs and individuals with traits will act in a coherent, 
but not necessarily a consistent manner, in a relative sense (Endler & 
Kocovski, 2001). For example, one would only expect an increase in state 
anxiety when an individual is faced with a situation relevant to the particular 
dimension of anxiety trait they possess (Endler & Kocovski, 2001). 
 
The measurement of anxiety has tended to differ in medical and psychological 
models. In the medical model, the predominant mode has leaned toward 
categorical definitions as defined by the DSM (American Psychiatric 
Association, 2013) or The International Classifications of Diseases (ICD) 
(World Health Organization, 2012). In psychological models, the predominant 
mode has been dimensional, assessing symptom levels obtained from 
validated symptom scales.  In the medical model, some conceptualisations 
have suggested a qualitative difference between an anxiety disordered state 
and the expression of anxiety (Endler & Kocovski, 2001). The dimensional 
approach suggests that anxiety exists on a spectrum, with those suffering 
symptoms at the high end being those who, as consequence, suffer social and 
other related consequences (Endler & Kocovski, 2001). Both approaches have 
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their utility. Although the dimensional approach is likely more appropriate 
and provides greater utility for research and clinical practice (Beesdo-Baum et 
al., 2012; Bjelland et al., 2009; Knappe et al., 2013; Trull & Durrett, 2005; 
Widiger, 1998), the use of categorical diagnoses have utility in regards to ease 
of communication and by simplifying disorders into states (e.g. present or not 
present) (Endler & Kocovski, 2001).  
 
The DSM/ICD anxiety disorders are examples of categorical 
conceptualisations of different anxiety states. This group of individual 
disorders are characterised by the presence of “anxiety” in addition to a 
constellation of symptoms that lead to deterioration in an individual’s level of 
biological, psychological and/or social functioning. Formal diagnosis of 
individual anxiety disorders are based upon reported symptoms, duration and 
disability criteria that are delineated in the DSM-V (American Psychiatric 
Association, 2013) and/or the ICD-10 (World Health Organization, 2004). 
According to the DSM-V (American Psychiatric Association, 2013), 
individual anxiety disorder subtypes include: 
 
Generalised anxiety disorder (GAD) 
Defined as excessive anxiety and worry, occurring on more days than not for 
at least six months, about a number of events or activities that the person finds 
difficult to control, and is associated with multiple symptoms of anxiety and 
worry (e.g. restlessness, easy fatigue, impaired concentration, irritability, 
muscle tension or sleep disturbance). 
 
Panic disorder (PD) 
Defined as the presence of unexpected, recurrent panic attacks that are 
followed by at least one instance of greater than one month of significant and 
related behaviour change, worry about consequences of an attack or concern 
about further attacks. 
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Agoraphobia  
Defined as anxiety or fear in situations where an individual believes their 
environment is difficult to escape or get help, with subsequent avoidance of 
such environments. 
 
Specific phobia 
Defined as a marked and persistent fear or anxiety that is excessive or 
unreasonable about a specific object or situation (e.g. animals, injections, 
heights, etc.), with exposure leading to an immediate anxiety response which 
impairs functioning. 
 
Social phobia (SP) 
Defined as a marked and persistent fear of one or more social performance 
situations where an individual is exposed to possible scrutiny by others, with 
the individual fearing they will act in a way that will be embarrassing or 
humiliating. The situation invokes anxiety symptoms, and the individual 
recognises this fear as being excessive or unreasonable. 
 
Obsessive-compulsive disorder (OCD) 
Defined as recurrent and persistent intrusive thoughts, impulses or images 
(obsessions) that cause marked anxiety or distress, with these leading to 
compensatory behaviours (compulsions) designed to relieve distress or 
prevent some dreaded event or situation which will result as consequence of 
the intrusive cognition. The individual must recognise the thoughts as their 
own, with the obsessions and compulsions taking more than one hour per day 
or significantly interfering with normal functioning. 
 
Post traumatic stress disorder (PTSD) 
Defined as a collection of symptoms including intrusive recollections, 
avoidance behaviours and cognitive effects with concurrent hyperarousal 
occurring for at least one month, which occurs after an individual has been 
exposed to a traumatic event in which they felt their own life, or the life of 
others, was in danger. 
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Common threads for all these anxiety disorders are that the symptoms lead to 
functional disturbance in social, occupational or other important domains 
(American Psychiatric Association, 2013). As can be deduced from the above 
definitions, the development of an “anxiety disorder” depends not only on the 
degree of anxiety present, but also upon other factors including an 
individual’s personal and sociocultural resources. 
 
In contrast to these categorical definitions, anxiety and anxiety disorders are 
also commonly measured using a variety of well-validated psychometric tools 
that utilise dimensional scales.  Commonly used scales, amongst the many 
that have been produced, include the Hamilton Anxiety Rating Scale 
(Hamilton, 1959), the Beck Anxiety Inventory (Beck, Epstein, Brown, & 
Steer, 1988) and the Hospital Anxiety and Depression Scale (Zigmond & 
Snaith, 1983).  Each of these tools utilises a series of standardised and 
validated questions to capture anxiety constructs that can then be compiled to 
inform symptom levels and/or diagnoses. For this doctoral research project, a 
series of well-validated tools was utilised, including instruments aimed 
specifically to measure symptoms in childhood and adulthood. Further 
descriptions of the individual psychometric tools utilised for this study are 
provided within the individual study methods sections. 
EPIDEMIOLOGY AND IMPACT OF ANXIETY SYMPTOMS AND 
DISORDERS 
The anxiety disorders as a group are consistently the most common of all 
psychiatric disorders across numerous different national epidemiological 
investigations. In Australia, data from the National Survey of Mental Health 
and Wellbeing 2007 demonstrated that 12-month and lifetime prevalence for 
all anxiety disorders combined was 14.4% and 26.3% respectively. Rates of 
individual disorders (12month: Lifetime) included 4.7%: 10.6% for SP, 6.4%: 
12.2% for PTSD, 2.7%: 5.9% for GAD, 1.9%: 2.8% for OCD, 2.6%: 5.2% for 
PD and 2.8%: 6.0% for agoraphobia (McEvoy et al., 2011). These data are 
similar to those derived from the National Comorbidity Survey Replication 
(NCS-R) (Kessler & Merikangas, 2004) in the United States. Utilising data 
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from a population-representative sample of 9282 participants aged 18 years 
and older, analysis of the NCS-R demonstrated a 12-month and lifetime 
prevalence of all anxiety disorders of 19.1% and 31.2% respectively, with 
rates of individual anxiety disorders (12month: Lifetime) 7.1%: 12.1% for SP, 
3.6%: 6.8% for PTSD, 2.7%: 5.7% for GAD, 1.2%: 2.3% for OCD, 2.7%: 
4.7% for PD and 0.9%: 1.3% for agoraphobia (Kessler, et al., 2005a; 2005b). 
These population surveys also demonstrated the significant comorbidity 
between disorders, with many individuals suffering symptoms characteristic 
of different anxiety disorder subtypes. Individuals with anxiety disorders also 
appear to be more likely to experience other comorbid psychiatric disorders 
including bipolar disorder, major depression and substance use disorders 
(Kessler, et al., 2005b). 
 
Anxiety disorders, although heterogeneous, are often characterised as chronic 
disorders that involve a waxing and waning of symptoms with few complete 
remissions (Wittchen, 2002; Yonkers, Bruce, Dyck, & Keller, 2003). The 
chronic nature of these illnesses imposes a significant burden on sufferers and 
wider society. For example, a review of studies exploring the human and 
economic burden from GAD demonstrated the substantial costs that this 
disorder imposes on sufferers, with evidence demonstrating reduced quality of 
life in areas such as “general health, physical health, bodily pain, vitality, 
mental health, role functioning due to physical and emotional difficulties, and 
social functioning” (Hoffman, Dukes, & Wittchen, 2008). These deficits are 
greater than those found in individuals with substance abuse disorders 
(Hoffman et al., 2008). The anxiety disorders also confer significant economic 
costs, not just through increasing health service utilisation as consequence of 
treating the disorder and other comorbid illnesses, but also through suboptimal 
work productivity and psychosocial dysfunction (Toghanian, Dibonaventura, 
Jarbrink, & Locklear, 2014). It is for these reasons that targeted efforts to 
identify means to improve prevention and treatment of anxiety disorders is a 
priority. 
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EPIDEMIOLOGY AND IMPACT OF CIGARETTE SMOKING 
Cigarette smoking is widely recognised as a major contributor to poor health 
and increased morbidity and mortality worldwide (Rostron, 2013; Rostron, 
Chang, & Pechacek, 2014). As consequence, many countries have made 
concerted efforts to reduce the levels of smoking amongst their populations. A 
key area of focus in these campaigns has been in preventing smoking 
initiation. 
 
Adolescence has been identified as a critical period of vulnerability for the 
commencement of smoking, particularly the years relating to secondary 
schooling (Norwegian Institute of Public Health, 2014). This period, and that 
extending into young adulthood, appears to be the time when lifelong 
smoking patterns are established. Adolescence is a time of substantial 
experimentation, and research indicates that individuals who experiment with 
smoking in adolescence are substantially more likely to establish regular 
smoking patterns than non-experimenters (Patton et al., 1998). Factors 
influencing experimentation include levels of anxiety and depression, and the 
influence of social factors such as peer pressure (Patton et al., 1998).  
 
In general, analyses suggest those who do not smoke during adolescence are 
substantially less likely to establish adult smoking behaviours. For example, 
in a longitudinal analysis tracking smoking behaviours from adolescence to 
adulthood, 72% of individuals who smoked in young adulthood (average age 
23 years) continued smoking in adulthood, compared to only 7% who did not 
smoke when they were young adults (Chassin, Presson, Rose, & Sherman, 
1996).  In an analysis of adolescent smoking patterns in the Norwegian 
Longitudinal Health Behaviour Study, Tjora, Hetland, Aaro & Øverland 
(2011) demonstrated that levels of daily smoking increased substantially 
during adolescence, from 3% in 13 year old (in 1990) to 31% in 18 years olds 
(in 1995). Numerous factors have been associated with a higher likelihood of 
commencing regular smoking, including having older siblings, and in 
particular best friends, that smoked. In addition, other important factors 
predictive of initiating smoking include lower parental SES (both directly and 
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indirectly) and whether the parents themselves smoke (Tjora, Hetland, Aaro, 
& Øverland, 2011).   
 
The role of parental smoking is interesting, as there are diverse and non-
mutually exclusive pathways through which an increased susceptibility to 
smoking may be developed. For example, parental smoking may increase 
smoking initiation through normalising smoking behaviours within the family 
unit and wider community. However, parental smokers may also increase the 
likelihood of smoking behaviours through passing on genes that increase the 
susceptibility to commence smoking (Schnoll, Johnson & Lerman, 2007), and 
also may increase the likelihood of smoking through changes induced by early 
life exposure to second-hand smoke in the home (Wang, Ho, Lo, & Lam, 
2012). 
 
Fortunately, public health campaigns aimed at reducing cigarette smoking 
have made a substantial impact on smoking levels in many countries. For 
example, estimates of the global rate of smoking between 1980 and 2012 
demonstrate that the age-standardised prevalence of smoking has decreased 
from 41.2% to 31.1% in men and 10.6% to 6.2% for women (Ng et al., 2014). 
Consistent with this, and relevant to this study, public health efforts in both 
Australia and Norway have led to quite substantial decreases in population 
levels of smoking over a similar period (1990-2010). For example, in 
Australia the prevalence of regular smoking for women has decreased from 
24% in 1992 to 18% in 2010, and from 29% to 22% for men over the same 
period (Scollo & Winstanley, 2012). In Norway, prevalence of adult daily 
smoking has decreased from 33% to 18% in women and 37% to 17% in men 
over a similar period.  In addition, Norway has also demonstrated a substantial 
reduction in teenage smoking over this period, reducing daily smoking in boys 
from 16% to 6% between 1993-2009, and from 15% to 6% in girls 
(Norwegian Institute of Public Health, 2014). 
 
A number of factors have been demonstrated to underpin higher levels of 
smoking initiation, including socioeconomic status and mental illness. 
Numerous studies have demonstrated how various measures of socioeconomic 
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status are strongly associated with levels of current smoking and smoking 
cessation (Lawrence, Hafekost, Hull, Mitrou, & Zubrick, 2013). Population 
smoking statistics from Australia demonstrate a robust inverse relationship 
between level of social advantage and levels of current smoking (Scollo & 
Winstanley, 2012). For example, individuals with the highest level of 
disadvantage on the Index of Relative Socio-economic Disadvantage (IRSD) 
were about twice as likely to smoke as individuals in the lowest IRSD 
category, irrespective of individual levels of education and income (Scollo & 
Winstanley, 2012). This finding may also indicate that the effect of the 
surrounding community in normalising smoking behaviours is important in 
establishing and sustaining smoking behaviours.  Consistent with these 
findings, individuals with the lowest levels of socioeconomic resources are 
also less likely to successfully quit smoking (Scollo & Winstanley, 2012).   
 
Similar findings are found in those with mental illness. For example, recent 
statistics generated from nationally representative samples in the United States 
have demonstrated that although smoking levels have declined substantially 
amongst those without mental illness in the last decade, the level of smoking 
in those with mental illness has decreased significantly more slowly (Cook et 
al., 2014). These findings call into account the effectiveness of public health 
campaigns targeting smoking reduction in individuals with mental illness, and 
also underpin the need for a greater understanding of the interrelationship 
between smoking and mental illness. 
 
In summary, similar to anxiety symptoms and disorders, smoking behaviours 
appear to be influenced greatly by early life experiences and genetic 
inheritance (Schnoll, Johnson & Lerman, 2007).  Once established in early 
adolescence and young adulthood, smoking appears to be difficult to stop, 
particularly in individuals with mental illness. 
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WHAT IS KNOWN ABOUT THE RELATIONSHIP BETWEEN SMOKING 
AND ANXIETY SYMPTOMS AND DISORDERS? 
A relationship between levels of smoking and anxiety symptoms has been 
observed for decades (Houston & Schneider, 1973; Lawton & Phillips, 1956; 
Schneider & Houston, 1970). Indeed, there is a commonly held community 
understanding that “being stressed leads to smoking”, or that smoking is 
undertaken in an effort to relieve anxiety (i.e. self-treatment). In support of 
this, a raft of well-conducted population based studies has investigated this 
association from an epidemiological perspective. Multiple studies have 
demonstrated a cross-sectional association (Acierno  et al., 1996; Breslau & 
Klein, 1999; Brown, Lewinsohn, Seeley, & Wagner, 1996b; Carroll et al., 
2009; Cougle, Zvolensky, Fitch, & Sachs-Ericsson, 2010; Cuijpers, Smit, ten 
Have, & de Graaf, 2007; Degenhardt & Hall, 2001; Farrell et al., 2003; 
Glassman et al., 1990; Grabe et al., 2001; Grant et al., 2005; Lasser et al., 
2000; Lawrence et al., 2010; Morris  et al., 2006; Sonntag  et al., 2000; 
Tobias et al., 2008; Vesga-Lopez et al., 2008; Wittchen, Stein, & Kessler, 
1999) where rates of smoking are positively associated with rates of anxiety 
symptoms and disorders. In this wide-ranging literature, anxiety disorders 
have been reported to be associated with increased rates of smoking, increased 
consumption of cigarettes per smoker, and lower rates of smoking cessation 
than non-anxiety disordered control groups (Lawrence et al., 2010; Tobias et 
al., 2008). In addition, increased anxiety symptoms, as measured on anxiety 
symptom scales, also appear to be correlated with increased rates of smoking 
(Mykletun  et al., 2008).  
 
This cross-sectional relationship, however, does not provide information 
regarding the direction of causation between smoking and anxiety symptoms 
and disorders. As previously mentioned, the positive correlation between 
these outcomes may be a consequence of three non-mutually exclusive 
relationships; either that increased anxiety leads to increased smoking 
behaviours, that smoking leads to increased anxiety, or that the positive 
correlation between smoking and anxiety are underpinned by a set of shared 
vulnerability factors.  
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Anxiety leading to increased smoking behaviour 
The majority of work that has attempted to understand the causal direction 
underpinning the smoking-anxiety association has focused on exploring 
whether anxiety symptoms are responsible for increasing rates of smoking. 
Interestingly, despite the commonly held view that higher levels of anxiety in 
an individual will increase smoking initiation or the rate of smoking in 
general, the literature is far from clear (Morissette et al., 2007). For example, 
in a random sample of 688 adolescents drawn from New York state who were 
followed over a period of 10 years, no association was detected between 
anxiety disorder status in adolescence and onset of smoking in adulthood 
(Johnson et al., 2000). However, in an analysis of 4500 children from the 
Greater Smoky Mountain Study, the presence of any anxiety disorder was 
associated with an increased likelihood of commencing smoking in later life 
(Costello, Erkanli, Federman, & Angold, 1999). Interestingly, adolescents 
with higher rates of anxiety or depression appear to be at greater risk of 
developing nicotine dependence (ND) (McKenzie, Olsson, Jorm, Romaniuk, 
& Patton, 2010), as defined by a score of >4 on The Fagerstrom Test for 
Nicotine Dependence (Fagerstrom, Heatherton, & Kozlowski, 1990). 
 
Through this work, a number of theories have been proposed that may explain 
the tendency for those with anxiety disorders to start smoking and/or increase 
their total consumption of cigarettes. These theoretical explanations are 
informed by both psychological (e.g. conditioning theory, cognitive theory, 
anxiety sensitivity (Zvolensky, Kotov, Bonn-Miller, Schmidt, & Antipova, 
2008)) and biological (e.g. nicotine effects and withdrawal) factors. One 
explanatory model that has common community recognition relates to the use 
of cigarettes as an anxiolytic agent (i.e. self-treatment). Evidence supports the 
contention that nicotine exposure does produce a subjective calming effect, 
although this is coupled with an increase in objective measures of 
physiological arousal (Perkins, 1995), hence this effect may in fact be related 
to relief of withdrawal phenomena (Parrott, 1995). In addition, investigations 
on smokers who relapse have suggested that anxiety is a common relapse 
antecedent (Brandon, Tiffany, Obremski, & Baker, 1990; Nagaya, Yoshida, 
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Takahashi, & Kawai, 2007; Shiffman, 1982). However, in an Australian 
longitudinal study, a relationship between high anxiety and smoking onset 
was dependent on the presence of other related factors including depression 
and peer smoking (Patton et al., 1998; Patton et al., 1996). Therefore at this 
juncture, despite a widely held community perception, the literature exploring 
whether anxiety or anxiety disorders do in fact increase smoking initiation is 
not clear (Morissette et al., 2007). 
Anxiety and smoking: underpinned by shared vulnerability? 
Other theorists in this research area have proposed models of shared 
vulnerability, where the act of commencing and perpetuating cigarette use and 
the development of increased anxiety symptoms and disorders are jointly 
influenced by other biological, psychological and/or social factors. In support 
of this, numerous so named “shared vulnerability factors” have been identified 
that contribute to both an increased likelihood of cigarette smoking behaviour 
and increased expression of anxiety symptoms and disorders. These include 
negative early childhood experiences, numerous issues associated with the 
early childhood environment (Baker, Brandon, & Chassin, 2004; Goodwin, 
Fergusson, & Horwood, 2004; Kassel, Stroud, & Paronis, 2003), problems 
with increased levels of impulsivity (Masse & Tremblay, 1997), problems 
with distress tolerance, higher levels of neurotic personality traits (Breslau, 
Kilbey, & Andreski, 1993; Byrne, Byrne, & Reinhart, 1995) and a range of 
comorbid psychiatric and substance use issues (Goodwin et al., 2004). Indeed, 
it is possible that these shared vulnerability factors are further underpinned 
and influenced by other factors (e.g. genetics, foetal insults) that are exerted 
very early in development. For example, a genetic linkage study identified 
certain loci on chromosomes 9 and 11, an area previously associated with 
increased PD, which correlated with an increased risk of cigarette smoking 
(Gelernter et al., 2004). In addition to these effects, it is also possible that 
anxiety disorders and cigarette smoking may alter the expression of certain 
vulnerability factors within an individual (e.g. cigarette smoking may 
reinforce poor distress tolerance). It is therefore probable that a range of 
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shared vulnerability factors, at least in part, contribute to the association 
between increased levels of smoking and anxiety behaviours.  
Smoking leading to increased anxiety symptoms and disorders 
As opposed to the previously discussed relationships, less investigation has 
been undertaken as to whether cigarette smoking itself may be a risk factor for 
the subsequent development of increased anxiety symptoms and disorders. 
This lack of investigation is surprising, as many aspects of the previous 
literature support such a relationship. In addition to cross-sectional studies 
demonstrating a link between anxiety disorders and cigarette smoking, 
analyses of multiple large prospective epidemiological studies also appear to 
support an association between cigarette smoking and the subsequent onset of 
increased anxiety symptoms and disorders.  For example, Breslau & Klein 
(1999) utilised data from 1,007 young adults (21 years to 30 years) who were 
followed prospectively over 5 years as part of the Detroit Epidemiologic 
Study to examine cigarette smoking as a predictor of subsequent anxiety 
behaviour. This prospective study demonstrated an increased risk of 
developing PD where individuals had been exposed to prior daily smoking 
(smoking daily >1 month), after controlling for gender and major depressive 
disorder (HR 13.13 (95% CI: 4.41-39.10)). Prior daily smokers who continued 
to smoke were even more likely to experience incident PD (HR 14.46 (95% 
CI: 4.81-43.5)). 
 
Similarly, in analysis of retrospective data from 4414 respondents aged 15-54 
years of age drawn from the NCS (Kessler, 2008), pre-existing daily smoking 
was demonstrated to be associated with a subsequent increased risk of 
developing PD (OR 2.6 (95% CI: 1.2-5.4)) and agoraphobia (OR 4.4 (95% CI: 
2.3-8.2)). A longer time since quitting smoking was associated with decreased 
odds of subsequent PD (OR 0.5 (95% CI: 0.4-0.7)), agoraphobia (95% CI: OR 
0.5 (95% CI: 0.5–0.8)) and SP (OR 0.6 (95% CI: 0.4-0.8)) (Breslau, Novak, & 
Kessler, 2004). 
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Some studies have also utilised samples incorporating younger adults and 
adolescents, although the quantum of this work is substantially less than that 
investigating onset of depression (Brown, Lewinsohn, Seeley, & Wagner, 
1996a; Goodman & Capitman, 2000; Wu & Anthony, 1999). For example, 
utilising the Oregon Adolescent Depression Project, a study that randomly 
selected a group of adolescents aged 14 to 18 years from Western Oregon in 
the USA, Goodwin, Lewinsohn, & Seeley (2005) demonstrated an association 
between smoking in adolescence and increased risk of PD in early adulthood 
(OR 5.1 (95% CI 2.4-10.5)), controlling for other anxiety disorders and a 
range of parental risk factors. Further, a large cohort (n=3021) of German 
adolescents and young adults drawn from the Early Developmental Stages of 
Psychopathology (EDSP) study was utilised to investigate the rate of anxiety 
disorder development observed at follow-up assessments in individuals 
deemed nicotine-dependent smokers at baseline. Baseline ND smoking was 
associated with an increased risk of developing PD, agoraphobia, PTSD and 
SP at follow up assessments. However, all associations were attenuated after 
controlling for other baseline comorbid conditions (e.g. depressive disorders, 
other anxiety disorders, alcohol and drug disorders, eating disorders) (Isensee 
et al., 2003). 
 
Some studies have explored the relationship between cigarette smoking and 
anxiety symptom expression. For example, the Young in Norway 
Longitudinal Study followed a group of 1500 Norwegians from age 13 years 
to 27 years and provided information of longitudinal relationships between 
smoking and anxiety symptoms. Anxiety symptom scores derived from the 
Hopkins Symptom Checklist demonstrated that non-ND smoking was 
associated prospectively with increased levels of anxiety symptoms (β=0.07, 
p<0.05). ND smokers experienced even greater levels of anxiety symptoms 
(β=0.14, p<0.001). However, inclusion of confounding variables including 
age, sex, mental health at age 20 years, socioeconomic status, parental care, 
parental divorce, education, conduct problems and use of cannabis eliminated 
the observed association in non-ND smokers. After inclusion of these 
covariates in the models, only ND smokers were associated with increased 
anxiety symptoms at age 27 years (β=0.09, p<0.01) (Pedersen & von Soest, 
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2009). In a study utilising information from 1943 participants aged 14-15 
years recruited in Victoria, Australia, who were followed for 10 years and 
asked about their smoking and mental health status, those who smoked in 
adolescence displayed higher levels of anxiety and depressive symptoms in 
young adulthood (Patton, Coffey, Carlin, Sawyer, & Wakefield, 2006) as 
measured using the Clinical Interview Schedule (Lewis, Pelosi, Araya, & 
Dunn, 1992). 
 
A major issue with the current literature investigating the association between 
smoking and anxiety disorders is its sheer size, marked heterogeneity and use 
of varying outcome measures. In many studies, anxiety symptoms and 
disorders were captured as secondary measures, where the primary focus of 
investigation was depression or other mental illness outcomes. Therefore, a 
few unmet needs are identified in the literature. First, there is a need for the 
literature to be drawn together in a comprehensive and systematic fashion, to 
provide greater clarity surrounding the potential directionality of the smoking-
anxiety disorder relationship. This finding could then be utilised for further 
scientific exploration. Second, although there is a need for greater exploration 
of this relationship in adult cohorts, there is a much more significant need for 
greater exploration of this relationships in cohorts utilising children and 
adolescents. These needs will be addressed in this thesis. 
HOW COULD SMOKING INCREASE ANXIETY SYMPTOMS AND 
DISORDERS? 
Apart from the previously outlined social factors that could underpin a 
relationship between smoking and a subsequent increase in anxiety symptoms 
and disorders, numerous psychological and biological theories have been 
proposed to understand this relationship. In this section, I will detail some of 
the prominent theories from each domain.  
Psychological Theories 
Multiple psychological theories (Morissette et al., 2007) have been utilised to 
understand how cigarette smoking may increase anxiety symptoms and 
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disorders. These theories include classical conditioning, cognitive theory, 
anxiety sensitivity and stress and coping models. 
Classical Conditioning 
From their review of the literature, Morissette et al. (2007) reported, 
“conditioning theory has been classically utilised to describe the onset and 
maintenance of anxiety disorders and cigarette smoking”. Classical 
conditioning is the process through which a neutral stimulus is paired with a 
fear-provoking stimulus, and through this pairing, the neutral stimulus 
provokes fear in certain conditions (Lissek et al., 2005; Pavlov, 1927). In 
reality, this may lead to a relatively neutral stimulus (e.g. being in a shopping 
mall) becoming anxiety provoking. The use of theories informed by 
knowledge of classical fear conditioning have been utilised in understanding 
anxiety disorder pathogenesis for decades (Watson & Rayner, 1920). Over 
time, a number of extensions to this paradigm have been incorporated, 
including those relating to incubation of fear responses and a motivation to 
continued avoidance (Eysenck, 1976). The use of a classical conditioning 
model for understanding anxiety development has been supported by meta-
analysis of quantitative studies, which demonstrated that patients with 
baseline anxiety demonstrate increased levels of fear learning and conditioned 
responses (Lissek et al., 2005). 
 
Similar theoretical work has also been undertaken in smoking behaviour. For 
example, a conditioned withdrawal model as proposed by Wikler (1973; 
1984) suggests that through continued pairing of withdrawal effects from 
substances (e.g. nicotine) with certain environmental stimuli, an individual 
can experience these “withdrawal” symptoms when in the presence of the 
“paired” environmental stimuli even when not withdrawing from the actual 
drug (e.g. nicotine). In nicotine, such conditioned responses have been 
demonstrated empirically to decrease activity of brain reward systems and 
produce negative affective valence (Kenny & Markou, 2005). Other 
conditioning models proposed in cigarette smoking include an appetitive 
model, where pairing of rewarding drug stimuli with environmental drug cues 
can lead to increased motivation for use when exposed to these environmental 
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drug cues (Geier, Mucha, & Pauli, 2000), and a conditioned response model 
where environmental cues are paired with the effects of nicotine repeatedly 
until the cues alone are able to produce nicotine drug effects in the absence of 
nicotine (Field & Duka, 2001). 
 
These interactive models can be extended to understand how, through pairing 
of smoking behaviour and anxiety responses, cigarette smoking could lead to 
increased anxiety (Morissette et al., 2007).  For example, cigarette smoking 
behaviour may become paired with increased anxiety (Morissette, Palfai, 
Gulliver, Spiegel, & Barlow, 2005) if smoking is undertaken during periods of 
higher anxiety. As these processes are paired, smoking related behaviours, 
even when undertaken in non-anxiety producing situations, may induce 
anxiety responses.  
Cognitive Theory 
Another substantive contribution to the anxiety pathogenesis literature utilises 
cognitive theory as its foundation. In cognitive theories of anxiety, 
maladaptive cognitive schemas, through a series of biases in attention, 
interpretation and memory, lead an individual to inaccurately interpret reality 
as threatening (and therefore fear producing) (Beck & Clark, 1997). This 
process results from distortion in a multistage information processing 
sequence.  
 
In the first stage (unconscious registration of the threat stimulus), individuals 
with anxiety propensity are more likely to register or overestimate 
environmental cues as a threat. In the second stage (activation of  “primal 
threat mode”), which in normal functioning leads to activation of processes to 
maximize safety, individuals with anxiety propensity, through a series of 
cognitive biases (e.g. negative automatic thoughts), facilitate an increased 
(overreacting) response to the threat proposed. In the third stage (“secondary 
activation of more elaborative and reflective modes of thinking”), the 
individual experiences non-automatic processes designed to evaluate the 
coping response to the threat. In individuals primed to experience biases 
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towards continuation of a threat-induced response, automatic anxiety 
responses are continued rather than terminated (Beck & Clark, 1997). 
 
Cognitive models propose that cigarette smoking results from automatic 
schemas that control drug use. In summary, the repeated skills required for 
smoking behaviour are stored in memory processes which are elicited as an 
automatic process when confronted with motivating stimuli (e.g. behavioural 
or environmental cues) (Tiffany, 1990). Cognitive theories of smoking and 
anxiety comorbidity suggest that automatic processes can occur together 
(Morissette et al., 2007), and may overlap. Therefore, environmental stimuli 
that previously induced pathological anxiety may become a cue for the 
automatic smoking schema (and vice versa). As physiological dependence on 
nicotine develops, the quantity and salience of smoking related cues can 
increase (Brandon, Herzog, Irvin, & Gwaltney, 2004). These cues can become 
associated with anxiety eliciting stimuli (e.g. initial withdrawal), leading to an 
increase in crossover of related cues. 
Anxiety Sensitivity 
Numerous investigations have also demonstrated “anxiety sensitivity”, the 
exhibition of fear in response to anxiety-related sensations due to beliefs that 
such sensations will provoke negative consequences (McNally, 2002a; Reiss, 
Peterson, Gursky, & McNally, 1986), as being significant in influencing the 
association between smoking and anxiety symptoms. Anxiety sensitivity is 
theorised to result from the interaction between genetic predisposition and life 
experiences, leaving an individual susceptible to enhanced fear when 
experiencing anxiety-related physical sensations (McNally, 2002b; Stein, 
Jang, & Livesley, 1999). Anxiety sensitivity has received most empirical 
investigation as an explanatory model for development of PD in the context of 
cigarette smoking. Cigarette smoking may act as a risk factor that increases 
panic related phenomenon via increasing exposure to negative bodily 
sensations within the individual. In combination with a predisposition (e.g. via 
genetics) to anxiety sensitivity, the smoking-induced bodily sensations may 
induce heightened fear responses (Johnson et al., 2013; McLeish, Zvolensky, 
& Bucossi, 2007), which overtime may become pathological anxiety-related 
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phenomena (Zvolensky & Bernstein, 2005). In this situation, anxiety 
sensitivity interacts with a lack of fear extinction, as sensitivity to bodily 
sensations in response to tobacco withdrawal may reinforce a fear response, 
thereby perpetuating a cue between smoking cessation and increased anxiety 
responses (preventing smoking cessation). Empirical investigation has 
confirmed that understanding and improving an individual’s anxiety 
sensitivity can assist anxiety treatment. For example, changes to anxiety 
sensitivity achieved through cognitive behavioural therapy have been 
associated with improvement of PD symptoms (Gallagher et al., 2013). 
Further, in another recent study, direct intervention on anxiety sensitivity by 
augmenting a smoking cessation program to target anxiety sensitivity, led to 
reduction in reported suicidality by participants (Capron, Norr, Zvolensky, & 
Schmidt, 2014). Anxiety sensitivity appears to act as a risk factor in 
adolescents as well (Schmidt et al., 2010).  
Models of Stress and Coping  
Another field of enquiry has focused on stress and coping models. Smokers 
often report that a motivating factor for relapse from abstinence or in 
continuing smoking is to reduce stress (Brandon et al., 1990; Shiffman, 1982; 
Wewers, 1988). In addition, the tendency toward anxiety appears to be related 
to an individual’s ability to cope with stressors (Morissette et al., 2007). The 
development of pathological anxiety or an anxiety disorder may therefore 
relate to an imbalance between the level of life stressors and an individual’s 
innate coping ability. Such an imbalance could potentially perpetuate coping 
strategies associated with avoidance or those aimed at obtaining short term 
stress relief, which can be associated with poor outcomes in the long term 
(Feldner, Zvolensky, & Leen-Feldner, 2004; Purdon, 1999). Cigarette 
smoking and ND have been associated with increased levels of stress and poor 
coping skills. Interestingly, although smokers appear to report greater levels 
of stress than non-smokers (Naquin & Gilbert, 1996), there appears to be 
limited evidence that smoking actually leads to stress reduction. According to 
Parrot (1995; 1998; 2006), smoking functions to alleviate the effects of 
nicotine depletion, such as negative affect and stress, and not the effects of 
other adverse life stress. Therefore, cigarette smokers may perceive a relief of 
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stress from smoking, but this is as a consequence of relief of their nicotine 
depletion. Therefore, the stress induced by adverse life effects is not only 
directly reduced in the immediate/short term, but is in fact also perpetuated 
over the long term, as more adaptive coping strategies and attention are 
deprioritised. In this regard, adverse life events may predispose a vulnerable 
individual to develop both increased anxiety and increased smoking 
behaviours. Poor coping mechanisms may facilitate smoking behaviour, 
which in turn traps individuals in a loop where they continue to smoke in an 
effort to relieve the anxiety derived from periodic nicotine withdrawals. 
Overtime, smokers may falsely attribute smoking behaviours as being anxiety 
relieving, despite the behaviour actually being an overall cause of increased 
anxiety through precipitating ND. This is represented by a self-medication 
hypothesis, where individuals smoke to relieve anxiety in the short term, only 
to have their levels of stress increase over the long term. This is further 
reinforced as smoking behaviour is used in preference to adaptive coping 
mechanisms, which further increases psychological dependence on smoking 
(Matheny & Weatherman, 1998; Morissette et al., 2007). 
 
Overall, this exploration of the literature demonstrates the substantial 
scholarly work that has been undertaken into psychological theories that may 
underpin a relationship between cigarette smoking and anxiety symptoms and 
disorders. As consequence, this area will not be a significant focus of this 
thesis. 
 
Biological effects 
Neurobiology of anxiety and anxiety disorders 
The neurobiology of anxiety disorders is a highly complex and evolving area 
of research. The symptoms of anxiety disorders appear to be mediated through 
disruption of normal processes within the emotional, rather than higher 
cognitive, centres of the brain (Martin, Ressler, Binder, & Nemeroff, 2009). 
Brain centres involved in emotional processing include structures such as the 
limbic cortex (involved in integrating sensory, affective and cognitive 
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information), the hippocampus (which plays integral roles in memory and 
feedback for, amongst other areas, the hypothalamic-pituitary-adrenal axis) 
and the amygdala. Each of these brain regions appears to be associated with 
certain processing tasks. For example, the amygdala “processes emotionally 
salient external stimuli and initiates the appropriate behavioural response” 
(Martin et al., 2009), whereas the higher cognitive areas are responsible for 
higher order functions (e.g. frontal lobe functions such as planning and 
decision making) and top down control of the emotion processing centres 
(Miller, 2000; Motzkin et al., 2014). Individuals with increased anxiety levels 
appear to display changes to these processing networks. For example, 
functional hyperactivity is noted in emotional processing centres in 
individuals with high levels of anxiety, in concert with observations that 
higher cortical centres appear to be unable to normalise these limbic responses 
to stimuli in a top-down fashion (Martin et al., 2009). 
 
Alterations in interactions between these brain centres are likely underpinned 
by changes to the brain’s communication processes. Multiple investigations 
have demonstrated numerous neurotransmitter and neuroendocrine signalling 
pathway disruptions in individuals with anxiety disorders. This is supported 
by observations that agents that act to modulate the serotonin, noradrenaline 
and dopamine neurotransmitter systems exert anxiolytic properties, 
confirming that there is at least some role for these systems regulation of 
anxiety responses (Johnson & Lydiard, 1995; Martin et al., 2009; Ressler & 
Nemeroff, 2000). In addition, numerous brain signalling molecules, such as 
the neuropeptides (e.g. cholecystokinin, neuropeptide-Y, vasopressin, 
corticotrophin releasing factor and oxytocin) that are often released co-
packaged with neurotransmitters, also appear to exert modulating effects on 
these limbic circuits (Martin et al., 2009). 
 
These factors are also influenced by genetics, especially genes that underpin 
expression and function of neurotransmitter receptors, expression of signalling 
molecules, and cellular functions including energy production, 
neuroplasticity, neurogenesis and apoptosis. Newer theories also suggest that 
anxiety control may be influenced by oxidative stress balance in the central 
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nervous system (Krolow et al., 2014). This may in fact be a mechanism 
through which exercise, a known anxiolytic, can exert positive effects on 
anxiety levels and anxiety control (Moylan et al., 2013a).  
Could cigarette smoking influence anxiety expression through biological 
effects? 
Multiple theories have been proposed for potential biological mechanisms that 
may underpin a relationship between cigarette smoking and anxiety 
expression. These include effects of cigarette smoke exposure on 
neurodevelopment, interactions related to negative physical health effects of 
smoking (e.g. by interacting with a propensity to increased anxiety 
sensitivity), acute and/or chronic physiological effects of smoking inducing 
anxiety (e.g. acute modulation of neurotransmitters, or chronic effects via 
effects of increased inflammatory and oxidative stress load), or through 
moderation of alarm sensors to the threat of suffocation (i.e. “the false 
suffocation theory”) (Klein, 1993).  
 
The majority of research into how smoking may increase levels of anxiety has 
occurred in the domain of panic symptoms and PD (Cosci et al., 2010).  This 
appears to be a sensible approach, as it is possible that smoking may be more 
likely to produce panic-type anxiety symptoms than other symptom subtypes 
due to the physical effects of smoking exerts on other organ systems (e.g. 
respiratory and autonomic disturbance) (Cosci et al., 2010). In this 
relationship, the literature points to a potential neurodevelopmental pattern. 
For example, earlier age of smoking initiation, particularly when occurring 
during years of highly active neurodevelopment such as childhood and 
adolescence, is associated with increased risk and earlier onset of panic 
disorder (Amering et al., 1999; Bernstein, Zvolensky, Schmidt, & Sachs-
Ericcson, 2007). Panic symptoms are influenced by respiratory sensitivity, 
and nicotine alters the sensitivity set point of cholinergic respiratory neurons 
(Coddou, Bravo, & Eugenin, 2009). From their review of the literature, Cosci 
et al. (2010) identified three potential hypotheses underpinning the association 
between cigarette smoking and subsequent increase in panic symptoms. The 
first hypothesis is the “moderational model” where the association is 
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explained by neuroticism. The second hypothesis is the “pathoplastic model”, 
where the effects of smoking are mediated by “exacerbating affective 
disturbances and negative health process” (Zvolensky, Schmidt, & McCreary, 
2003). Such effects include the direct negative health effects (e.g. induction of 
chronic obstructive pulmonary disease), acute physiological effects (e.g. 
increased noradrenaline and autonomic sensations) and negative self-
perception of health status (Zvolensky & Bernstein, 2005) that is induced 
through cigarette smoking. The third hypothesis is the “false suffocation 
alarm” theory, as originally proposed by Klein (1993). This theory suggests 
smoking may induce hypersensitivity to suffocation signals thereby making it 
more likely an individual may experience panic symptoms in response to 
normal life experiences.  
 
Some work has explored the role of smoking in mediating other anxiety 
disorder symptoms. For example, follow-up of individuals affected by a 
fireworks factory explosion in The Netherlands demonstrated that those who 
were smokers at time of traumatic incident displayed enhanced levels of 
severe anxiety symptoms (OR 2.32 (1.19-4.53)) and disaster related PTSD 
(OR 2.64 (1.05-6.62)) 4 years after the event, controlling for baseline 
symptoms, demographic characteristics and life events (Van der Velden et al., 
2007). These results supported those of Koenen et al. (2005), who 
demonstrated that ND was associated with an increased risk of developing 
PTSD in trauma exposed men (HR 1.98 (1.61-2.42)) and that shared genetic 
effects explained 63% of this association. These associations have been 
hypothesised to result from alterations to neurobiology (e.g. alterations to the 
hypothalamic-pituitary-adrenal axis, sympathetic nervous system 
hyperactivity and alteration to neurotransmitter system functioning) and 
through psychological effects (Fu et al., 2007).  
A neurodevelopmental model: is this supported by the biological 
literature?
One potential mechanism by which smoking may increase rates of anxiety 
could be through altering the neurodevelopmental trajectory of an individual’s 
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anxiety trait. Many anxiety disorders are known to display a very early age of 
onset (Merikangas et al., 2010), and given this, exposure to environmental 
cigarette smoke during gestation and childhood may be important in 
development of adult anxiety problems. Second hand smoke exposure has 
been shown to be associated with increased symptoms of generalised anxiety 
in children aged 8-15 years (Bandiera et al., 2011), and earlier onset of 
smoking (e.g. <15 years vs. >15 years) is associated with higher rates of adult 
anxiety disorders (Jamal, Does, Penninx, & Cuijpers, 2011).  Therefore, 
smoking exposure in early life may be an important contributor to adult 
anxiety. 
 
A large body of literature has demonstrated that exposure to cigarette smoke 
in early life, including in utero, can interfere with normal development of 
physiological systems. For example, early exposure to cigarette smoke (either 
second hand environmental exposure or via maternal-foetal transfer) has been 
associated with multiple physical health consequences in children, including 
increased rates of stillbirth (Flenady et al., 2011), lowered birth weight 
(Jaddoe et al., 2008), childhood asthma (Neuman et al., 2012), obesity (Gorog 
et al., 2011), decreased intelligence (O'Callaghan et al., 2010), and increased 
hyperactivity, impulsivity and conduct problems (Batstra, Hadders-Algra, & 
Neeleman, 2003; Brook, Zhang, Rosenberg, & Brook, 2006; Day, Richardson, 
Goldschmidt, & Cornelius, 2000; Huizink & Mulder, 2006). 
 
Exploration within animal models also suggests that cigarette smoke exposure 
in early life may be associated with modulation of systems responsible for 
anxiety control.  Cigarette smoke exposure is known to interfere with normal 
neurodevelopment (DeBry & Tiffany, 2008; Picciotto, Brunzell, & Caldarone, 
2002; Slikker, Xu, Levin, & Slotkin, 2005; Slotkin, 2004), and supra-
physiological exposure to nicotine has been associated with the development 
of childhood behavioural and social problems (Brion et al., 2010; Nicoll-
Griffith et al., 2001; Piquero et al., 2002), demonstrating the capacity for such 
exposure to potentially alter neurodevelopmental trajectories. Numerous 
animal studies have demonstrated that exposure to cigarette smoke and 
nicotine, both in utero and in early post natal life, is associated with increased 
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level of anxiety behaviours in rats that extends into adulthood (Eppolito et al., 
2010). The timing of exposure to nicotine/cigarette smoke appears to be 
important, with the largest observed effects on anxiety behaviours observed 
during times of high-activity neurodevelopment (e.g. in utero, very early life, 
adolescence). In addition to nicotine, neurodevelopmental trajectories may be 
susceptible to a range of other cigarette smoke components. For example, 
cigarette smoke is also a significant source of exogenous free radicals 
(Stedman, 1968) and contains thousands of chemicals that can increase 
oxidative and nitrosative stress (O&NS) load.  Investigations have 
demonstrated that smokers, and those exposed to passive smoke, have 
decreased levels of antioxidant enzymes (Sobczak, Golka, & Szoltysek-
Boldys, 2004; Swan & Lessov-Schlaggar, 2007). Alterations in O&NS 
balance(Atmaca, Kuloglu, Tezcan, & Ustundag, 2008; Chakraborty, Singh, 
Dasgupta, Mandal, & Nath Das, 2009; Herken et al., 2006; Ozdemir, 
Cetinkaya, Ersan, Kucukosman, & Ersan, 2009; Tezcan, Atmaca, Kuloglu, & 
Ustundag, 2003) and inflammation (Brambilla et al., 1997; Denys, Fluitman, 
Kavelaars, Heijnen, & Westenberg, 2004; Fluitman et al., 2010; Konuk et al., 
2007; Maes et al., 1998; O'Donovan et al., 2010; Rapaport, 1998) have been 
associated with increased anxiety and anxiety disorders.  
 
Overall, the biological literature does provide some support for how smoking 
may increase anxiety symptoms and disorders through modulating 
development of the central nervous system. However, a significant unmet 
need is for this literature to be comprehensively synthesised as a basis for 
future research endeavours. This need will be addressed in this thesis. 
A neurodevelopmental model: is this supported by the 
epidemiological literature?
Given the observations in animal models, a few studies have investigated 
whether exposure to cigarette smoke in early life (e.g. in utero) is associated 
with a change in anxiety symptoms in childhood, adolescence and adulthood. 
Behavioural symptoms observed in childhood tend to be divided into two 
main categories, externalising symptoms (e.g. conduct issues, attention deficit 
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issues, oppositionality and acting out) and internalising symptoms (e.g. 
depressive and anxiety issues). A substantial literature has focussed on the 
relationship between exposure to cigarette smoking during pregnancy (via 
maternal-foetal transfer) (Wakschlag et al., 2002) and childhood externalising 
symptoms, demonstrating an association between maternal smoking during 
pregnancy and increased childhood behavioural problems. It should be noted 
that this area of research is subject to considerable debate in regards to 
establishment of causal inference (D'Onofrio, Lahey, Turkheimer, & 
Lichtenstein, 2013; Knopik, 2009; Thapar & Rutter, 2009), as relationships 
between smoking and childhood behavioural problems are potentially 
confounded by genetic risks in addition to social and environmental factors 
(Agrawal et al., 2008; D'Onofrio et al., 2013; Ellingson et al., 2014; Ellingson 
et al., 2012; Gilman, Gardener, & Buka, 2008).  In contrast to the substantial 
investigation and debate surrounding the association between smoking and 
externalising symptoms, relatively little investigation (Ashford et al., 2008; 
Brion et al., 2010; Carter, Paterson, Gao, & Iusitini, 2008; Robinson et al., 
2010; Williams et al., 1998) has been undertaken assessing the contributing 
role of exposure to cigarette smoke exposure to development of internalising 
(anxiety and depressive) symptoms.  Although the available literature is 
heterogeneous, some studies have demonstrated a positive relationship. For 
example, in the RAINE study, an analysis of 2758 mother-child pairs 
followed prospectively during pregnancy and early childhood, children 
displayed higher internalising symptoms in childhood (OR 1.55, 95% CI: 
1.14-2.11) if their mother did not quit smoking by week 18 of pregnancy, 
controlling for multiple confounders (Robinson et al., 2010).  However, 
analysis of other large cohorts including the Avon Longitudinal Study and 
The Generation R Study either failed to find associations, or displayed 
associations of higher rates of internalising symptoms in children exposed to 
maternal smoking during pregnancy that were subsequently confounded when 
covariates including socioeconomic status, parental alcohol exposure and 
psychopathology were included in models (Brion et al., 2010; Roza et al., 
2009).  This inconsistency in the available literature may be consequence of 
power issues, varying ages of assessment, and differences in covariates 
included in models, which renders consensus about this area challenging. 
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There is a need for this area to be explored in a larger cohort to more 
comprehensively address this area of research and provide more definite 
findings. This will be undertaken in this thesis.  
 
CONCLUSION 
Overall, the current literature provides some support for the concept that 
exposure to cigarette smoke may increase the subsequent risk of developing 
anxiety symptoms and disorders, and that exposure at different life and 
developmental stages may be important in understanding this relationship. 
However, exploration of this literature elicits a number of questions that 
remain unanswered. Although it would be impossible to answer all of these 
questions, the project has been focussed to answer five questions (Chapter 3) 
that will contribute substantially to the overall thesis aim: to determine 
whether cigarette smoking represents a plausible risk factor for the 
development of increased anxiety symptoms and disorders.  
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3 STUDY AIMS AND QUESTIONS 
For this research study, the overall aim is to determine whether cigarette 
smoking represents a plausible risk factor for the development of increased 
anxiety symptoms and disorders. To contribute to this question, the thesis will 
seek to answer five main questions: 
 
1) How does the extant epidemiological literature inform the understanding of 
whether cigarette smoking may be considered a plausible risk factor for the 
onset of anxiety disorders? 
 
2) Is there a plausible biological model through which exposure to cigarette 
smoke could influence the expression of anxiety symptoms and disorders? 
 
3) In a well-characterised population-based observational study of women 
aged 20+ years, is there an association between having a diagnosed anxiety 
disorder and prior exposure to regular cigarette smoking? 
 
4) In a well-characterised cohort of children and adolescents, is there an 
association between cigarette smoking and increased anxiety symptoms in 
early adulthood?  
 
5) In a well-characterised very large cohort following mothers and their 
offspring, is there an association between maternal smoking during pregnancy 
and increased anxiety and depressive symptoms in childhood? 
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1 CHAPTER FOUR 
The first stage of this research aimed at addressing Research Questions 1&2: 
 
1) How does the extant literature inform the understanding of whether 
cigarette smoking may be considered a plausible risk factor for the onset of 
anxiety disorders? 
 
2) Is there a plausible biological model through which exposure to cigarette 
smoke could influence the expression of anxiety symptoms and disorders? 
 
To answer these questions two separate projects, which are subsequently 
detailed in Chapters 5&6, were undertaken. A short bridging chapter (Chapter 
7) is included at the end of these chapters to briefly summarise the findings 
and how they informed the subsequent research studies performed. 
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Abstract
Background: Multiple studies have demonstrated that rates of smoking and nicotine dependence are increased in
individuals with anxiety disorders. However, significant variability exists in the epidemiological literature exploring
this relationship, including study design (cross-sectional versus prospective), the population assessed (random
sample versus clinical population) and diagnostic instrument utilized.
Methods: We undertook a systematic review of population-based observational studies that utilized recognized
structured clinical diagnostic criteria (Diagnostic and Statistical Manual of Mental Disorders (DSM) or International
Classification of Diseases (ICD)) for anxiety disorder diagnosis to investigate the relationship between cigarette
smoking, nicotine dependence and anxiety disorders.
Results: In total, 47 studies met the predefined inclusion criteria, with 12 studies providing prospective information and
5 studies providing quasiprospective information. The available evidence suggests that some baseline anxiety disorders
are a risk factor for initiation of smoking and nicotine dependence, although the evidence is heterogeneous and many
studies did not control for the effect of comorbid substance use disorders. The identified evidence however appeared
to more consistently support cigarette smoking and nicotine dependence as being a risk factor for development of
some anxiety disorders (for example, panic disorder, generalized anxiety disorder), although these findings were not
replicated in all studies. A number of inconsistencies in the literature were identified.
Conclusions: Although many studies have demonstrated increased rates of smoking and nicotine dependence in
individuals with anxiety disorders, there is a limited and heterogeneous literature that has prospectively examined
this relationship in population studies using validated diagnostic criteria. The most consistent evidence supports
smoking and nicotine dependence as increasing the risk of panic disorder and generalized anxiety disorder. The
literature assessing anxiety disorders increasing smoking and nicotine dependence is inconsistent. Potential issues
with the current literature are discussed and directions for future research are suggested.
Keywords: agoraphobia, anxiety disorder, cigarette smoking, epidemiology, generalized anxiety disorder, nicotine
dependence, obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder, specific phobia
Background
Anxiety disorders (ADs) represent the most common
mental illness diagnoses across many countries [1,2] and
are associated with significant impairment to health and
quality of life [3,4]. Multiple population-based epidemio-
logical studies have identified increased rates of smoking
amongst individuals with mental illness, and increased
rates of mental illness amongst smokers [5]. Specifically,
ADs have been reported to be associated with increased
rates of smoking, increased consumption of cigarettes
per smoker, and lower rates of smoking cessation than
non-anxiety disordered control groups [6,7]. In addition,
increased anxiety symptoms as measured on symptom
scales appear to be correlated with increased rates of
smoking [8].
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The relationship between ADs, smoking behavior and
nicotine dependence (ND) could be explained by three
non-mutually exclusive relationships. Firstly, smoking
behavior and/or ND may increase the chances of devel-
oping an AD. Potential mechanisms underpinning this
include adverse effects of smoking on neurodevelopment
and neurotransmitter pathways modulating anxiety that
may predispose individuals to developing enhanced anxi-
ety, or direct effects to the respiratory and autonomic
systems that may alter physical responses to anxiety pro-
voking situations [9,10]. Secondly, ADs may increase
smoking behavior and the risk for ND. Mechanisms for
this could include a propensity for those with increased
anxiety to commence smoking, or use of cigarettes as an
anxiolytic self-treatment [11,12]. Thirdly, the relationship
may be underpinned by a shared vulnerability factor or
group of factors that increase the likelihood of smoking,
ND and AD development (for example, low socioeco-
nomic status) [2,13].
However, a number of inconsistencies exist within the
current literature examining the relationships between
cigarette smoking, ND and ADs. Firstly, many currently
available population-based epidemiological investigations
have utilized clinical symptom severity scales rather
than validated diagnostic instruments to make AD diag-
noses. Secondly, many studies utilizing validated diag-
nostic instruments have been cross-sectional, and
therefore unable to provide insight into the direction of
causality underpinning the association. Thirdly, many
investigations have been drawn from clinical populations
as opposed to whole population samples, potentially
introducing selection biases. An accurate assessment of
the association between cigarette smoking, ND and vali-
dated ADs, including direction of causality and potential
variation amongst differing anxiety disorder subgroups
or populations, may help inform targeted interventions
in at risk populations.
This paper aims to critically review the available epi-
demiological studies that have utilized general popula-
tion samples and validated diagnostic instruments based
upon recognized Diagnostic and Statistical Manual
(DSM) [14] or International Classification of Diseases
(ICD) systems [15], exploring the relationship between
cigarette smoking, ND and ADs. Structured diagnostic
instruments have advantages, as they are replicable
across studies, and in some cases include an interview
(for example, the Composite International Diagnostic
Interview (CIDI)). These interviews often document date
of onset and recent symptom expression, allowing for
assessments of temporality. A particular focus for this
review is on studies that have utilized prospective
designs and can therefore provide insight into the direc-
tion of the potential underlying causal relationships.
Methods
Systematic review search strategy
A systematic review of the English language literature
exploring relationships between ADs, ND and cigarette
smoking was undertaken. The aim was to provide a
descriptive overview of the available literature, with a
focus on information that could inform understanding
of direction of causality. A computerized search strategy
of medical databases PubMed and EMBASE utilized the
following search strategies, was limited to English lan-
guage literature and human studies. No date restrictions
were placed. PubMed: ‘Anxiety Disorders’ (MeSH) AND
(Smoking(Title/Abstract) OR Tobacco(Title/Abstract)
OR Nicotine(Title/Abstract) OR Cigarette(Title/
Abstract)) AND Anxiety AND (’humans’ (MeSH terms)
AND English); EMBASE: ‘#1 AND #2 AND #3’ where
#1 = ‘’anxiety disorder’/exp AND (humans)/lim AND
(english)/lim AND (embase)/lim’, #2 = ‘smoking:ab OR
tobacco:ab OR cigarette:ab OR nicotine:ab AND
(humans)/lim AND (english)/lim AND (embase)/lim’
and #3 = ‘’anxiety’/exp AND (humans)/lim AND (eng-
lish)/lim AND (embase)/lim’.
Extraction of references
All extracted references were combined and duplicate
references deleted. Titles and abstracts of all references
were initially assessed for relevance to the review topic.
Full texts of references identified as potentially contain-
ing relevant information were assessed against the pre-
determined inclusion criteria for quality and relevance.
For completeness, bibliographies of extracted references
were manually searched for further relevant references.
Where relevant references were discovered, their biblio-
graphies were manually searched.
Inclusion criteria
The following inclusion criteria were applied to the avail-
able references. Included studies needed to utilize a ran-
dom sample, drawn from the general population,
investigating the association between ADs, ND and cigar-
ette smoking. The included population must have been
assessed for panic disorder (PD), generalized anxiety dis-
order (GAD), obsessive-compulsive disorder (OCD),
social phobia (SP), specific phobia (SPP), post-traumatic-
stress disorder (PTSD) and/or agoraphobia (AG), utiliz-
ing a recognized and validated structured diagnostic tool
or documented clinician diagnosis in line with either
ICD-9/ICD-10 or DSM-III or DSM-IV criteria. The cri-
teria establishing cigarette smoking must have been
clearly documented, either as dichotomous (yes/no) or
through frequency of cigarette consumption. ND must
have been diagnosed through a recognized diagnostic
tool linked to ICD or DSM criteria. The criteria for ND
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mirror those of other substance dependence disorders,
and include (amongst others) symptoms of tolerance,
withdrawal, increasing use and difficulty quitting. All
data must have represented new information and not
replication of previous study results.
Literature search and application of inclusion criteria
The structured computerized literature search was per-
formed on 18 November 2011 yielded 298 references from
PubMed and 138 references from EMBASE. In all, 36
records were duplicated after compilation of search
results, leaving 400 unique records. Initial review of titles
and abstracts revealed 91 records with potentially relevant
information for the review. Manual searching of the biblio-
graphies from these 91 references revealed 16 further
potential references. Full text review of these 107 refer-
ences revealed 47 studies meeting the inclusion criteria.
See Figure 1 for search strategy flowchart and Figure 2 for
breakdown of studies.
Data extraction
All data were extracted upon the following variables: (1)
study name, (2) study population, (3) study design (pro-
spective, quasiprospective or cross-sectional), (4) definition
of AD diagnosis, (5) definition of smoking status, (6) statis-
tical parameters utilized and (7) primary results presented.
A focus on measures of association (for example, odds
ratio (OR), hazard ratio (HR)) was taken. Where available,
both unadjusted and adjusted measures were extracted.
Data were extracted into a preprepared structured Micro-
soft Excel database (Microsoft; Redmond, WA, USA).
Results
There were 47 studies meeting inclusion criteria. The stu-
dies were broken down by type and direction of analysis
(prospective, quasiprospective and cross-sectional) and are
represented in Additional files 1, 2, 3, 4, 5.
Prospective studies
A total of 13 studies were identified that utilized popula-
tion-based samples to assess a prospective relationship
between ADs, smoking behavior, and ND. These studies
comprised random population samples drawn from the
United States, New Zealand, Germany and The Nether-
lands, with some samples used in multiple studies. Discus-
sion of the included studies has been grouped below based
on the sample used.
Influence of anxiety disorders on risk of later smoking or
nicotine dependence
(A summary of this section is as follows (see also Addi-
tional file 1, Table S1): the best available evidence is equi-
vocal, but suggests that certain baseline ADs are risk
factors for onset of smoking and nicotine dependence,
although results vary across studies and across different
disorders. The best available studies failed to control for
comorbid substance use disorders.)
The first published prospective data were drawn from
the Oregon Adolescent Project Depression project, which
randomly recruited adolescents (aged 14 years to 18 years)
from high schools in Western Oregon, USA in 1987 to
1989 and followed them at two time points (1 year later,
and on their 24th birthday). Assessment of ADs was
undertaken utilizing the Schedule for Affective Disorders
and Schizophrenia for School-Age Children (K-SADS) for
DSM-III revision (DSM-III-R) [16], and smokers were
defined as those smoking ≥ 3 times per week. Brown et al.
[17] demonstrated no difference in the odds for incident
smoking at 1-year follow-up in those with versus without
any ADs at baseline, both unadjusted and after controlling
for a variety of demographic and other risk factors. This
finding of no association was replicated in the 24-year-old
follow-up [18] although only PD, and not grouped ADs,
was used as the exposure variable.
Breslau et al. [19] utilized a random population sample
of 1,007 young adults (21 years to 30 years), drawn from
the Detroit Epidemiologic Study, to examine PD as a pre-
dictor of cigarette smoking. Baseline assessment occurred
in 1989 and three follow-ups (1990, 1992 and 1994) were
conducted. Diagnosis of PD was made through use of the
National Institute of Mental Health Diagnostic Interview
Schedule [20] for DSM-III-R criteria, and ‘daily smoking’
was defined as smoking daily for ≥ 1 month. Risk of smok-
ing onset was increased in those with PD at baseline (HR
= 2.20 (95% CI 1.10 to 4.42)), but this significance was lost
when controlled for the presence of major depressive dis-
order (MDD). Breslau et al. [21] extended their investiga-
tion, incorporating two further follow-ups (1999 and
2001) to assess the interaction between PTSD and ND
over 10 years. After adjusting for gender, race and educa-
tion, the odds of incident ND at follow-up was 4.03 (95%
CI 2.10 to 7.72) in those with baseline PTSD versus those
without a trauma history.
Johnson et al. [22] followed a random sample of adoles-
cents from New York state, assessed at baseline in 1983
(mean age 14 years) and at two subsequent follow-ups in
1985 to 1986 (mean age 16 years) and 1991 to 1993 (mean
age 22 years). Diagnosis of ADs (grouped and individual)
at baseline was made using the Diagnostic Interview Sche-
dule for Children (DIS-C) [23] to DSM-III criteria. Smok-
ing assessment was by self-report, and categorized into
smoking > 1 pack (20+ cigarettes) versus smoking < 1
pack (1 to 19 cigarettes) per day (not non-smokers). After
adjusting for a variety of demographic and other risk
factors no association was detected between adolescent
anxiety disorder status and onset of smoking in adulthood.
The Early Developmental Stages of Psychopathology
(EDSP) study has been utilized to assess the association
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between ADs, ND and smoking behavior. In this study, a
random community cohort of 3,021 adolescents and
young adults (age 14 years to 24 years) was sampled from
metropolitan Munich. The cohort was assessed at baseline
(1995) and two follow-ups, the first between 1996 and
1997 and the second between 1998 and 1999 (a third fol-
low-up was subsequently conducted in 2005 to 2006) [24].
AD and ND diagnoses were made utilizing an updated
version [25] of the Composite International Diagnostic
Interview [26] for DSM-IV criteria and smoking was
assessed by self-report. Isensee et al. [27] categorized par-
ticipants from the EDSP into non-smokers, occasional
smokers, non-dependent regular smokers and dependent
regular smokers (see Additional file 1, Table S1 for defini-
tions) and calculated odds ratios for incident smoking by
baseline AD status. No associations were found between
baseline AD status and odds of incident smoking. Sonntag
et al. [28] extended this study in SP but once again found
Figure 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) search strategy flow diagram.
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no association, although a positive association was found
between those with social fears symptoms and later devel-
opment of ND.
Woodward et al. [29] utilized a New Zealand birth
cohort to compare the risk of DSM-IV ND between the
ages of 18 and 21, dependent upon diagnosis of ADs
between the ages of 14 to 16. A linear association was
found between increasing number of ADs at age 14 to
16 (0 to 3+) and subsequent ND diagnosis, although
this was not significant after controlling for childhood
sexual abuse, alcohol abuse, parental changes and devi-
ant peer affiliations.
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Figure 2 Included studies: prospective, quasiprospective and cross-sectional association information obtained from each study.
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Chou et al. [30] utilized the National Epidemiologic
Survey on Alcohol and Related Conditions (NESARC)
to investigate the association between ADs and ND in
adults age 60 years and older (n = 8,012). Diagnoses
were made utilizing the Alcohol Use Disorders and
Associated Disabilities Interview Schedule for DSM-IV
criteria (AUDADIS-IV) [31] and the risk of incident ND
was assessed between baseline (2000 to 2001) and fol-
low-up (2004 to 2005). No associations were found
between baseline AD status and subsequent ND.
Cuijpers et al. [32] utilized data from the Netherlands
Mental Health Survey and Incident Study (NEMESIS) to
investigate the relationship between incident ADs
(expressed as incident rate ratios) and previous smoking
status. The NEMESIS study randomly recruited adults
(18 years to 64 years) from 90 municipalities in The
Netherlands, undertaking baseline assessments and 2 fol-
low-ups at 1 year and 3 years (n = 4,796). The CIDI [26]
was used for DSM-III-R diagnoses, and smoking was
assessed by self-report, with participants placed into 4
categories (non-smokers, 1 to 9 cigarettes daily, 10 to 19
cigarettes daily and 20+ cigarettes daily). In a follow-up
analysis, having 12-month (incidence rate ratio (IRR)
4.46 (P < 0.05)) and lifetime GAD (IRR 4.46 (P < 0.05))
was associated with increased risk of smoking onset at
follow-up.
Johnson et al. [33] utilized the prospective follow-up of
the full NESARC database (n = 34,653) to assess the
impact of AD on smoking onset and persistence.
Grouped ADs were associated with reduced daily smok-
ing onset (OR 0.62 (95% CI 0.39 to 0.99)) when adjusting
for demographics and socioeconomic status, but not with
smoking persistence. Interestingly, comorbid substance
use was an effect modifier; respondents with a comorbid
substance use disorder (for example, alcohol, marijuana,
amphetamines, opioids, sedatives, tranquilizers, cocaine,
inhalants, hallucinogens, heroin, and other drugs) and
AD demonstrated an increased risk of daily smoking
onset (OR 2.22 (1.01 to 4.91)), whereas those without
comorbid substance use disorder had a decreased risk of
smoking onset (OR 0.43 (0.23 to 0.78)).
Most recently, Swendsen et al. [34] utilized a 10-year
follow-up of 5,001 participants drawn from the National
Co-morbidity Survey (NCS) to investigate mental disor-
ders as a risk factor for onset of daily smoking or ND. The
NCS, conducted in the US between 1990 and 1992, was a
stratified multistage probability sample of 8,098 non-
institutionalized residents (age 15 years to 54 years), utiliz-
ing the CIDI (V1.1), that assessed the interaction between
smoking, ND and DSM-III-R mental disorders. The
NCS2, performed in 2001 to 2002, was a 10-year re-inter-
view of 5,001 participants from the NCS, but which uti-
lized an updated version CIDI (V3.0) for DSM-IV criteria.
After adjusting for sociodemographic characteristics, the
odds of commencing daily smoking was increased for
respondents with baseline PD, SP, GAD and specific pho-
bia, but not for those with baseline PTSD or agoraphobia.
In contrast, in those respondents with baseline daily smok-
ing the odds of ND onset were raised in PTSD, agorapho-
bia and specific phobia, but not PD, SP or GAD. When
considering the whole population odds of ND onset, hav-
ing baseline PTSD, SP and specific phobia conferred an
increased risk (see Additional file 1, Table S1).
Smoking and nicotine dependence as risk factors for later
anxiety disorders
(A summary of this section is as follows (see also Addi-
tional file 2, Table S2): the available prospective evidence
associating smoking and nicotine dependence as risk fac-
tors for incident anxiety disorders is limited and hetero-
geneous. However, smoking has been demonstrated as a
risk factor for grouped anxiety disorders, panic disorder
and generalized anxiety disorder in a number of studies,
although these findings are not replicated in all studies.)
Data from the Oregon Adolescent Depression Project
were utilized to assess the relationship between baseline
smoking status and incident ADs. Goodwin et al. [18]
demonstrated an association between increased odds of
PD diagnosis at age 24 in those with daily smoking at
baseline versus those not smoking daily (OR 5.1 (2.4 to
10.5)), which remained significant after controlling for
other ADs and parental risk factors. No other associa-
tions were found.
Utilizing data from the Detroit Epidemiologic Study,
Breslau et al. [19] found increased risk of subsequent PD
onset in individuals with prior daily smoking even when
controlling for gender and MDD (HR 13.13 (4.41 to
39.10)). In addition, prior daily smokers who continued to
smoke were more likely to experience incident PD (HR
14.46 (4.81 to 43.5)) when controlled for gender and
MDD.
In the New York Adolescent Cohort, relationships
were discovered between odds of adult ADs when
grouped (OR 10.78 (1.48 to 78.55)), GAD (OR 5.53
(1.84 to 16.66) and PD (OR 15.58 (2.31 to 105.14) when
comparing baseline > 1 pack per day smokers versus < 1
pack per day smokers [22]. Data from the EDSP studies
[27] demonstrated relationships between increased inci-
dent PD, agoraphobia, SP and PTSD when comparing
baseline ND smokers versus non-users, however all
associations became non-significant when controlled for
comorbid conditions at baseline (depressive disorders,
panic attacks, other ADs, alcohol and drug disorders,
and eating disorders). In the NESARC study, Chou et al.
[30] assessed the relationship between ND at baseline
and subsequent ADs, finding no associations.
Cuijpers et al. [32] utilized data from the NEMESIS to
investigate the relationship between incident ADs
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(expressed as incident rate ratios) and past smoking sta-
tus. Smoking at 1-year follow-up was associated with
increased incidence of grouped ADs (IRR 1.77 (1.10 to
2.86)) and GAD (IRR 3.80 (1.09 to 13.21)) after control-
ling for demographics and other risk factors. No other
relationships were found (see Additional file 2, Table
S2).
Quasiprospective studies
(A summary of this section is as follows: a small number
of studies have utilized a single time point analysis and ret-
rospective self-report patient data to draw quasiprospec-
tive associations between smoking, ND and ADs. These
studies generally indicate increased smoking behaviors or
nicotine dependence in individuals with pre-existing anxi-
ety disorders, and vice versa, although studies are limited
by the retrospective nature of data.)
Baseline anxiety disorders and risk of smoking or
nicotine dependence
See also Additional file 3, Table S3. Breslau et al. [35]
examined the 4,411 participants who completed the
tobacco supplement of the NCS to assess the interaction
between smoking, ND and DSM-III-R ADs, utilizing dis-
crete time survival models with ADs as time dependent
variables and controlling for race, gender, education and
age. The onset of daily smoking was the age at which
respondents first smoked daily for ≥ 1 month. Increased
odds for daily smoking were found in patients with pre-
existing (OR 1.9 (1.05 to 3.7)) or currently active GAD
(OR 2.1 (1.1 to 3.9)), pre-existing (OR 1.6 (1.3 to 1.8)) or
currently active specific phobia (OR 1.5 (1.3 to 1.8)), pre-
existing (OR 1.5 (1.2 to 1.7)) or currently active SP (OR
1.3 (1.1 to 1.6)), and pre-existing (OR 2.1 (1.6 to 2.9)) or
currently active PTSD (OR 2.0 (1.4 to 2.9)).
Breslau et al. [35] further investigated the odds of smok-
ing persistence and the transitioning from daily smoking
to ND based upon pre-existing and currently active ADs.
Increased odds of transitioning from daily smoking to ND
were found in individuals with pre-existing and currently
active agoraphobia, specific phobia, SP and PTSD. Inter-
estingly, having pre-existing, but not currently active, PD
was also strongly associated with increased odds of daily
smoking to ND transition (OR 5.8 (3.0 to 11.6)). No asso-
ciations existed between odds of smoking persistence and
any pre-existing AD.
Koenen et al. [36] utilized data from the national Viet-
nam Era Twin (VET) registry and retrospective self-report
of age of onset to test prospective onset associations
between DSM-III-R ADs and ND. Associations were con-
trolled for various demographic and other risk factors and
time-dependent covariates (conduct disorder, MDD, alco-
hol and drug abuse or dependence) were entered into
models. The results demonstrated that pre-existing PTSD
was associated with increased odds of subsequent ND (OR
1.73 (1.38 to 2.17)). Utilizing the Greater Smoky Mountain
Study (GSMS), a longitudinal representative study of 4,500
children (aged 9 years, 11 years and 13 years) from
western North Carolina, USA, Costello et al. [37] found
children, both boys and girls, with any AD were more
likely to commence smoking than those without an AD
(see Additional file 3, Table S3).
Smoking and nicotine dependence and risk of incident
anxiety disorders
See also Additional file 4, Table S4. Breslau et al. [38] uti-
lized the NCS, including respondent recall about their
age of smoking and ND onset, to assess the effect of
these parameters on developing ADs. Adjusting for
demographic characteristics, pre-existing daily smoking
(defined as onset > 1 year prior to disorder onset) was
associated with increased odds of PD (OR 2.6 (1.2 to
5.4)) and agoraphobia (OR 4.4 (2.3 to 8.2)). The role of
ND was assessed across all ADs. In this analysis, ND
smokers and non-ND smokers maintained increased
odds of PD and agoraphobia, but no other ADs. The only
other associations were found in relation to past smokers
(without ND) who exhibited decreased odds of PTSD
(OR 0.2 (0.1 to 0.5)) when controlled for demographics
and other pre-existing psychiatric disorders. Breslau et al.
[38] extended their study by comparing the age of smok-
ing onset (early vs not early; see Additional file 4, Table
S4 for definitions), standardized pack years of smoking
and time since quitting against odds of AD diagnosis. No
association was found between early onset smoking and
ADs, but increased years since quitting was associated
with decreased odds of subsequent PD (OR 0.5 (0.4 to
0.7)), agoraphobia (OR 0.5 (0.5 to 0.8)) and SP (OR 0.6
(0.4 to 0.8)). The associations between standardized pack
years of smoking were not significant in all ADs except
PD, where increased pack years of smoking appeared
protective in current smokers but a risk factor in past
smokers, and GAD where increased pack years was asso-
ciated with increased odds of GAD in both current and
past smokers.
In a separate analysis utilizing a subsample of NCS data,
Breslau et al. [19] investigated the interaction between
smoking characteristics and subsequent onset of PD. Sig-
nificant relationships were discovered between prior daily
smoking (HR 2.93 (1.84 to 4.66)) and smoking persistence
in prior daily smokers (HR 3.18 (1.99 to 5.10)) and subse-
quent onset of PD. In addition, pre-existing ND was asso-
ciated with increased odds of subsequent PTSD onset (OR
2.24 (1.78 to 2.83)) in the aforementioned study drawn
from the VET registry [36].
Cross-sectional studies
(A summary of this section is as follows (see also Addi-
tional file 5, Table S5): a large number of studies have
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reported cross-sectional relationships between cigarette
smoking, nicotine dependence and anxiety disorders.
Many demonstrate higher rates of smoking and nicotine
dependence in those with anxiety disorders, and vice
versa. However, their utility is limited due to their inher-
ent inability to provide insight into direction of causality.)
Almost all studies included in this review reported
cross-sectional associations between smoking and/or
ND and ADs. Studies providing cross-sectional informa-
tion [6,7,17,19,23,27,28,32,39-67] are listed in Additional
file 5, Table S5. Descriptions of some selected larger
studies utilizing population-based data are detailed
below.
Smoking or nicotine dependence by anxiety disorder
status
Lasser et al. [59] utilized the NCS to demonstrate
increased rates of current and lifetime smoking in
respondents with current and lifetime SP (39.5% and
54%), agoraphobia (38.4% and 58.9%), PD (35.9% and
61.3%), specific phobia (40.3% and 57.8%), PTSD (45.3%
and 63.3%) and GAD (46% and 68.4%) when controlling
for gender, age and geographical region. Utilizing the
NCS-R data, Cougle et al. [44] explored the role of
comorbidity in the association between ADs and smoking
behavior. After controlling for demographics, depression
and drug abuse/dependence, associations between
increased odds of lifetime and 12-month daily smoking
were observed with PTSD (Lifetime: OR 1.58 (1.21 to
2.06); 12-month: OR 1.46 (1.08 to 1.97)), 12-month daily
smoking with PD (OR 1.42 (1.04 to 1.94)), and Lifetime
daily smoking with GAD (OR 1.23 (1.05 to 1.61)).
In a nationally representative sample of the New
Zealand population, individuals with ADs (grouped)
had a smoking prevalence of 30.4% (27.7 to 33.0), and
consumed approximately 16% of all cigarettes in New
Zealand [7]. In Australia, data from the nationally
representative National Survey of Mental Health and
Wellbeing 2007 reported rates of current and daily
smoking in those with individual ADs (range for cur-
rent smoker: 33% to 45%; range for daily smoker: 27%
to 42%) well above the rates in respondents not report-
ing a mental disorder (current: 13.6%; daily: 10.8%) [6].
Cougle et al. [44] demonstrated increased odds of ND
in patients with SP (OR 1.31 (1.01 to 1.71)), GAD (OR
1.59 (1.21 to 1.98)) and PTSD (OR 1.47 (1.01 to 2.16))
when adjusting for demographics, depression and drug
abuse/dependence. Utilizing the NESARC for adults
aged 18 to 25 years [46], the odds of 12-month ND
were significantly increased for respondents with life-
time specific phobia (OR 1.8 (1.16 to 2.88)) after con-
trolling for other psychiatric disorders, smoking and
demographic characteristics.
Anxiety disorder by smoking or nicotine dependence
status
Utilizing the German Transitions in Alcohol Consumption
and Smoking study, Schumann et al. [64] calculated unad-
justed odds ratios for individual ADs based on smoking
and ND status. When comparing ND ever smokers
(respondents with ND who had smoked at least one cigar-
ette daily for ≥ 4 weeks at some point in their life) to non-
ND ever smokers, increased odds were found for PD (OR
2.92 (1.78 to 2.73)), SP (OR 3.07 (1.70 to 5.57)), specific
phobia (OR 2.09 (1.63 to 2.68)), GAD (OR 4.26 (1.85 to
9.84)) and PTSD (OR 2.08 (1.13 to 3.83)). Grant et al. [52]
used data from NESARC to compare the odds of ADs on
ND status. Unadjusted odds ratios with individual ADs as
dependent variables were greater across all assessed ADs.
Point estimates for odds ratios ranged from 2.6 for SP to
4.6 for PD with agoraphobia for respondents with versus
without ND. Data from the UK National Households Sur-
vey [49] demonstrated increased rates of GAD (4.1% vs
2.4%), specific phobia (1.5% vs 0.8%) and PD (1.5% vs
0.5%) in respondents with ND versus those without ND.
Degenhardt et al. [45] utilized the 1997 National Survey of
Mental Health and Wellbeing in Australia to demonstrate
increased odds of ADs (grouped) in current smokers ver-
sus never smokers (OR 1.50 (1.21 to 1.87)) when adjusted
for demographic status, other drug use and neuroticism.
Discussion
Our systematic review of the literature revealed a total of
17 studies that provided prospective or quasiprospective
information regarding the relationship between ADs, ND
and cigarette smoking. Of these studies 14 provided pro-
spective or quasiprospective information on the role of
ADs on the risk of smoking or ND, and 7 studies provided
the role of daily smoking or ND on onset of ADs. A
further 31 studies reported only cross-sectional relation-
ships between smoking, ND and ADs. The association
between smoking, ND and ADs could be explained by
three non-mutually exclusive relationships; smoking and
ND leads to increased ADs, the reverse association, or a
shared vulnerability model where a factor or group of fac-
tors increase smoking, ND and AD expression.
Are anxiety disorders a risk factor for smoking onset?
A relatively common hypothesis links increased anxiety
with smoking onset and increased smoking behaviors.
Multiple studies conducted in both general and clinical
populations have demonstrated increased rates of smok-
ing amongst individuals with all AD subtypes [68-70],
although exceptions exist [71]. The results of these pro-
spective, quasiprospective and cross-sectional studies are
inconsistent, and importantly, many of these studies
have failed to take into account the important role of
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comorbid substance use disorders. In a study of patients
with ADs where those with alcohol and substance use
disorders were excluded, rates of smoking were lower
than the control population [72], indicating comorbid
illness is important in understanding this association.
This review found a limited and heterogeneous litera-
ture evaluating the prospective effect of ADs on smoking
onset in random population samples. The available data
varied significantly on population characteristics (whole
population vs specific age range), length of prospective
follow-up (1 year to 10 years), diagnostic tool utilized
and smoking definition. On balance, the 10-year follow-
up of the National Comorbidity Survey [34] represents
the likely best evidence available to date. From this analy-
sis, baseline PD, SP, GAD and specific phobia, but not
PTSD or agoraphobia, were associated with increased
odds of commencing daily smoking. There are however
important considerations in interpreting this study. First,
the diagnostic classification system utilized in the first
NCS (DSM-III-R) was updated in the NCS2 (DSM-IV).
Although there is a large concordance between these
diagnostic classifications across most ADs, some signifi-
cant differences exist, particularly in the criteria of PTSD,
which may have altered relative prevalence rates [73].
Second, and most importantly, the presented analyses did
not control for the presence of other psychiatric disor-
ders or for alcohol or drug abuse/dependence. As noted
by Cougle et al. [44], ADs are often comorbid disorders,
particularly with MDD and substance abuse disorders. In
other presented prospective studies, univariate relation-
ships between PD and smoking onset failed to sustain
significance when comorbid MDD was included in the
analytic models [19], and the presence of a comorbid
substance use disorder reversed the direction of effect of
baseline AD from protective to causative in the NESARC
cohort [33]. The NCS follow-up revealed larger increased
odds of daily smoking onset in respondents with alcohol
or other substance abuse/dependence (OR point esti-
mates between 2.6 and 4.2). As such, it is probable that
some of the association between ADs and smoking is due
to effects of comorbid substance abuse disorders.
Considering that most of the other available prospective
studies failed to find significant associations between ADs
and subsequent onset of smoking, it is currently difficult
to draw definitive conclusions regarding AD as a risk fac-
tor for smoking. One potential factor that should be taken
into account is the populations considered in the available
literature. Population-based studies suggest that the aver-
age age individuals first use cigarettes has been declining,
and now ranges between 12 years and 16 years [74]. In
addition, smokers who commence earlier are more likely
to persist than those that commence at a later age [75].
Given that most of the included studies assessed adult
populations, it is possible many participants with ADs
were already smoking and hence new onset smoking was
relatively rare in assessed populations. In contrast to
cross-sectional analyses, very limited prospective informa-
tion is available on varying characteristics of smoking
behavior (for example, persistence) and ADs in the avail-
able prospective studies.
Some studies have used a quasiprospective design, pair-
ing cross-sectional data with retrospective self-report data,
to assess the impact of ADs on smoking status. Such stra-
tegies are limited by recall bias, and any conclusions
drawn must consider this. Analysis of the NCS by Breslau
et al. [35] found increased odds of daily smoking in those
with a variety of pre-existing or current ADs. However,
these analyses did not control for the effects of comorbid
substance use disorders or other psychiatric disorders and,
additionally, were limited to onset of daily smoking as
opposed to smoking more generally. When considering
the effects of pre-existing ADs on smoking persistence, no
significant associations were found.
A number of theories are proposed to explain why ADs
may lead to increased rates of smoking. Theoretical expla-
nations are informed by both psychological (for example,
conditioning theory, cognitive theory, anxiety sensitivity
[76]) and biological (for example, nicotine effects and
withdrawal) factors. One explanatory model relates to the
use of cigarettes as an anxiolytic agent (that is, self-treat-
ment). Evidence supports that nicotine exposure does pro-
duce a subjective calming effect, although this is coupled
with an increase in objective measures of physiological
arousal [77]. Tachyphylaxis and homeostatic adjustment
however implies that acute and chronic effects of cigar-
ettes, as with any agents that induce tolerance and depen-
dence, may differ substantially. Treatment of this extensive
literature is beyond this review, although we refer readers
to a number of excellent comprehensive reviews on this
subject [78-81], which include identification of the metho-
dological challenges in exploring the effect of anxiety traits
and states on smoking behaviors.
Are anxiety disorders a risk factor for later nicotine
dependence?
Inconsistent although clearer associations between base-
line ADs and subsequent ND were found in the literature.
In the 10-year follow-up of the NCS [34], having baseline
PTSD, agoraphobia and specific phobia were associated
with increased odds of onset of ND amongst already smo-
kers, and PTSD, SP and specific phobia were associated
with increased odds for ND amongst the whole popula-
tion. The clear association between baseline PTSD and
ND was replicated by Breslau et al. [21] in the Detroit
Epidemiologic Study, while Isensee et al. [27] found base-
line PD to be associated with increased risk for subsequent
ND. Given anxiety disorders are associated with negative
affect [82], and negative affect is linked to increased
Moylan et al. BMC Medicine 2012, 10:123
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smoking motivation [83], it is possible that negative affect
may underpin an increased likelihood to developing ND in
those with ADs. Further evidence demonstrating an effect
of duration of anxiety disorder diagnosis and later ND
severity would be useful.
Is smoking or nicotine dependence a risk factor for
onset of anxiety disorders?
A limited number of prospective studies are available
assessing smoking or ND as risk factors for incident ADs
in population-based epidemiological studies. The avail-
able literature supports ND as increasing the odds of
later PTSD, and smoking as increasing the odds for some
(PD and GAD), but not all, ADs and interpretation of
some analyses are complicated by non-inclusion of
potential confounders. For example, the prospective odds
of PD onset were increased in the Oregon Adolescent
Depression Project, the New York Adolescent Cohort
and the EDSP in individuals with a history of prior smok-
ing versus non-smokers. This result remained significant
when controlling for other ADs in the Oregon Adoles-
cent Depression Study, but failed to maintain significance
when comorbid psychiatric disorders were controlled for
in the EDSP study. However, smoking as a risk factor for
PD is supported by the Detroit Epidemiologic Study,
which found increased risk of PD onset in prior daily
smokers, with a stronger association in prior daily smo-
kers who continued to smoke. These analyses controlled
for MDD, but not other psychiatric or substance use dis-
orders. The use of quasiprospective methodology on data
from the NCS allowed further exploration of this rela-
tionship. These data suggested that daily smoking was a
risk factor for increased odds of PD and agoraphobia,
with analyses controlling for other psychiatric disorders
including substance use disorders [38]. A demonstrated
dose-dependent relationship would support a causal
association between cigarette smoking and subsequent
onset of ADs. Breslau demonstrated that increased stan-
dardized pack years of smoking were associated with
increased odds of GAD, but decreased odds of PD [38] in
dose dependent fashion.
The interaction between panic, PD and cigarette smok-
ing has received more investigation in epidemiological
and laboratory-based studies than other ADs, and the
evidence was recently reviewed [84]. The literature has
demonstrated that earlier age of smoking initiation is
associated with increased risk of PD [85], and smokers
demonstrated earlier PD onset in comparison to non-
smokers [86]. Given the somatic nature of panic attack
symptomatology, it is possible that smoking may be more
likely to produce panic-type AD symptoms secondary to
the physical effects of smoking (for example, respiratory
and autonomic disturbance). Panic is influenced by
respiratory sensitivity, and nicotine alters the sensitivity
set point of cholinergic respiratory neurons [87]. From
their review of the literature, Cosci et al. [84] nominated
three potential hypotheses underpinning the association
between cigarette smoking and panic. The first is a ‘mod-
erational model’, whereby neuroticism moderates the
panic/smoking association. The second is a ‘pathoplastic
model’, where smoking influences PD expression by
‘exacerbating affective disturbances and negative health
process’ [88], including a combination of direct negative
health effects (for example, induction of chronic obstruc-
tive pulmonary disease (COPD)), acute physiological
effects (for example, increased noradrenaline and auto-
nomic sensations) and negative self-perception of health
status [89]. The third is the ‘false suffocation alarm’ the-
ory, proposed by Klein [90], who suggested that smoking
may induce hypersensitivity to suffocation signals and
increase the risk of experiencing panic. The suffocation
false alarm may potentially be mediated by episodic dys-
function in regulation of endogenous opioid function
[91].
A number of studies have assessed the interaction of
smoking and PTSD. A population-based follow-up investi-
gation of individuals affected by a fireworks factory explo-
sion in The Netherlands found that those who were
smokers at time of traumatic incident had an increased
chance of experiencing severe anxiety symptoms (OR 2.32
(1.19 to 4.53)) and disaster related PTSD (OR 2.64 (1.05 to
6.62)) at 4-year follow-up, controlling for baseline symp-
toms, demographic characteristics and life events [92].
This supports the results of Koenen et al. [36], who
demonstrated that the presence of ND increased the risk
of developing PTSD in trauma exposed men (HR 1.98
(1.61 to 2.42)) and that shared genetic effects explained
63% of the ND-PTSD association. A number of neurobio-
logical (for example, alterations to the hypothalamic-pitui-
tary-adrenal axis, sympathetic nervous system
hyperactivity alteration to neurotransmitter system func-
tioning) and psychological factors may contribute to a
PTSD, ND and cigarette smoking association (see Fu et al.
[93] for review). ND may increase ADs by exacerbating
anxiety responses [94], or by facilitating other psychiatric
states (for example, depression) that may predispose indi-
viduals to develop anxiety. In addition, the number of ND
symptoms and nicotine withdrawal symptoms has been
robustly correlated in a dose-dependent fashion with
increasing anxiety disorder diagnosis [56]. In reference to
other ADs, supportive evidence was found for smoking
increasing the odds of developing GAD, while no evidence
was found to support smoking as a risk factor for onset of
SP, although some evidence supports the reverse associa-
tion in female ND smokers [28].
In assessing smoking or ND as a risk factor for ADs,
one factor that must be considered is that ADs have
been estimated to exhibit a median age of onset of only
Moylan et al. BMC Medicine 2012, 10:123
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6 years [95]. Given the early age of AD development,
from early childhood through adolescence, exposure to
environmental cigarette smoke may influence AD devel-
opment. Exposure to second-hand smoke has been
demonstrated to be positively associated with symptoms
of GAD, but not PD in children and adolescents age 8
years to 15 years [96]. Additionally, early onset smoking
(10 to 15 years) has been associated with an earlier
onset of ADs when compared to late onset smoking (>
15 years) [97]. It is possible that exposure to cigarette
smoke in critical periods of brain development may be
one factor that predisposes individuals to subsequent
develop ADs. A number of biological pathways may
underpin this effect, including alteration in neurotrans-
mitter function, and induction of oxidative and nitrosa-
tive stress that may overwhelm intrinsic defenses
inhibiting normal neuronal cell functions, including neu-
roplasticity and neurogenesis.
Shared vulnerability between smoking, ND and ADs
A number of shared vulnerability factors contribute to
cigarette smoking behavior and ADs, including early child-
hood experiences and environment [83,98,99], problems
with impulsivity [100] and distress tolerance and neurotic
personality traits [101,102]. Indeed, it is possible that these
shared vulnerability factors are further underpinned by
other factors (for example, genetics, fetal insults), and ADs
and cigarette smoke could alter their expression (for
example, cigarette smoking may reinforce poor distress
tolerance). For a more detailed discussion of the role and
interaction of shared vulnerability factors see the review
by Morissette et al. [79].
Limitations and directions for future research
It is important to consider the limitations of this study
design in interpreting the results. This review was
designed deliberately to only consider random, large gen-
eral population samples where validated structured diag-
nostic tools were utilized to make diagnoses. Effort was
made to identify all studies meeting inclusion criteria,
although it is possible some important sources of infor-
mation were not identified, particularly from non-English
language journals. The inclusion criteria were designed
to allow for selection of only the best quality evidence
not restricted by certain biases (for example, selection
bias, recall bias) although as consequence of this a num-
ber of identified studies involving samples drawn from
clinic populations [72,103-105] and studies which utilized
anxiety symptom scores [8] or non-validated diagnostic
tools (for example, self-report) as end points were
excluded from final analysis. The heterogeneous nature
of included studies, particularly in regards to population
demographics; smoking definition; diagnostic criteria uti-
lized; diagnostic group included; and comorbid factors
included in analysis also complicates interpretation. A
number of future studies would assist in clarifying issues
from this review. First, the continuation of current pro-
spective cohorts over longer periods and the recruitment
of new cohorts, incorporating and measuring changes to
smoking behavior over time, would assist in clarifying the
relationship between smoking and ADs. Similarly, given
the early onset nature of many ADs, maternal and birth
cohorts assessing these issues would assist greatly in dee-
pening our understanding. Exploration of the effects of
quitting on anxiety and depression would also clarify
associations. In addition, further exploration of potential
biological mechanisms underpinning associated effects of
smoking and ADs would help to elucidate shared vulner-
abilities underpinning both ADs and smoking.
Conclusions
A large literature has demonstrated that individuals with
ADs have higher rates of smoking and ND than those
without ADs, although most extant information is drawn
from cross-sectional studies. In terms of prospective stu-
dies, there exists a limited heterogeneous literature exam-
ining the relationship between cigarette smoking, ND and
ADs in population-based epidemiological studies utilizing
structured diagnostic tools linked to ICD or DSM criteria.
The available prospective evidence provides support for
smoking and ND as being risk factors for the onset of PD
and GAD, although varied results are found across studies.
In addition, some ADs have been associated with subse-
quent onset of smoking and ND, although many studies
failed to include comorbid substance use disorders and
other psychiatric disorders in analyses.
Additional material
Additional file 1: Table S1. Prospective longitudinal studies
investigating influence of anxiety disorders on subsequent risk of
smoking and nicotine dependence (ND).
Additional file 2: Table S2. Prospective longitudinal studies
investigating influence of smoking and nicotine dependence (ND) on
subsequent risk of anxiety disorders.
Additional file 3: Table S3. Quasiprospective studies investigating
influence of anxiety disorders on subsequent risk of smoking and
nicotine dependence (ND).
Additional file 4: Table S4. Quasiprospective studies investigating
influence of smoking and nicotine dependence (ND) on subsequent risk
of anxiety disorders.
Additional file 5: Table S5. Cross-sectional studies investigating
associations between anxiety disorders, nicotine dependence (ND) and
smoking.
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Abstract
Multiple studies have demonstrated an association between cigarette smoking
and increased anxiety symptoms or disorders, with early life exposures potentially
predisposing to enhanced anxiety responses in later life. Explanatory models sup-
port a potential role for neurotransmitter systems, inﬂammation, oxidative and
nitrosative stress, mitochondrial dysfunction, neurotrophins and neurogenesis,
and epigenetic effects, in anxiety pathogenesis. All of these pathways are affected
by exposure to cigarette smoke components, including nicotine and free radicals.
This review critically examines and summarizes the literature exploring the role
of these systems in increased anxiety and how exposure to cigarette smoke may
contribute to this pathology at a biological level. Further, this review explores the
effects of cigarette smoke on normal neurodevelopment and anxiety control, sug-
gesting how exposure in early life (prenatal, infancy, and adolescence) may pre-
dispose to higher anxiety in later life. A large heterogenous literature was
reviewed that detailed the association between cigarette smoking and anxiety
symptoms and disorders with structural brain changes, inﬂammation, and cell-
mediated immune markers, markers of oxidative and nitrosative stress, mito-
chondrial function, neurotransmitter systems, neurotrophins and neurogenesis.
Some preliminary data were found for potential epigenetic effects. The literature
provides some support for a potential interaction between cigarette smoking,
anxiety symptoms and disorders, and the above pathways; however, limitations
exist particularly in delineating causative effects. The literature also provides
insight into potential effects of cigarette smoke, in particular nicotine, on neuro-
development. The potential treatment implications of these ﬁndings are discussed
in regards to future therapeutic targets for anxiety. The aforementioned pathways
may help mediate increased anxiety seen in people who smoke. Further research
into the speciﬁc actions of nicotine and other cigarette components on these
pathways, and how these pathways interact, may provide insights that lead to
new treatment for anxiety and a greater understanding of anxiety pathogenesis.
Introduction
Cigarette smoking is the single biggest contributor to
death and morbidity worldwide (Gellert et al. 2012).
Smoking rates are signiﬁcantly higher in anxiety-
disordered populations (Lasser et al. 2000; Tobias et al.
2008; Lawrence et al. 2010), and numerous studies support
a relationship between cigarette smoking and psychiatric
disorders (see review Dome et al. 2010). Three nonmu-
tually exclusive models may explain the smoking–anxiety
association (Moylan et al. 2012a). First, smoking may lead
to increased anxiety; second, anxiety may increase smoking
rates; or third, smoking and anxiety rates may both be
inﬂuenced by shared vulnerability factor(s).
ª 2013 The Authors. Published by Wiley Periodicals, Inc. This is an open access article under the terms of the Creative
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Evidence suggests that individuals with increased anxiety
are more likely to smoke (Brown et al. 1996; Patton et al.
1998; Sonntag et al. 2000; Goodwin et al. 2005; Cuijpers
et al. 2007; Swendsen et al. 2010). Multiple factors have
been proposed to explain this, including use of cigarettes to
reduce anxiety (i.e., self-treatment) and an increased sus-
ceptibility of those with anxiety in initiating smoking in
response to peer pressure (Patton et al. 1998; Tjora et al.
2011). In addition, smoking appears to increase the risk of
developing increased anxiety (Breslau and Klein 1999;
Johnson et al. 2000; Isensee et al. 2003; Goodwin et al.
2005; Cuijpers et al. 2007; Pedersen and von Soest 2009).
Potential explanatory models for this include the effects of
smoking on neurotransmitters, neurobiology, respiratory
health and autonomic control (Klein 1993; Niedermaier
et al. 1993; Zvolensky et al. 2003; Zvolensky and Bernstein
2005; Preter and Klein 2008), in addition to effects on nor-
mal neurodevelopmental (Dwyer et al. 2008; Iniguez et al.
2009). Finally, numerous shared vulnerability factors have
been identiﬁed that may increase the likelihood of both
smoking and increased anxiety (Reichborn-Kjennerud
et al. 2004; Hettema et al. 2005). For example, lower socio-
economic status is associated with both increased smoking
behaviors (Schaap and Kunst 2009; Tjora et al. 2011) and
anxiety (Kessler et al. 2005).
Despite the signiﬁcant health impacts arising from the
comorbidity between smoking and anxiety, the biological
mechanisms underpinning this association have received
less investigation than for other psychiatric disorders. The
relationship between smoking and anxiety is complex as
evidence supports that cigarette smoke can reduce anxiety
in some smokers (see review Morissette et al. 2007). In
addition, smokers often report increased anxiety post
smoking cessation, although recent data conﬂict with this
ﬁnding (Bolam et al. 2011; McDermott et al. 2013). There
is also signiﬁcant heritability in both anxiety expression
and smoking behaviors.
Recent advances in understanding the etiology of mood
and anxiety disorders support a key role for neurotransmit-
ter systems, the immune system, oxidative and nitrogen
stress (O&NS), mitochondrial dysfunction, neurotrophins
(NTs) and neurogenesis, and epigenetic effects in patho-
genesis (Berk et al. 2011; Moylan et al. 2012b). All of these
systems are affected by exposure to cigarette smoke.
This review critically examines and summarizes the
literature that has explored how cigarette smoking may
increase the likelihood of developing increased anxiety
and anxiety disorders. In this review, we focus on rele-
vant biological mechanisms (e.g., neurotransmitter sys-
tems, inﬂammation, oxidative and nitrosative stress,
mitochondrial dysfunction, dysregulation of NTs and
neurogenesis, and epigenetic effects) that potentially
mediate how smoking may inﬂuence anxiety symptoms.
Extensive literature has explored numerous psychological
and social contributors to a relationship between anxiety
and cigarette smoking. Readers interested in these path-
ways should consult the numerous excellent reviews
available (Zvolensky et al. 2005; Morissette et al. 2007;
Ameringer and Leventhal 2010). These reviews also con-
tain discussions regarding anxiety deﬁnition and symp-
tom structures of different anxiety disorders. Our aim
with the discussion of these speciﬁc pathways was to
provide a framework for future research that can be
integrated with other theories of anxiety development,
to hopefully lead to a holistic understanding of anxiety
pathogenesis.
Methods
For this narrative review, we searched biomedical databases
PubMed, Embase, and PsycInfo in mid-2012 using terms
“anxiety”, “anxiety disorder”, “panic disorder”, “post trau-
matic stress disorder”, “obsessive compulsive disorder”,
“generalized anxiety disorder”, “social phobia”, “inﬂamma-
tion”, “immune”, “tobacco”, “cigarette”, “smoke”, “nico-
tine”, “oxidative stress”, “nitrogen stress”, “mitochondria”,
“neurotrophin”, “neurogenesis”, and “psychiatry” in vari-
ous combinations to identify relevant papers for the out-
lined sections. We did not limit the search by year of
publication, but did limit to English language publications.
We were deliberately inclusive in identifying relevant
papers due to the scant availability of research in some
areas. All bibliographies of identiﬁed papers were searched
for further relevant information. Once acquired, studies
were grouped into the following headings: clinical studies,
structural brain changes and clinical correlates, neurotrans-
mitter systems, inﬂammation and cell-mediated immune
activation, oxidative and nitrosative stress, mitochondrial
function, NTs and neurogenesis, epigenetics and neurode-
velopmental effects.
Where possible, we presented literature pertaining to
individual anxiety disorder states (e.g., panic disorder
[PD], post traumatic stress disorder [PTSD], generalized
anxiety disorder [GAD] etc.). Where this was not possible
(e.g., in discussion of studies pertaining to psychological
stress or anxiety symptom scores, or in animal studies),
we have presented results relating to “anxiety” in general.
Clinical Studies
Cigarette smoking as risk factor for anxiety
disorders – epidemiological studies
In addition to many studies demonstrating a cross-
sectional relationship between cigarette smoking and anxi-
ety disorders, numerous population-based studies (Breslau
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and Klein 1999; Johnson et al. 2000; Isensee et al. 2003;
Goodwin et al. 2005; Cuijpers et al. 2007; Chou et al.
2011) have demonstrated smoking as being prospectively
associated with increased rates of anxiety disorders (see
review Moylan et al. 2012a). Although most have utilized
adult populations, some studies have demonstrated ado-
lescent smoking as being associated with increased rates of
some anxiety disorders (Johnson et al. 2000; Goodwin
et al. 2005). For example, in a study utilizing data from
the Oregon Adolescent Depression Project, the odds ratio
of expressing PD at age 24 when comparing baseline (age
14–18) daily smoking to nondaily smoking was 5.1 (95%
CI 2.4–10.5), which remained signiﬁcant after controlling
for other anxiety disorders and parental risk factors.
Similarly, increased odds of numerous adult anxiety disor-
ders (GAD: OR 5.53 [1.84–16.66] and PD: OR 15.58
[2.31–105.14]) and all anxiety disorders when grouped
(OR 10.78 [1.48–78.55]) was discovered for baseline
(age 14) heavy smokers (20+ cigarettes day) versus non-
heavy smokers (1–19 cigarettes daily) in adolescence
(Johnson et al. 2000). Breslau and Klein (1999) also dem-
onstrated smoking as increasing the risk of ﬁrst onset of
both PD and panic attacks. In addition, nicotine depen-
dence has been associated with increased odds of anxiety
disorders (OR: 2.2 for men, 2.6 for women) (Breslau et al.
1991).
Laboratory/Biological Studies
Structural brain changes and clinical
correlates
Cigarette smoking and anxiety disorders are both associ-
ated with structural brain changes. Cigarette smoking has
been associated with diverse changes, including reduction
in integrity of cerebral white matter microstructure (Gons
et al. 2011), reduced prefrontal cortices (PFC) gray matter
volumes (Brody et al. 2004; Zhang et al. 2011a), reduced
gray matter volume or density in the anterior and posterior
cingulate gyri (Brody et al. 2004; Gallinat et al. 2006), and
reduced volume of frontal and temporal cortices and cere-
bellum (Gallinat et al. 2006) which may be consequence of
direct toxic or adaptive effects. Importantly, these changes
appear correlated with magnitude of cigarette exposure.
For example, the measured volumes of frontal lobes, tem-
poral lobes, and the cerebellum of smokers are inversely
correlated with magnitude of life exposure to tobacco
smoke, measured in pack years (P = 0.001) (Gallinat et al.
2006). In addition, pack years of smoking is inversely corre-
lated with density of PFC gray matter (Brody et al. 2004).
These changes overlap to some degree with neuroimaging
changes observed in mood and anxiety disorders (Moylan
et al. 2012b). Correlates of these structural changes may be
associated with cognitive deﬁcits as consequence of ciga-
rette smoking (Durazzo et al. 2010), which have been
repeatedly demonstrated in smoking populations (Richards
et al. 2003; Nooyens et al. 2008; Peters et al. 2008; Sabia
et al. 2012). For example, smoking is associated with
reduced cognitive performance, and cognitive performance
improves with increasing time since smoking cessation
(Gons et al. 2011).
Individuals with anxiety disorders exhibit structural
brain changes potentially resulting from illness related or
secondary effects, although investigation in this area is still
evolving (Damsa et al. 2009). Many studies have demon-
strated the essential role of the amygdala, anterior insula,
and anterior cingulate cortex in the key processing of fear
conditioning and extinction, and potential role of the PFC
structures as possible moderators of amygdala fear
responses during extinction (Holzschneider and Mulert
2011). Studies have identiﬁed volumetric brain changes in
patients with PD (Asami et al. 2008, 2009; Hayano et al.
2009), including reduction in the anterior cingulate cortex
(Johnson et al. 2000; Asami et al. 2008), right ventromedial
cortex and amygdala, bilateral insular cortex, occipito-
temporal gyrus (Pedersen and von Soest 2009) and lateral
temporal cortex (van Tol et al. 2010). In patients with
GAD, volumetric assessment has produced inconsistent
results including increased (De Bellis et al. 2000; Schienle
et al. 2011) and decreased amygdala (Milham et al. 2005)
volumes and alterations to the PFC (Schienle et al. 2011),
which possibly relates to heterogeneity of samples used.
Lifetime GAD has also been associated with reduced hippo-
campal volumes, an effect independent of major depressive
disorder (Hettema et al. 2012). Functional studies have uti-
lized various symptom provocation models for speciﬁc
anxiety symptoms dependent upon the disorder being
studied. Besides results in obsessive–compulsive disorder
(OCD), where the predominant response is hyperactivity of
the anterior cingulate cortex (Deckersbach et al. 2006), the
majority of studies demonstrate hyperactivity of brain
regions associated with the fear response (amygdala), and
hypoactivity in areas thought to regulate the fear responses
(e.g., anterior cingulate cortex, PFC) (Holzschneider and
Mulert 2011).
Changes to white matter microstructure are present in
both smokers and individuals with anxiety disorders. Cig-
arette smoking appears to inﬂuence the integrity of white
matter (measured by change in fractional anisotropy
[FA]); however, variables such as age and nicotine depen-
dence appear to moderate this effect (Paul et al. 2008;
Gons et al. 2011). In available studies, cigarette smoking
is associated with increased measures of FA, although
levels of FA are negatively correlated with cigarette expo-
sure and nicotine dependence. For example, a study of
adults (33.7  7.9 years) by Hudkins et al. (2012)
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investigating white matter microstructure demonstrated
that smokers exhibited higher FA in multiple white mat-
ter regions than age-matched controls, but that the mag-
nitude of cigarette consumption and nicotine dependence
was negatively correlated with FA. Higher FA in smokers
was also shown in other studies (Jacobsen et al. 2007;
Paul et al. 2008), although FA increased with lower levels
of cigarette exposure (Paul et al. 2008). In a further
study, levels of FA were lower in smokers than non-
smokers (Berk et al. 2011). Attempting to resolve these
conﬂicting results, Hudkins et al. (2012) hypothesized
that FA could be increased in smokers, particularly in
adolescent smokers, due to the direct effects of nicotine
stimulating glial proliferation and activity (Paul et al.
2008; Hudkins et al. 2012). This effect would be more
pronounced in adolescence, as white matter proliferation
is faster in adolescence than adulthood. As exposure to
cigarette smoking continues through adult life, FA would
decrease faster in smokers than nonsmokers, secondary to
potential toxic effects of cigarette smoke, leading to lower
FA overtime (Hudkins et al. 2012). Similar to ﬁndings in
smoking, a number of studies have demonstrated altered
white matter structural integrity across various anxiety
disorders (for review see Ayling et al. 2012). For example,
patients with PD demonstrated higher FA values in the
left anterior and right posterior cingulate correlated with
symptom severity (Han et al. 2008). Further, studies in
patients with GAD demonstrated reduced FA in the unci-
nate fasciculus (Hettema et al. 2012) (connecting the
amygdala and orbitofrontal cortex), a result also demon-
strated in social phobia (SP) (Phan et al. 2009; Baur et al.
2011), and increased FA in the right postcentral gyrus
(Zhang et al. 2011b). In PTSD, lowered FA has been
found in areas including the left frontal gyrus, internal
capsule, and midbrain (Kim et al. 2005; Schuff et al.
2011). Changes in integrity of white matter pathways con-
necting fear areas, including the uncinate fasciculus and
corpus callosum, have been associated with trait anxiety
states (Kim and Whalen 2009; Baur et al. 2011; Westlye
et al. 2011).
We are aware of only one study assessing the effect of
psychiatric disorders and smoking on white matter integ-
rity. Zhang et al. (2010a), assessing patients with schizo-
phrenia, demonstrated reductions in FA of the left
anterior thalamic radiation/anterior limb of the internal
capsule that were both independent and additive in
smokers and patients with schizophrenia, such that smok-
ers with schizophrenia had the largest reductions in FA.
No studies to our knowledge have yet been conducted in
patients with anxiety disorders.
In summary, gross and microstructural changes to key
brain regions and white matter tracts are present in
cigarette smokers and patients with anxiety disorders.
Changes to white matter microstructure in certain regions
connecting fear response areas have been associated with
trait anxiety states, and it is possible that cigarette smoke
could negatively affect these pathways. Future research into
these areas may provide important insights into anxiety
pathogenesis.
Neurotransmitter systems
The importance of speciﬁc neurotransmitter systems has
been extensively demonstrated in anxiety disorders, with
current ﬁrst-line pharmacological therapies interacting
predominantly with the serotonergic, noradrenergic, can-
nabinoid, cholinergic, and dopaminergic systems. In addi-
tion, some of these agents are also effective in enhancing
smoking cessation (Jorenby et al. 1999), suggesting a
plausible biological interaction between these systems and
nicotine dependence. Many studies have demonstrated
that nicotine and cigarette smoke affect diverse neuro-
transmitter systems. However, how these may predispose
to increased anxiety is very complex, involving interaction
between systems and differing effects of cigarette compo-
nents.
Much scientiﬁc work has explored the inﬂuence of
nicotinic acetylcholine receptors (nAChRs) on brain func-
tion. The nAChRs are widely distributed throughout the
central nervous system (CNS), located within synapses
(pre and post synaptic), on cell bodies, dendrites, and
axons (Bertrand 2010). Cholinergic innervation is wide-
spread throughout the brain innervating nearly every neu-
ral zone. Many cholinergic projections do not terminate
at synapses, but rather nonsynaptically where they
contribute to diffuse volume transmission (Dani and
Bertrand 2007). This could be the case for most hippo-
campal and cortical projections (Descarries et al. 1997),
and would be similar to the action of other neurotrans-
mitters including serotonin, dopamine, and noradrenaline
(Vizi et al. 2010). What differentiates cholinergic trans-
mission from these other neurotransmitters is that move-
ment of acetylcholine (ACh) is via diffusion that is
limited by acetylcholinesterase hydrolysis and not a reup-
take pump (Dani and Bertrand 2007). Differently located
nAChRs appear to exert different effects. Unlike in the
periphery, where nAChR activation underpins fast neuro-
transmission at neuromuscular junctions, the role of fast
transmission appears limited centrally although recent
results suggest a possible role in hippocampal pyramidal
neurons (Grybko et al. 2011). Many studies have identi-
ﬁed a role for nAChRs in modulating neurotransmitter
concentrations, with activation of presynaptic nAChRs
known to enhance release of neurotransmitters acetyl-
choline, dopamine, noradrenaline, serotonin, glutamate,
and gamma-aminobutyric acid (GABA) (Dani and
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Bertrand 2007). This appears to be consequence of facili-
tating increasing concentration of intracellular Ca2+
through augmenting calcium inﬂux and altering activity
of voltage-gated Ca2+ channels within the terminal. Alter-
ations in multiple receptor regulated intracellular Ca2+
pathways are linked to mood and anxiety disorders (Plein
and Berk 1999, 2001; Berk et al. 2001).
Numerous investigations have explored how activation
of nAChRs by nicotine can exert effects on mood and
anxiety symptoms. Nicotine can lead to both anxiogenic
and anxiolytic effects that appear to depend upon the
animal strain, dosing regimen, and experimental para-
digm utilized. Exposure to nicotine in rat models leads to
upregulation of nAChRs (Slotkin 2004) that is shortly fol-
lowed by desensitization as exposure is continued. Activa-
tion of nAChRs, particularly the a4b2 and a7 subtypes,
appears to enhance release of serotonin in several brain
regions, including the dorsal raphe nucleus (Reuben and
Clarke 2000; Ma et al. 2005). Interestingly, a4b2 receptor
knockout mice demonstrate an increase in basal anxiety
(Ross et al. 2000), suggesting a role for these receptors in
anxiety regulation. These receptors also upregulate dopa-
mine and noradrenergic neurons (Lichtensteiger et al.
1988), with these effects likely important in mediating the
anxiolytic effects of nicotine (McGranahan et al. 2011).
Data from a human study demonstrated that cigarette
smoking upregulated dopamine release from the limbic
system, a ﬁnding that correlated with improvement in
mood and anxiety symptoms, although the improvement
in anxiety symptoms didn’t appear dependent upon nico-
tine (Brody et al. 2009). Acute activation of nAChRs by
nicotine appears to produce anxiolytic effects in mouse
models that can be blocked by nAChR antagonist meca-
mylamine. In addition, nicotine appeared to attenuate
expression of c-Fos in numerous brain areas normally
upregulated during stress, including the paraventricular
hypothalamic nucleus, lateral hypothalamus, central
amygdaloid nucleus, medial amygdaloid nucleus and
cingulate and retrosplenial cortices (Hsu et al. 2007). In
one controlled study conducted in humans, administra-
tion of nicotine also improved mood in nonsmokers with
major depression (McClernon et al. 2006). In contrast to
these ﬁndings, acute administration of nicotine into the
lateral septum of rats precipitated an anxiogenic effect
that was at least partially mediated by serotonin 1A recep-
tors (Cheeta et al. 2000). Enhanced anxiety is a known
initial side effect to the early administration of selective
serotonin reuptake inhibitors (SSRIs) (Spigset 1999), a
time of signiﬁcantly increased serotonergic transmission.
It is possible that enhanced release of serotonin via
nAChR activation may partially explain nicotine’s anxio-
genic effects in some circumstances. It should be noted,
however, that acute effects of nicotine generally appear to
differ from chronic effects, with homeostatic adaptations
potentially underpinning longer term effects.
In this context, the above results suggesting an acute
anxiolytic effect of nicotine in animal models contrasts
sharply with knowledge that most available anti-
depressants are antagonists of nAChRs (Shytle et al. 2002)
and physostigmine, a potent acetylcholinesterase inhibitor,
produces increased depressive and anxiety symptoms
when administered (Janowsky et al. 1974). A further
observation that may help clarify these seemingly conﬂict-
ing effects is that of nicotine-induced nAChR desensitiza-
tion. Desensitization of nAChRs is a complex process that
occurs with normal cholinergic transmission and varies
with degree of transmission and receptor subtype (Dani
and Bertrand 2007). As nicotine enters the brain more
gradually and is cleared more slowly than endogenous
ACh, nicotine has the ability to induce more sustained
desensitization of nAChRs (DeBry and Tiffany 2008). In
this regard, exogenous nicotine can potentially exert a
more profound inhibition of nAChRs than endogenous
acetylcholine, leading to a potential decrease in release of
various neurotransmitters. To support this, desensitization
of nAChRs by low concentrations of nicotine lead to
reduced release of GABA and dopamine in mice brains
(Grady et al. 2012). These effects may underpin observa-
tions in human studies of depression, where nicotine and
other cigarette components altering neurotransmitter sys-
tem may partially explain development of depressed states
(Dome et al. 2010). For example, smoking has been asso-
ciated with impaired serotonin function as measured by
fenﬂuramine challenge and measurement of colony-
stimulating factor (CSF) levels of 5-hydroxyindoleacetic
acid (Malone et al. 2003). However, this mechanism is
likely more complex than a simple up- or downregulation
of neurotransmitter release and responses vary with dif-
ferent nAChR subtypes. For example, long-term potentia-
tion responses in the hippocampal CA1 region appear
differentially affected by a7- and b2-containing nAChRs
(Nakauchi and Sumikawa 2012). One factor that further
complicates interpretation of this research relates to nico-
tine withdrawal, which is anxiogenic in animal and
human studies (Picciotto et al. 2002). In this regard, anx-
iolytic effects of nicotine exposure may be secondary to
relief of withdrawal (Mueller et al. 1998).
As it currently stands, the best explanation for how
both agonism and antagonism of nAChRs may exert anti-
depressant and anxiolytic effects relates to desensitization.
Direct exposure to nicotine can facilitate rapid desensiti-
zation of nAChRs, such that an indirect antagonist effect
is rendered. This “functional antagonism” (Gentry and
Lukas 2002) may underpin the antidepressant and
anxiolytic effects of nicotine (Picciotto et al. 2008),
although further research into the various effects of differ-
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ent nAChR subtypes and their relative activation/desensi-
tization balance is required.
It is also important to consider how other components
of cigarette smoke inﬂuence neurotransmitter function.
Smoking exerts effects on monoamine oxidase (MAO)
expression, including downregulation of MAO-A and
MAO-B in the brain (Fowler et al. 1996a,b) as well as inﬂu-
encing methylation of MAO promoter genes (Rendu et al.
2011). Free radicals, another highly concentrated compo-
nent of cigarette smoke, can stimulate production of cell-
mediated immune cytokines such as interferon-gamma
(IFN-c) (Nunes et al. 2012). These proinﬂammatory
cytokines can inﬂuence serotonin metabolism, by activating
indoleamine 2,3-dioxygenase to preferentially convert tryp-
tophan into tryptophan catabolites, including kynurenine
and quinolinic acid, in lieu of serotonin. This can precipi-
tate a relative deﬁcit in both tryptophan and serotonin,
which has been, although not exclusively, associated with
increased depressive and anxiety symptoms (Argyropoulos
et al. 2004; Bell et al. 2005; Kulz et al. 2007).
Inﬂammation and cell-mediated immune
activation
Inﬂammation and activation of cell-mediated immune
functions appears to be associated with psychiatric disor-
ders (Dantzer et al. 2008; Miller et al. 2009; Wager-Smith
and Markou 2011; Moylan et al. 2012b). Stress-induced
inﬂammatory mediators may impair key brain processes
in the hippocampus and PFC, including neuronal and
synaptic plasticity, neurogenesis, long-term potentiation,
and regulation of NTs. These actions may form part of
anxiety disorder pathogenesis (for review see Hovatta
et al. 2010) similar to their role in major depressive disor-
der (for reviews see Maes et al. 2011a; Moylan et al.
2012b). Cigarette smoking promotes increased systemic
inﬂammation and cell-mediated immune reactivity, pro-
cesses thought key to the pathogenesis of chronic physical
disorders such as chronic obstructive pulmonary disease
(Bhalla et al. 2009; Nikota and Stampﬂi 2012) and ath-
erosclerosis (Ambrose and Barua 2004; Armani et al.
2009). These actions may also contribute to pathogenesis
of anxiety.
Numerous studies have investigated levels of inﬂamma-
tory mediators in anxiety disorders and increased anxiety
states (Wadee et al. 2001). The results are heterogeneous,
endorsing both increases and decreases in mediators. For
example, psychological stress has been associated with
increased production of proinﬂammatory cytokines
including tumor necrosis factor-alpha (TNF-a),
interleukin-6 (IL-6), interleukin-1 receptor antagonist
(IL-1Ra), and IFN-c, coupled with decreased production
of anti-inﬂammatory cytokines including interleukin-10
(IL-10) and interleukin-4 (IL-4), with higher anxiety
responses associated with signiﬁcantly greater IFN-c
(Maes et al. 1998). In another study, clinically anxious
individuals with a Hospital Anxiety and Depression Scale
(HADS) score  8 demonstrated signiﬁcantly higher
levels of IL-6 and lower levels of serum cortisol, but no
difference in C-reactive protein (CRP), compared with
nonanxious individuals after controlling for depression
and neuroticism (O’Donovan et al. 2010).
Others studies, however, have demonstrated an inverse
relationship between psychological stress and levels of
TNF-a (Chandrashekara et al. 2007). Studies in patients
with OCD also demonstrate varying (Brambilla et al.
1997; Monteleone et al. 1998; Denys et al. 2004; Konuk
et al. 2007) expression of plasma TNF-a, interleukin-
1-beta (IL-1b), and IL-6. The ﬁrst cytokine study per-
formed in OCD found no increase in levels of interleu-
kin-1 (IL-1), IL-6, or soluble interleukin-2 receptor (sIL-
2R), although severity of compulsive symptoms was posi-
tively correlated with concentrations of plasma IL-6 and
interleukin-6 receptor (IL-6R) (Maes et al. 1994), suggest-
ing that IL-6 signaling may be associated with compulsive
behavior. In another study comparing OCD and general-
ized social anxiety disorder (GSAD), lipopolysaccharide-
induced production of IL-6 was decreased in OCD but
maintained in GSAD (Fluitman et al. 2010). Interestingly,
patients with OCD generally demonstrate lower rates of
smoking than in other anxiety disorders (Bejerot and
Humble 1999), with results also suggesting possible cho-
linergic supersensitivity in these disorders (Lucey et al.
1993).
Few studies have investigated inﬂammatory cytokines
levels (Marazziti et al. 1992; Brambilla et al. 1999) and
alterations of other immune cell markers (Rapaport
1998; Park et al. 2005) in PD, with data showing hetero-
geneous results. No signiﬁcant changes in any of these
variables could be found during CO2 inhalation-induced
panic (van Duinen et al. 2008). Numerous investigations
support upregulated inﬂammatory activity in PTSD (for
review see Gill et al. 2009), including increased produc-
tion of IL-6 (Maes et al. 1999; Bob et al. 2010),
increased TNF-a, IFN-c, IL-1b, and decreased produc-
tion of interleukin-8 (IL-8) and interleukin-2 (IL-2).
More recently, increases in a number of proinﬂammato-
ry cytokines and chemokines (IL-6, IL-1a, IL-1b, IL-8,
monocyte chemotactic protein-1 [MCP-1], macrophage
inﬂammatory protein-1 a [MIP-1a], eotaxin, granulocyte
macrophage CSF [GM-CSF], interferon-alpha [IFN-a])
were observed in patients with PD and PTSD (Hoge
et al. 2009).
A number of factors may help explain the above heter-
ogeneous results, including differences between anxiety
disorder subtypes, study design, and confounding factors.
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Despite these heterogeneous results, other insights suggest
increased inﬂammation contributes to anxiety pathogene-
sis. For instance, cytokine-based immunotherapy can lead
to increased anxiety symptoms (Maes et al. 2001). Fur-
thermore, depressive and anxiety symptoms induced by
administration of cytokines are responsive to selective
SSRIs (Gupta et al. 2006; de Knegt et al. 2011).
We are not aware of any studies that have assessed
the impact of cigarette smoking on inﬂammatory medi-
ator expression in anxiety disorders. However, there is
evidence that smoking and depression act synergistically
to increase inﬂammation (Nunes et al. 2012). Further,
in a study assessing cytokine levels in the gingival cre-
vicular ﬂuid in patients with periodontal disease, levels
of inﬂammatory cytokines IL-6 and IL-8 were both pos-
itively correlated with increasing psychological stress, as
measured by the Modiﬁed and Perceived Stress Scale
(Linn 1986), and cigarette smoking (Giannopoulou et al.
2003).
Oxidative and nitrosative stress
Free radicals are by-products of oxidative phosphorylation
that, at low or moderate concentrations, participate in
normal cellular processes such as signaling pathways,
mitosis, apoptosis, and responses to injury or infection
(Valko et al. 2007). However, damage can occur to cellu-
lar components, including proteins, nucleic acid, carbohy-
drates, and lipids when levels of oxidative free radicals
increase beyond the antioxidant capacity of cells. Increases
in free radical concentrations can occur through both
increased production of reactive oxygen species (ROS)
and reactive nitrogen species (RNS) and/or decreased
expression of antioxidants (Hovatta et al. 2010). Damage
to these cellular components can alter the structure and
function of membrane fatty acids and proteins, and alter
or damage DNA and mitochondrial function leading to
cell death (Maes et al. 2011b).
Increased plasma markers of O&NS have been repeat-
edly demonstrated in anxiety-disordered populations and
animal models of anxiety (for review see Hovatta et al.
2010). In addition, increased hippocampal oxidative stress
is anxiogenic (de Oliveira et al. 2007). For example,
plasma markers of increased lipid peroxidation (malondi-
aldehyde [MDA], thiobarbituric acid reactive substances
[TBARS]) have been demonstrated in OCD (Ersan et al.
2006; Chakraborty et al. 2009; Ozdemir et al. 2009), SP
(Atmaca et al. 2008), PD (Kuloglu et al. 2002), and PTSD
(Tezcan et al. 2003). Further, studies in populations with
anxiety disorders have demonstrated increased activity of
antioxidant enzymes superoxide dismutase (SOD), catalase
(CAT), xanthine oxidase, glutathione reductase (GSR),
and glutathione peroxidase (Kuloglu et al. 2002; Tezcan
et al. 2003; Herken et al. 2006; Atmaca et al. 2008; Ozd-
emir et al. 2009). Although these effects are not consistent
across all studies (Ozdemir et al. 2009; Hovatta et al.
2010), it suggests that increased levels in oxidative stress
do appear in anxiety-disordered populations. Psychological
stress appears to be associated with increased O&NS and
brain region speciﬁc O&NS induced cellular damage (Hov-
atta et al. 2010), as demonstrated by increased superoxide
production in the mitochondria of rat hippocampus and
PFC under chronic mild stress (Lucca et al. 2009), and
increased NO production in rat hippocampus (Harvey
et al. 2004) and in rat cortex (Olivenza et al. 2000) in a
stress–restress animal model. Psychological stress
(e.g., examination stress) is accompanied by an increase in
inﬂammatory markers, lipid peroxidation, oxidative dam-
age to DNA, and reduced antioxidant activity in the
plasma (Wadee et al. 2001; Sivonova et al. 2004).
Increased stress levels (e.g., increased perceived workload)
and the impossibility to cope with stress have been associ-
ated with elevated 8-hydroxydeoxyguanosine (8-OHdG)
levels (Irie et al. 2005).
ROS and RNS interact in a bidirectional fashion with
proinﬂammatory cytokine signaling pathways (Hovatta
et al. 2010) leading to enhanced O&NS. One example is of
neopterin, which is synthesized from macrophages after
stimulation by proinﬂammatory cytokines (IFN-c). Pro-
duction of neopterin increases production of NO through
upregulating inducible nitric oxide synthase (iNOS) gene
expression (Maes et al. 2012). Further, the proinﬂammato-
ry cytokines IL-1b and TNF-a increase superoxide produc-
tion by stimulating arachidonic acid release, leading to
nicotinamide adenine dinucleotide phosphate (NADPH)
oxidase activation (Chenevier-Gobeaux et al. 2007), and
activation of proinﬂammatory transcription factors,
including nuclear factor k b (NFkb) and the cyclic adeno-
sine monophosphate (cAMP) response element binding
(CREB) family, appear to regulate the production of
O&NS by modulating the activity of NOS, cyclooxygenase
2 (COX2), and NADPH oxidase (Hovatta et al. 2010).
Alterations in activity of these particular enzymes have also
been linked to anxiety behaviors. For example, enhanced
anxiety resulted from the downregulation of NOS through
administration of a NOS inhibitor in one study (Masood
et al. 2009). However, these results were not replicated in
another study, which demonstrated that downregulation of
NOS by stimulation of serotonin 1A receptors (5-HT1aR)
lead to an anxiolytic effect, mediated by an increase in
CREB phosphorylation resulting from decreased NO pro-
duction (Zhang et al. 2010b). Increased activation of CREB
in the nucleus accumbens is associated with increased neu-
ronal survival (Mantamadiotis et al. 2002) and has also
been associated with reduced anxiety (Barrot et al. 2005).
Inhibition of phosphodiesterase E2 (PDE2), which in turn
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inhibits activity of NADPH oxidase, reduces anxiety behav-
ior associated with induced oxidative stress (Masood et al.
2009). Increased hippocampal NADPH oxidase 1 activity
appeared to increase anxiety behavior in rats with adjuvant
arthritis (Skurlova et al. 2011).
Subchronic oxidative stress may mediate anxiety
responses through effects on NTs and enzymatic activity.
Subchronic oxidative stress appears to induce downregu-
lation of brain-derived neurotrophic factor (BDNF), gly-
oxalase 1 (GLO1), and GSR1 (Salim et al. 2011). BDNF is
a critical brain NT and also acts as a potential antioxidant
mediator (Lee and Son 2009; Chan et al. 2010). Local
increases in GLO1 and GSR1 enzyme expression, whose
functions include protection against dicarbonylglycation
and production of glycation end products (Hambsch
2011), have previously been associated with increased
anxiety-like behaviors (Hovatta et al. 2005). However,
Salim et al. (2011) demonstrated that subchronic oxida-
tive stress downregulates GLO1 and GSR1 via induction
of calpain expression in the hippocampus, predisposing
to increased protein glycation and subsequent further oxi-
dative stress. This increased oxidative stress, in concert
with calpain activation (Shumway et al. 1999), is pro-
posed to induce NFjB transcription, leading to enhanced
production of proinﬂammatory cytokines (IL-1, CRP,
TNF-a) and inﬂammatory-mediated cellular damage
(Salim et al. 2011). The induction of calpain mediated
decreased expression of BDNF (see section Neurotrophins
below) (Salim et al. 2011).
Cigarette smoke, a signiﬁcant source of exogenous free
radicals (Stedman 1968), contains thousands of chemicals
that increase O&NS, and smokers or those exposed to pas-
sive smoke appear to have signiﬁcantly reduced circulating
antioxidants (Sobczak et al. 2004; Swan and Lessov-Schlag-
gar 2007). Many studies have demonstrated changes con-
sistent with increased O&NS in the brains of animals
exposed to cigarette smoke. Such changes include increased
levels of ROS (Luchese et al. 2009) and RNS including
superoxide, TBARS, carbonylated proteins (Tuon et al.
2010), measures of lipid peroxidation (Anbarasi et al.
2005a; Stangherlin et al. 2009; Thome et al. 2011), and
reduction of antioxidant enzymes (Stangherlin et al. 2009)
including SOD (Luchese et al. 2009), catalase (Luchese
et al. 2009), glutathione peroxidase, GSR, glutathione, and
vitamins (A, C, E) (Anbarasi et al. 2006a). It should be
noted that there are some exceptions to this trend (Delibas
et al. 2003; Fuller et al. 2010). Although some studies
report an increase in these antioxidant enzymes after acute
exposure to cigarette smoke (Baskaran et al. 1999), this is
likely an adaptive response designed to protect against oxi-
dative damage (Hilbert and Mohsenin 1996). Over the
longer term, chronic cigarette exposure appears to over-
whelm these adaptive host antioxidant responses (Hulea
et al. 1995; Anbarasi et al. 2006a) leaving the system vul-
nerable to cellular damage. The importance of deteriora-
tion in antioxidant levels is underlined by the fact that
cigarette smoke-induced increases in markers of lipid per-
oxidation are prevented by vitamin E (Thome et al. 2011).
Furthermore, another study demonstrated that active exer-
cise reduced expression of oxidative stress produced sec-
ondary to cigarette smoke exposure in rats (Tuon et al.
2010). The ability of exercise to modulate oxidative stress
may also partially underpin its therapeutic effect on anxiety
disorders (Moylan et al. 2013).
Exogenous nicotine administration to isolated cell lines
in vitro reduces antioxidant constituents (e.g., glutathione)
and increases markers of lipid peroxidation (MDA) and
lactate dehydrogenase activity (Yildiz et al. 1998, 1999),
effects blocked by addition of detoxifying enzymes SOD
and CAT (Yildiz et al. 1998, 1999). Investigations into the
effects of nicotine on oxidative stress in CNS cells have been
more limited. In a study that utilized chronic nicotine
exposure administered for 10 days, results demonstrated
increased levels of TBARS and HNE (4-hydroxynonenal)
in the brain (Bhagwat et al. 1998). Cigarette smoke can
also increase levels of brain heat shock protein 70 kDa
(Anbarasi et al. 2006b).
Only one study to our knowledge has simultaneously
assessed the association between cigarette smoke exposure,
anxiety symptoms, and brain oxidative stress markers. In
this study, rats exposed to cigarette smoke showed
increased markers of brain lipid peroxidation and
decreased plasma ascorbic acid. When rats were addition-
ally treated with pecan nut shell extract, a substance with
antioxidant properties, improvements were demonstrated
in anxiety symptoms (interpreted as withdrawal symp-
toms) and markers of lipid peroxidation (Reckziegel et al.
2011).
Mitochondrial function
Mitochondria are important sources of oxidative stress
and many abnormalities in mitochondrial function have
been found in psychiatric disorders (for review see Manji
et al. 2012). Although still requiring much investigation,
multiple factors support a role for mitochondrial dysfunc-
tion in increasing anxiety. First, patients exhibiting mito-
chondrial disorders commonly demonstrate psychiatric
symptoms including increased anxiety (Miyaoka et al.
1997; Anglin et al. 2012). Second, recent investigations
have discovered decreased levels of glycolysis enzymes
coupled with increased expression of components
associated with the electron transport chain in high-
anxiety trait animal models, potentially increasing vulner-
ability to production of ROS and subsequent cellular
damage (Filiou et al. 2011). These results were coupled
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with observations of altered levels of proteins associated
with neurotransmission in high-anxiety mice thought to
be consequent to mitochondrial protein alteration (Filiou
et al. 2011). The authors hypothesize that mitochondria
may underpin a “unifying link between energy metabo-
lism, oxidative stress, and neurotransmission alterations”
that were observed between high- and low-anxiety trait
mice. Third, mitochondria-targeted antioxidant SkQ1 has
been associated with decreased expression of anxiety
behaviors in rats (Stefanova et al. 2010). Finally, mutant
mice with reduced function of Bcl-2, a key modulator of
mitochondrial function, demonstrate increased anxiety
behavior (Einat et al. 2005).
Exposure to cigarettes can lead to mitochondrial
dysfunction (Miro et al. 1999; Anbarasi et al. 2005b), as
demonstrated by increased levels of cholesterol, lipid per-
oxides and increased cholesterol/phospholipid ratio, in
conjunction with decreased mitochondrial enzymes in
those exposed to cigarette smoke. However, chronic
cigarette smoking was not associated with derangement of
mitochondrial function in a separate study, but did
prevent exercise-induced improvement in mitochondrial
function (Speck et al. 2011). A potential explanation for
absence of demonstrable mitochondrial dysfunction in
this study may relate to the use of SWISS mice in the
experimental design that were demonstrated to be highly
resistant to cigarette smoke-induced oxidative stress
(Rueff-Barroso et al. 2010). Recent evidence suggests that
nicotine exposure may worsen mitochondrial function
through direct effects on membrane potential and granu-
larity of desensitizing a7 nAChRs (Gergalova and Skok
2011). Given these preliminary results, investigation of
therapies that promote mitochondrial function in patients
with anxiety disorders would be fruitful. These studies
should take in account smoking status.
Neurotrophins and neurogenesis
Increasing evidence supports a role for NTs and neuro-
genesis in development of anxiety disorders and anxiety
symptoms, although certain mediators may exert varying
effects on different anxiety symptoms. Animal models
have demonstrated stress-related changes to neurogenesis
in areas associated with mood and anxiety disorders
including the hippocampus (Cirulli et al. 2010). Expo-
sure to neonatal stress can reduce expression of hippo-
campal BDNF via altering gene expression (Roth et al.
2009; Roth and Sweatt 2011), which may facilitate vul-
nerability to mood and anxiety as consequence of
decreased neuronal survival (Gomez-Pinilla and Vayn-
man 2005). In addition, altered levels of BDNF and their
Trk B receptors may occur in dopaminergic pathways
projecting from the ventral tegmental area in the mid-
brain to the nucleus accumbens (Yu and Chen 2011).
Changes in BDNF appear associated with increased anxi-
ety behaviors. Intrahippocampal injections of BDNF in
rats lead to an increase in anxiety assessed by facilitatory
avoidance and the light–dark test. This was blocked by a
5HT1a antagonist suggesting a modulatory role of sero-
tonin (Casarotto et al. 2012). Social deprivation stress
leads to the development of anxiety in mice, and this
appears to be modulated by reductions in BDNF (Berry
et al. 2012). In a cross-sectional study of a healthy pop-
ulation, plasma BDNF levels were negatively associated
with somatization, obsessive–compulsiveness, interper-
sonal sensitivity, and anxiety (Bhang et al. 2012). BDNF
may also be a modulatory factor in the development of
PTSD (Rakofsky et al. 2012).
Another NT that appears important in anxiety regula-
tion is nerve growth factor (NGF). NGF is increased
under conditions of stress in both animal models and
humans (Aloe et al. 1986, 1994, 2002), and appears to be
important in resilience to stress-related neuropsychiatric
disorders (for review see Alleva and Francia 2009). Inter-
estingly, animal models demonstrate that increases in
release of NGF are most marked under conditions of
stressful behavioral interactions between animals, with
lesser increases seen under physical restraint stress (Aloe
et al. 1986; Branchi et al. 2004; Alleva and Francia 2009).
Further evidence suggests that levels of ﬁbroblast growth
factor 2 (FGF2) in the hippocampus are decreased in
animals with higher anxiety and lower response to novelty
(Perez et al. 2009) and that early life administration of
FGF2 is able to prevent increased anxiety in later life
(Turner et al. 2011).
Maternal exercise can lead to increased expression of
NTs, including VEGF and BDNF, in the PFC of offspring
that is associated with decreased anxiety (Aksu et al.
2012). Exercise also appears able to protect against the
negative effect of maternal deprivation on expression of
these NTs (Uysal et al. 2011).
Cigarette smoking and nicotine in particular appear to
exert effects on expression of NTs, although the literature
is sparse and heterogeneous. For example, cigarette smok-
ing and repeated nicotine exposure has been associated
with decreased expression of BDNF in animal models
(Yeom et al. 2005; Tuon et al. 2010). In addition, plasma
levels of BDNF are signiﬁcantly lower in smokers than
nonsmokers in human studies, with levels increasing with
greater duration of smoking abstinence (Kim et al. 2007;
Bhang et al. 2010). However, other results have suggested
that nicotine exerts a positive effect on BDNF levels. For
example, nicotine administration has been associated with
increased levels of BDNF and FGF-2 in animal striatum
(Maggio et al. 1997). The neurotrophic augmenting
effects of nicotine in this situation is hypothesized to
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underpin a therapeutic beneﬁt of cholinergic stimulation
on Parkinson’s disease by protecting dopaminergic
neurons from damage. In a further study, traumatic brain
injury revealed a positive effect of chronic cigarette smok-
ing on BDNF expression (Lee et al. 2012). Nicotine expo-
sure has also been associated with signiﬁcant increases in
NGF (French et al. 1999; Hernandez and Terry 2005) in
the hippocampus and with transient decreases in NT-3
(French et al. 1999), although once again results are not
consistent which may relate to differences in nicotine
administration (Hernandez and Terry 2005).
Differences in NT expression in response to cigarette
smoking are likely dependent upon numerous factors,
including the relative roles of nicotine and other compo-
nents of cigarette smoke (e.g., free radicals) and the devel-
opmental stage at which exposure occurs. Given the key
role of NTs in brain neurodevelopment, distortion to dif-
ferent NTs in early development may facilitate disordered
growth in brain architecture (Abreu-Villaca et al. 2003a;
DeBry and Tiffany 2008). Such effects may leave the over-
all system more vulnerable to disorders such as increased
anxiety. If exposure occurs later, alterations to NTs may
undermine normal compensatory and protective mecha-
nisms available to neuronal cells, leaving cells at greater
risk of damage or induced apoptosis. Future studies
should evaluate the roles of nicotine and other constitu-
ents of cigarette smoke on the levels of NTs correlated
with anxiety and depressive behaviors in animal models,
taking into account the different stages of development at
which exposure can occur.
Epigenetic effects
The study of epigenetic changes in anxiety disorders is a
relatively new ﬁeld, although some preliminary evidence
suggests that cigarette smoke may lead to changes in gene
expression predisposing to increased anxiety. For exam-
ple, smoking has been associated with epigenetic regula-
tion of MAO-B via a reduction in methylation of its gene
promoter. This change leads to increased production of
MAO-B persisting long after smoking is ceased (Launay
et al. 2009) that can alter neurotransmitter concentra-
tions. In addition, prenatal exposure to environmental
tobacco smoke has been demonstrated to modify expres-
sion of genes controlling key functions such as synaptic
function, neurogenesis, axonal growth, and cellular sur-
vival in the developing hippocampus (Mukhopadhyay
et al. 2010). Data from cardiovascular research have also
demonstrated the potential of gestational cigarette smoke
exposure to upregulate expression of genes associated
with production of proinﬂammatory substances in devel-
oping primates, which may increase vulnerability to vas-
cular disease in later life (Villablanca et al. 2010). In
depression, preliminary research has identiﬁed interrela-
tionships between levels of gene methylation and inﬂam-
matory mediators that may contribute to pathogenesis via
alteration of tryptophan metabolism (Uddin et al. 2011).
Investigation of epigenetic changes may provide insights
into how cigarette smoking can impact gene expression in
potentially contributing to pathogenesis of anxiety disor-
ders, although empirical data are currently very limited.
One potential genetic inﬂuence that could be explored is
the role of prototoxin gene LYNX2. LYNX2 encodes for
proteins that modulate activity of neuronal nAChRs, the
neural target of smoking-ingested nicotine. LYNX2-
encoded proteins modify nAChR receptor control of
glutamate release from the medial PFC. Loss of LYNX2
was associated with increased glutamatergic activity and
increased anxiety behaviors in one study, suggesting a
possible role in controlling anxiety responses (Tekinay
et al. 2009). Further studies are required to assess whether
LYNX2 functioning may affect the alterations to nAChRs
provoked by prolonged nicotine exposure in smokers.
The above ﬁndings (summarized in Fig. 1) suggest a
potential role for inﬂammation, O&NS, mitochondria,
NTs, and epigenetic alterations in the pathogenesis of
anxiety disorders, although further investigation is
required to delineate these relationships. Cigarette smok-
ing can modulate all of these pathways, potentially
distorting cellular functioning and neuronal architecture
predisposing to higher vulnerability to developing anxiety
disorders.
Cigarette Smoke Exposure, Nicotine,
and Altered Neurodevelopment:
Increasing the Risk of Anxiety
Disorders?
Cigarette smoke is known to be deleterious to neurode-
velopment (Picciotto et al. 2002; Slotkin 2004; Slikker
et al. 2005; DeBry and Tiffany 2008), and exposure to
cigarette smoke in early neurodevelopment appears to
increase the risk of developing anxiety in later life (Bandi-
era et al. 2011; Jamal et al. 2011). During early neurode-
velopment, cigarette exposure can be direct (e.g., early
adolescent smoking, in utero exposure to maternal smok-
ing), or second hand as environmental smoke exposure
(Bandiera et al. 2011). Given the diversity of active com-
pounds in cigarette smoke, we focus here primarily on
the speciﬁc inﬂuence of nicotine (Newman et al. 2002a)
on neurodevelopment. However, as cigarette smoke con-
tains many substances that either directly (e.g., free radi-
cals) or indirectly (e.g., metals) exert effects on O&NS
stress pathways, immune and mitochondrial functions, it
is possible these effects also inﬂuence neurodevelopment
and potentially subsequent anxiety risk.
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Nicotine readily crosses the placenta and enters the
fetal blood stream in utero (Lambers and Clark 1996).
Exposure in utero has also been associated with later
behavioral and social problems (Nicoll-Grifﬁth et al.
2001; Piquero et al. 2002; Brion et al. 2010), suggesting
the potential to alter neurodevelopmental trajectories.
Nicotine’s action as a speciﬁc agonist of nAChRs is facili-
tated by the very early expression (prior to neurulation)
of these receptors in the developing CNS (Atluri et al.
2001; Schneider et al. 2002). Cholinergic inputs are criti-
cal during brain development, underwriting many key
processes including axonal and synaptic growth, promot-
ing neurogenesis, facilitating planned apoptosis, and
initiating the switch between neuronal replication and dif-
ferentiation (Slotkin 2004). Increasing evidence suggests
nicotine agonism of nAChRs may exert deleterious neuro-
developmental effects. Given the rapid rate of neurodevel-
opment in utero, deleterious effects will likely be most
signiﬁcant during this time, but might continue to occur
at any time when there is signiﬁcant development
(e.g., during adolescence) (DeBry and Tiffany 2008).
Agonism of nAChRs by nicotine is more prolonged
than that exerted by acetylcholine in normal cholinergic
transmission due to differences in concentration and
clearance. Nicotine presented in utero is usually present
in higher concentrations, and is more slowly cleared, than
endogenous acetylcholine (DeBry and Tiffany 2008). As
consequence, nicotine can induce enhanced nAChR acti-
vation, facilitating adaptive effects such as receptor
desensitization, and if excessive, direct toxicity (DeBry
and Tiffany 2008). These “neuroteratogenic” effects occur
at doses well below that required for growth impairment.
Figure 1. Multiple pathways that are associated with development of anxiety disorders are affected by cigarette smoke and nicotine, including
diverse neurotransmitter systems, inﬂammation and the immune system, oxidative and nitrosative stress, neurotrophins and neurogenesis,
mitochondrial function, and epigenetic inﬂuences. It is possible these pathways may underpin how exposure to cigarette smoke could increase
anxiety symptoms and expression of anxiety disorders. 5-HT, 5-hydroxytryptophan; BDNF, brain-derived neurotrophic factor; CAT, catalase; CMI,
cell-mediated immune; DA, dopaminergic; DRN, dorsal raphe nucleus; FGF2, ﬁbroblast growth factor 2; GPX, glutathione peroxidase; GSR,
glutathione reductase; IFN-c, interferon-gamma; IL-1, interleukin 1; IL-1RA, interleukin 1 receptor antagonist; IL-10, interleukin-10; IL-12,
interleukin-12; IL-6, interleukin 6; MAO, monoamine oxidase; MDA, malondialdehyde; NA, noradrenergic; NGF, nerve growth factor; O&NS,
oxidative and nitrosative stress; PICs, proinﬂammatory cytokines; SOD, superoxide dismutase; SSRI, selective serotonin reuptake inhibitor; TBARS,
thiobarbituric acid reactive substances; TNF-a, tumor necrosis factor-alpha; TRYCATs, tryptophan catabolit.
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Animal models have demonstrated that nicotine exposure
leads to quite profound distortion of early neural devel-
opment characterized by increased apoptosis and enlarge-
ment of intercellular spaces (Roy et al. 1998). Even
though substantial recovery appears to occur such that
brains with grossly distorted architecture in utero do not
appear grossly abnormal in adolescence or adulthood,
there remain long-lasting effects of nicotine exposure to
neuronal architecture, cellular functioning and survival,
and DNA expression and regulation. For example, prena-
tal nicotine exposure has been associated with persisting
alterations in cellular architecture in the hippocampus
(Roy et al. 2002; Abdel-Rahman et al. 2005; Oliveira-
da-Silva et al. 2009) and somatosensory cortex (Roy and
Sabherwal 1994), decreased DNA expression in brainstem,
forebrain, and cerebellum (McFarland et al. 1991), persis-
tently enhanced markers of cellular damage and apoptosis
(e.g., c-fos and ornithine decarboxylase; Slotkin et al.
1991; Trauth et al. 1999). Many effects have demonstrated
persistence into adolescence. For example, decreased syn-
aptic activity in noradrenergic and dopaminergic neurons
evident in the early postnatal period of rats exposed to
nicotine prenatally has been demonstrated to reemerge
with pubertal onset (Navarro et al. 1988), either as
reduced activity or as reduced responsiveness to normal
cholinergic stimulation (Seidler et al. 1992). Prenatal
exposure to nicotine also causes ongoing alteration to
nAChRs that extend in adolescence (Gold et al. 2009). In
addition, genetic proﬁling studies have revealed that ado-
lescent genes coding for the ventral tegmental area, some
of which encode for neurite development, psychological
disorders, development disorders, and nervous system
development, appear more vulnerable to long-term effects
of chronic nicotine exposure than adult genes (Doura
et al. 2010).
Evidence supports that exposure to nicotine prenatally
and during early postnatal life leads to increased anxio-
genic behaviors in rats (Eppolito et al. 2010). Interest-
ingly, measures of increased anxiety behavior in the
Elevated Plus Maze in those rats exposed to prenatal nico-
tine were present in adulthood but not in adolescence,
and although the result was more prominent in female
rats, males also demonstrated the response (Eppolito
et al. 2010). The exposure to nicotine before and shortly
after birth was associated with impairment to fear extinc-
tion (Eppolito et al. 2010), which replicated results from
chronic nicotine exposure in adolescence but not adult-
hood (Smith et al. 2006). This may suggest that exposure
to nicotine in high-activity neurodevelopmental periods
may exert more deleterious effects than in adulthood. It
is possible that chronic administration of nicotine, via
altered nAChR activity, may inﬂuence gene expression
and plasticity in the medial PFC and amygdala (Brown
and Kolb 2001; Li et al. 2004; Polesskaya et al. 2007).
This interaction may underpin the lack of extinction
learning displayed in rats that are exposed to chronic
nicotine (Eppolito et al. 2010).
Nicotine induces production of oxidative stress markers
and reduces antioxidant defenses, contributing a major
proportion of the net oxidative stress from cigarette use
(Bhagwat et al. 1998; Yildiz et al. 1998; Guan et al. 2003;
Qiao et al. 2005; Das et al. 2009), although nicotine is
known exhibit both pro- and antioxidant effects (Li et al.
2000; Tizabi et al. 2003). Nicotine increases lipid peroxi-
dation markers that can be prevented by coadministration
of free radical scavenger vitamin E (Qiao et al. 2005) and
has demonstrated antimitotic properties (Qiao et al.
2003). Increased production of O&NS, and antimitotic
properties, has been demonstrated during cell differentia-
tion (in association with increased in nAChR density)
(Qiao et al. 2003, 2005). It is possible that the balance
between damaging and protective effects of nicotine may
depend upon the degree of stimulated oxidative stress – a
small amount of oxidative stress could have positive
effects in stimulating normal cellular processes, but signif-
icantly increased oxidative stress could overwhelm protec-
tive mechanisms leading to direct cellular damage
(Newman et al. 2002a).
Given the increased level of O&NS present in adoles-
cence, it could be hypothesized that vulnerability to toxic
effects of nicotine-induced oxidative stress would be
heightened (Qiao et al. 2005). Nicotine has demonstrated
adverse neurobiological effects during adolescence, with
these effects seemingly dependent on only early small and
infrequent exposure to nicotine (Abreu-Villaca et al.
2003b). In keeping with this hypothesis, administration of
nicotine for 1 week to adolescent rats resulted in a signiﬁ-
cant increase in TBARS with effects that would have been
observed at low levels of exposure (Qiao et al. 2005).
Other mechanisms of nicotine-induced damage may
include upregulation of mRNA expression encoding pro-
teins associated with cell death and cell differentiation.
For example, increased levels of such proteins (p53) and
reduction of DNA were found in the hippocampus, cor-
tex, and midbrain in adolescent rats (Trauth et al. 2000).
These effects were not of the same magnitude as those
seen with nicotine exposure in utero (Levin and Slotkin
1998).
Nicotine also exerts effects on numerous trophic factors
(DeBry and Tiffany 2008; Son and Winzer-Serhan 2009),
including upregulation of FGF (Belluardo et al. 2004),
PDGF (platelet-derived growth factor), BDNF (Kenny
et al. 2000), Trk A (Formaggio et al. 2010), and NGF. It
is possible that exacerbated expression of these growth-
supporting factors via nicotine’s agonism of nAChRs may
interfere with normal neurodevelopmental processes. As
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nicotine’s stimulation of nAChRs is potentially more pro-
longed than normal cholinergic transmission, expression
of NTs may be higher than required for normal neuro-
development, with this higher expression leading to
disordered development of neuronal architecture (Abreu-
Villaca et al. 2003c). Such effects may predispose an
increased risk of developing anxiety and other psychiatric
disorders in later life.
Therapeutic Implications for Anxiety
Disorders
A number of these insights may have treatment implica-
tions for anxiety-based disorders and symptoms. It is
hypothesized that adaptation and desensitization of
nAChRs may underpin the effect of cigarettes on anxiety
and mood regulation (Mineur and Picciotto 2010), based
on the association between higher smoking rates and
mood dysregulation (e.g., depression) (Covey et al.
1998), animal models demonstrating antidepressant
effects of acute nicotine on learned helplessness (Semba
et al. 1998) and other depression behaviors (Djuric et al.
1999; Tizabi et al. 1999), the effect of antidepressants
such as bupropion as smoking cessation aids (Hurt et al.
1997) and that some antidepressants also serve as non-
competitive inhibitors of nAChRs (Shytle et al. 2002).
Many of these effects apply to increased anxiety, suggest-
ing that certain central nAChRs may serve as a new
potential treatment target.
Numerous studies have demonstrated potential for use
of centrally acting nAChR antagonists in anxiety treatment.
For example, the nAChR antagonist mecamylamine has
produced anxiolytic improvement in multiple animal
models (Newman et al. 2002b). Mecamylamine was dem-
onstrated to be a useful augmentation agent to SSRI treat-
ment of major depression (George et al. 2008), and
administration of mecamylamine also appears capable of
blocking dexamethasone-induced anxiety, which occurs
concurrently with upregulation of BDNF levels (Park et al.
2011). The anxiolytic effects of nAChR antagonism have
also been conﬁrmed using an alternative agent, lobeline
(Roni and Rahman 2011). Human data on the use of
nAChR antagonist for anxiety are scarce. A possible insight
comes from the use of bupropion, which blocks reuptake
of noradrenaline and dopamine but in addition exerts a
noncompetitive antagonist effect at several subtypes of
nAChRs (Arias 2009). Bupropion has demonstrated signiﬁ-
cant anxiolytic effects equivalent to the action of SSRIs in
treatment of patients with major depressive disorder, and
this effect on nAChRs may underpin part of this effect,
although other explanations are possible (e.g., effect on
noradrenergic and dopaminergic systems) (Papakostas
et al. 2008). Future randomized studies will provide insight
into therapeutic possibilities exploiting modiﬁcation of
nAChRs in treating anxiety disorders.
Other potential agents worthy of consideration include
agents that can guard against inﬂammatory- and O&NS-
mediated effects. For example, the tetracyclic antibiotic mi-
nocycline, which exerts strong anti-inﬂammatory effects,
has been shown to potentially modulate anxiety behaviors
after cardiac arrest (Neigh et al. 2009). In addition, inhibi-
tion of COX2 has been shown in animal models to prevent
anxiety development (Casolini et al. 2002), and celecoxib,
a COX-2 inhibitor, has shown beneﬁt as an augmentation
agent to SSRIs in depression (Muller et al. 2006). Antioxi-
dant treatments, such as n-acetylcysteine, have shown some
promise in augmentation of treatment in mood disorders
(Berk et al. 2012), and exploration of their utility in anxi-
ety disorders would be of use.
Further research exploring the effects of agents that
inﬂuence the identiﬁed pathways may provide important
new avenues for therapy for pathological anxiety. In addi-
tion, such work will be important in further understand-
ing the biological pathways facilitating development and
reinforcement of cigarette smoking. These efforts may
assist the development of more advanced treatments for
smoking cessation, particularly in patients with anxiety
disorders who exhibit poor rates of success to traditional
cessation strategies (Piper et al. 2011).
Limitations and Directions for Future
Research
A number of interpretational caveats must be considered
when considering the evidence presented. First, the litera-
ture discussed above is drawn from a variety of sources,
utilizing differing measures of anxiety (e.g., different diag-
nostic measures for individual anxiety disorders, different
symptoms scale measures of anxiety or psychological
stress, different animal anxiety models) and different rates
of smoking or nicotine exposure. Studies also employed
various confounders and other study designs which make
cross-comparisons difﬁcult. Where possible, we have
discussed individual anxiety disorder diagnoses noting the
signiﬁcant distinctions between different disorder groups.
In particular, evidence suggests that different anxiety dis-
order subtypes display signiﬁcantly different rates of smok-
ing (Kalman et al. 2005). However, the scant literature
available for some pathways prevented an analysis by dis-
order subtype, with most evidence on potential pathway
effects drawn from cross-sectional investigations of animal
models. The cross-sectional nature of this literature
impeded conclusions regarding causation, and it is possi-
ble that observations highlighted (e.g., smoking with
changes to brain volume) may be unidirectional, bidirec-
tional, or mediated by other shared factors. In addition,
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there currently exists a paucity of research assessing a par-
ticular pathway in concert with smoking and anxiety. Few
prospective data are available assessing the impact of
changes to speciﬁc systems on anxiety symptoms in
response to cigarette smoking. In addition, aside from the
inherent difﬁculties in translating animal model data to
humans, many of the above associations displayed vari-
ability in results depending upon study variables, including
animal model used or experimental design. In addition,
much of the literature has focused solely on the role of
nicotine and not the other known toxic ingredients of cig-
arette smoke including free radicals and metals. There was
also signiﬁcant variability in expression and function of
these systems between different groups (e.g., men vs.
women) and individuals within these groups, and hence
much further work is required to ascertain how these
inﬂuences draw together. Understanding reasons under-
pinning differential expression between groups may help
clarify further key elements to anxiety development.
Women, for example, are known to exhibit higher rates of
anxiety disorders, which likely relates to a combination of
biological (e.g., different hormonal compositions) and psy-
chological factors, and hence further analysis of these
effects on the described pathways may prove enlightening.
The acute and long-term effects of any agent that causes a
robust homeostatic adaptation are often quite different;
this needs to be taken into account in interpretation of
acute data, and in extrapolating to management strategies.
Future research efforts in this area should attempt to
address some of these challenges. First, it would be useful
to ascertain the effects of nicotine versus other cigarette
constituents to the above pathways in humans. The use
of populations with high consumption of Snus, such as
Norway, presents as opportunity for such analyses to be
conducted prospectively, and combined with follow-up
behavioral assessments, serum analysis of relevant markers
(e.g., inﬂammatory or O&NS), assessment of genetic
function, and functional and structural imaging. Such
studies could be extended over time to investigate speciﬁc
changes between different anxiety disorders (e.g., PD,
GAD, PTSD), different subsets of the population (e.g.,
cultural or gender groups), and in individuals with other
risk elements known to inﬂuence these similar pathways
(e.g., history of childhood trauma, comorbid medical ill-
ness). It is likely that interindividual differences in genet-
ics and epigenetic alterations will also complicate these
effects, and as such further exploration of this evolving
area will be of foremost importance. Given that effects on
multiple pathways may exert incremental increases in risk
for developing anxiety, triangulation of potential effects
involving a combination of animal and human models
will likely be required as power to detect small effects will
only be found in very large studies.
Conclusion
Many studies have suggested that cigarette smoking may
increase the risk of developing increased anxiety, although
conﬁrmation of this causality is yet to be conﬁrmed. Evi-
dence into pathogenesis of anxiety disorders and
increased anxiety symptoms potentially supports a role
for diverse neurotransmitter systems, the immune system,
O&NS, mitochondrial function, and epigenetic regulation,
although the literature is heterogeneous and scant in cer-
tain areas. Ingredients that are present in cigarette smoke,
including nicotine and other toxic chemicals, exert inﬂu-
ences on all of these pathways. These effects may at least
partially underpin the biological mechanisms through
which smoking may contribute to increased anxiety, and
potentially serve as a useful framework for further
research efforts. Similar pathways are likely to be opera-
tive in other states characterized by ﬁght, ﬂight, freeze
responses such as anger, mood disorders (e.g., depressive
states), and psychotic disorders. The exposure to nicotine
and other cigarette ingredients may also exert neurodevel-
opment inﬂuences capable of changing anxiety trajecto-
ries, underscoring the importance of reducing exposure to
cigarette during gestation and throughout childhood.
Centrally, nAChRs appear to be a crucial mediator of the
anxiety-modifying effects of cigarette smoke and may rep-
resent a future therapeutic target for anxiety disorders. In
addition, anti-inﬂammatory and antioxidant agents may
assist in improving anxiety symptoms, as they may do in
depression. Further studies addressing this area may elicit
insights into new therapeutic opportunities.
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1 CHAPTER SEVEN: SUMMARY 
The two projects detailed in Chapters 5 & 6 provided substantial information 
to inform the overall research study aim, and provided guidance to the next 
stage of investigation required. 
 
From Chapter 5, the systematic review of population-based epidemiological 
studies demonstrated evidence supporting cigarette smoking as being 
prospectively associated with increased anxiety disorders, particularly PD and 
GAD. These associations were most convincingly demonstrated where 
exposure to cigarette smoking had occurred at earlier stages in life (i.e. during 
adolescence).  
 
This observation provided an interesting insight. If cigarette smoking was a 
risk factor for the development of anxiety disorders, could it be that the timing 
of exposure was important? Other areas of psychiatric research (e.g. that 
exploring the association between cannabis and psychosis (Bossong and 
Niesink, 2010)) have demonstrated that certain environmental exposures can 
deleteriously affect normal neurodevelopment. The precipitated disruption to 
neurodevelopment, secondary to these environmental exposures could 
potentially leave individuals susceptible to increased expression of psychiatric 
disorders, especially if occurring at the time of peak onset risk for these 
disorders. Could a similar process work with cigarette smoking and anxiety 
disorders, such that exposure during key stages of neurodevelopment would 
SUMMARY OF CHAPTERS FOUR & FIVE 
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increase an individual’s susceptibility to anxiety based problems, whereas 
exposure at other times exert less effect? 
 
To explore this possibility, the comprehensive literature review detailed in 
Chapter 6 focussed on potential biological pathways that may underpin how 
cigarette smoke exposure could increase anxiety symptoms and disorders. 
Through exploration of this wide-ranging literature, support was engendered 
for disturbance in numerous biological pathways that can underpin this 
relationship. In concert with our hypotheses, evidence was found supporting 
cigarette smoke as being deleterious to neurodevelopment, particularly when 
exposure occurred during key neurodevelopmental stages (e.g. in utero, 
childhood and adolescence). Cigarette smoke exposure during these critical 
periods in animal models was also associated with behavioural changes 
consistent with increased anxiety. 
 
From these projects the possibility that the timing of cigarette smoke exposure 
on anxiety symptom and disorder outcomes was explored. As outlined in the 
literature review (Chapter 2), numerous limitations in the existing literature 
highlighted the need for studies exploring the association between anxiety 
symptoms and disorders and cigarette smoke exposure during different stages 
of life. In the research project, it was therefore decided to undertake three 
separate projects in different longitudinal cohorts addressing exposure in three 
life stages: adulthood (Chapter 8), childhood and adolescence (Chapter 9), and 
in utero (Chapter 10).  
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ABSTRACT 
Rates of cigarette smoking are higher among individuals with anxiety 
disorders. The aim of this study was to determine whether exposure to 
cigarette smoking increased the odds of developing an anxiety disorder. We 
therefore undertook a nested case-control study within the Geelong 
Osteoporosis Study, a large population based cohort of women who had 
undergone structured psychiatric assessment using the Structured Clinical 
Interview for DSM-IV-TR (SCI-I/NP) and reported on cigarette smoking. 
Contrary to our hypothesis, we found no association between exposure to 
cigarette smoking and subsequent anxiety disorder diagnosis (either grouped 
anxiety disorder or panic disorder specifically) and indeed found a small 
protective effect of low quantity (1-9 cigarettes per day) prior regular cigarette 
smoking on subsequently diagnosed anxiety disorders (OR 0.40 (0.17-0.95)) 
after controlling for age, although small cell numbers requires cautious 
interpretation. The implications, but also possible methodological issues that 
may have affected our observations, are discussed. 
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INTRODUCTION 
 
Increased levels of anxiety symptoms and anxiety disorders are associated 
with higher rates of cigarette smoking in multiple cross-sectional population 
based studies (Tobias et al., 2008, Lawrence et al., 2010; Lasser et al., 2000; 
Brown et al., 1996; Cuijpers et al., 2007; Goodwin et al., 2005b; Sonntag et 
al., 2000; Swendsen et al., 2010). Further, a large number of population-based 
epidemiological studies has explored the inter-relationship between cigarette 
smoking and anxiety symptoms and disorders, presenting data suggesting that 
smoking may represent a risk factor for onset of certain anxiety disorders 
(Moylan et al., 2012).  
 
Multiple theories have been proposed to explain why cigarette smoking may 
increase rates of anxiety symptoms and disorders (Moylan et al., 2013c).  
First, numerous psychological theories have been proposed (Morissette et al., 
2007), including those relating to theories of classical conditioning (e.g. 
conditioned anxiety relating to nicotine withdrawal (Wikler, 1973; 1984), 
cognitive theory (Beck and Clark, 1997) (e.g. overlap of automatic 
behavioural responses promoting smoking and increased anxiety) and anxiety 
sensitivity (e.g. smoking increasing body sensations, which in turn increase 
anxiety due to beliefs these sensations will lead to negative consequences 
(Reiss et al., 1986; McNally, 2002)). Second, smoking may alter 
neurobiology through direct effects on brain structure, neurotransmitter 
systems, inflammation and cell mediated immune activation, oxidative and 
nitrosative stress, mitochondrial function, functions of neuroplasticity and 
neurogenesis, and altering gene expression through epigenetic effects (Moylan 
et al., 2013c).   
 
Further, smoking may interact through effects on other bodily systems. For 
example, a review of literature exploring the interrelationship between 
cigarette smoking and panic symptoms and disorders by Cosci et al. (2010) 
supported three possible explanatory models for how smoking may contribute 
to panic. These included a model where trait neuroticism mediated the 
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relationship; a “pathoplastic model” (Zvolensky et al., 2003), wherein 
smoking enhanced the risk of panic disorder through increasing the rate of 
negative health effects (e.g. inducing respiratory and cardiovascular disease, 
increased levels of physical sensations) and a negative self perception of one’s 
own health (Zvolensky and Bernstein, 2005); and Klein’s “false suffocation 
alarm” theory (Klein, 1993), where smoking is suggested to increase an 
individual’s sensitivity to suffocation signals, inducing panic symptoms. 
 
In a recent systematic review (Moylan et al., 2012) of population-based 
studies assessing the interrelationship between smoking and anxiety, the most 
consistent finding supported cigarette smoking as a risk factor for the 
subsequent onset of panic disorder and generalized anxiety disorder. The 
literature, however, was heterogeneous and this pattern was not observed in 
all studies. We therefore decided to utilize 10 years of longitudinal data 
derived from the Geelong Osteoporosis Study (GOS) cohort to investigate 
whether a prior history of regular smoking is associated with subsequent onset 
of anxiety disorders, and panic disorder specifically.  
 
Prior analyses of data from the GOS cohort demonstrated that regular 
cigarette smoking was associated with an increased risk of de novo major 
depression in women (Pasco et al., 2008).  We therefore hypothesised that a 
prior history of regular smoking would be associated with an increased 
likelihood of developing any anxiety disorder, and panic disorder specifically. 
We decided to initially assess anxiety disorders as a group to enhance the 
power available to observe an effect. We subsequently chose to focus on panic 
disorder as we predicted this as a disorder in which an effect was most likely 
to be observed and it was the highest prevalence individual anxiety disorder in 
the GOS cohort (Williams et al., 2010). We also hypothesised that, consistent 
with a dose-dependent relationship, an increased smoking “dose” (higher 
number of cigarettes regularly smoked) would be associated with a greater 
likelihood of developing an anxiety disorder.  
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METHODS 
Geelong Osteoporosis Study 
This research project was nested within the GOS, an ongoing population-
based study that was initially designed to investigate the epidemiology of 
osteoporosis among Australian women (Pasco et al., 2012).  The study has 
since been expanded to include measurement of psychiatric illness and a range 
of other medical illnesses. The included population was recruited between 
1993 and 1997 and has been followed up with follow-up assessments at 2 
years, 4 years, 6 years, 7 years, 8 years and 10 years post-baseline. 
 
Sampling Frame 
Participants for the GOS were randomly drawn from the Barwon Statistical 
Division (BSD) of the Australian Commonwealth Electoral Roll.  Due to 
compulsory voting in Australia, Australian citizens 18 year or over are 
included on the Australian Electoral Roll. Census data produced around 
baseline (1996) reported the population of the BSD as 221687 (113072 
female). The BSD was comparable to the Australian population on multiple 
characteristics including age, country of birth, marital status, weekly income 
and age left school (Pasco et al., 2012). 
 
The inclusion criterion for the study was being a female resident of the BSD. 
Exclusion criteria (Pasco et al., 2012) were being unable to provide written 
informed consent and being resident in the BSD for <6 months.  
 
Study Participants 
An age-stratified sample of participants was recruited comprising 12 strata.  
Invitations to participate were sent by mail to randomly selected participants, 
with follow up letters sent to individuals who did not respond. Initially 2390 
individuals were approached, with 444 declining to participate and 432 
excluded (107 died, 209 unable to be contacted, 115 left region, one was 
pregnant), leaving a total of 1494 participants at baseline. These individuals 
were followed for a decade.  Study population available at the individual 
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follow up assessments were 2 year: 1386 eligible, 1180 participated, 4 year: 
1299 eligible, 907 participated, 6 year: 1217 eligible, 1051 participated, 7 
year: 1187 eligible, 866 participated and 10 year: 1067 eligible, 881 
participated. In addition, a new sample was drawn from the 2005 electoral roll 
of 246 women aged 20-29 years between 2006 and2008. 
 
Relevant for this study, a total of 1095 women (age range 20-94) in total had 
undergone a diagnostic psychiatric assessment at the time of analysis. These 
included women from both the initial recruitment and from the 2006-2008 
recruitment.  
Ethics  
The GOS study was approved by the Barwon Health, Human Research Ethics 
Committee. All participants provided written informed consent. The study has 
been supported by funding from the Victorian Health Promotion Foundation, 
National Health and Medical Research Council, The Geelong Regional 
Medical Research Foundation, Barwon Health, Perpetual Trustees, Dairy 
Research and Development Corporation, The University of Melbourne, 
Ronald Geoffrey Arnott Foundation, ANZ Charitable Trust, The American 
Society for Bone and Mineral Research and Amgen (Europe) GmBH (Pasco 
et al., 2012). 
 
Study Process 
Participants at each assessment filled detailed questionnaires collecting a wide 
variety of information related to lifestyle risk factors (e.g. smoking, alcohol 
use, physical activity), exposure to diseases and demographic information. In 
addition, participants provided blood and urine samples, anthropometric 
measures (e.g. height, weight, waist and hip circumference), bone mineral 
density and dietary information, and at later assessment, information on mood 
and anxiety disorders. Full descriptions of measures are available in the GOS 
cohort profile (Pasco et al., 2012). Detailed descriptions of measures relevant 
for this research project are presented subsequently. 
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Exposure: Smoking 
Smoking was documented by self-report at all assessments, although the 
information measured differed at different time points. 
 
At baseline, respondents were asked to report the following: 
 
1) Whether they had ever smoked manufactured cigarettes regularly 
 
If Yes: 
How many years (in total) they had been a regular smoker 
How many cigarettes they smoked each day (on average) 
The largest number of cigarettes they smoked regularly each day 
Whether they currently smoked 
If not, at what age they ceased smoking regularly. 
 
The same questions were also administered for hand rolled cigarettes and 
cigar/pipe smoking. 
 
An individual was considered to have been a regular smoker at some stage if 
they responded “yes” to question 1 above. We utilised the average number of 
cigarettes smoked each day to sub-categorise individuals into four smoking 
dose groups: no regular smoking, 1-9 cigarettes smoked regularly, 10-19 
cigarettes smoked regularly, and 20+ cigarettes smoked regularly. 
 
In the absence of a specific question being asked about the age of onset of 
smoking, we calculated an age of smoking onset-using information for the 
baseline assessment taking a conservative approach. For those who identified 
as current smokers, we subtracted the number of years they reported as 
smoking regularly from their age at the time of assessment. For those who did 
not identify as current smokers at baseline, we subtracted the number of years 
they reported as smoking regularly from their self-reported age of smoking 
cessation. These calculations do not take into account episodes of cessation 
and recommencement of smoking, and therefore it is possible they may inflate 
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the age of onset of smoking. However, in lieu of there being specific 
information on age of onset in the data, this was considered to be the most 
accurate measure of age of smoking onset possible. 
 
Outcome: Anxiety Disorders 
Assessments of psychiatric disorders were conducted at the 10 year follow up 
appointment by trained personnel using the Structured Clinical Interview for 
DSM-IV-TR Research Version, Non-patient edition (SCID-I/NP) (First et al., 
2002). Diagnoses for anxiety disorder subtypes, including generalized anxiety 
disorder, panic disorder, social phobia, obsessive-compulsive disorder and 
agoraphobia without panic disorder were made per DSM-IV-TR criteria 
(American Psychiatric Association., 2000). For each diagnosis, participants 
were asked to determine an age of onset. 
 
The SCID-I/NP also produced diagnoses for the full range of axis 1 disorders, 
including major depressive disorder, dysthymia and bipolar disorder. 
 
Covariates 
A series of covariates was identified for potential inclusion as confounders in 
our analysis. These included demographics variables (e.g. age), alcohol 
consumption, habitual physical activity, socio-economic status and certain 
physical disease states (cardiovascular disease, respiratory disease and 
diabetes). 
 
Alcohol consumption 
Participants were asked to report their alcohol consumption including 
information on whether they had ever drunk alcohol, how often they usually 
drank alcohol (never, <1 per week, 1-2 per week, several times per week, 
every day) and an estimate on the number of standard glasses of individual 
alcohol types they consume per week. For this study, alcohol intake was 
deemed to be present if alcohol was reported as being consumed at least 
several times per week. 
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Habitual physical activity 
Participants were asked to report their habitual physical activity levels. 
Respondents self-reported their level of activity on a 7-point scale, ranging 
from: 
1. Very active (“moves, walks and work energetically; participates in 
vigorous activity” 
2. Active (“Walks at brisk pace, does normal housework or other work; 
engages in light exercise”) 
3. Sedentary (“walks reasonable distances, dose light housework, 
shopping or equivalent; normal activities of day-to-day living but no 
appreciable exercise”) 
4. Limited (“little walking outside home, but prepares meals, does very 
light housework or equivalent”) 
5. Inactive (“sits in chair or lies in bed most of the time; walks 
independently from bed to chair to toilet but requires assistance for 
greater movement”) 
6. Chair or bedridden (“cannot walk from bed to chair to toilet without 
considerable assistance”). 
7. Bedfast (“not able to walk”) 
 
Participants were dichotomized into active versus not active, with reporting in 
categories 1&2 deemed active and reporting in 3 or lower deemed inactive or 
sedentary. 
Socioeconomic status 
The process for calculating the participants’ socio-economic status was 
undertaken in accordance with previous investigations in this dataset (Brennan 
et al., 2009, Brennan et al., 2010). The participants’ socio-economic status 
was obtained using the Socio-economic Index for Areas index scores based on 
Australian Bureau of Statistics census data for the district that their individual 
residential address existed within (Adhikari, 2006). The Socio-economic 
Index for Area provides three different aggregate indices of socio-economic 
status including the Index of Relative Social Disadvantage (IRSD), the Index 
of Economic Resources (IER) and the Index of Education and Occupation 
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(IEO)(Pink, 2008). The IRSD is the only index that only accounts for 
disadvantage, and not advantage and disadvantage together (Brennan et al., 
2010; Pink, 2008). For the purpose of this study, we utilized the IER, which 
aggregates variables relating to household income, dwelling size, levels of 
home ownership, level of unemployment and rental and mortgage payment 
costs. A low score on the IER is reflective of a relatively poorer access to 
economic resources, with a high score reflective of a relatively greater access 
to economic resources (Pink, 2008). We used these scores and subsequently 
categorized individuals into quintile groups, with 1 representing the lowest 
level of socioeconomic status and 5 representing the higher level of 
socioeconomic status. 
 
Exposure to disease states 
Individuals self-reported their exposures to certain diseases including the age 
of onset of each individual disease state. For this analysis we included self-
report of respiratory disease (“asthma”, “emphysema”, “chronic bronchitis”) 
and cardiovascular disease (“hypertension”, “angina”, “coronary heart 
disease”). 
Study Design 
In this nested case-control study, we utilised data from all women who had 
undergone a psychiatric assessment to assess the association between having 
any diagnosed anxiety disorder / panic disorder only and a prior history of 
exposure to regular cigarette smoking. Cases were identified as individuals 
with a diagnosis of anxiety disorder / panic disorder only; controls had no 
history of diagnosed anxiety disorder. Smoking in cases was recognised for 
those who self-reported regular cigarette smoking exposure prior to the self-
reported onset of their anxiety disorders. We excluded individuals for whom it 
was unclear if smoking preceded onset of anxiety disorder. 
 
In Australia regular smoking, particularly amongst women, is very rare prior 
to the age of 14(White and Smith, 2008). We therefore chose a priori to 
exclude any cases where anxiety disorders were diagnosed prior to the age of 
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15, as these would be unlikely to have been at risk for the prospective 
association we wanted to investigate.    
Statistical Analyses 
All statistical analyses were undertaken using Stata (version 11.2). We 
produced standard descriptive statistical techniques to characterize the 
individuals that participated in each study. We performed logistic regression 
modelling with anxiety disorders (yes/no), and then panic disorder only, as the 
dependent variable and regular cigarette smoking as the independent variable. 
We report these coefficients as both unadjusted and adjusted for potential 
confounding variables including age, socioeconomic status, a history of 
cardiovascular and respiratory disease, physical activity level and alcohol 
consumption. Age is defined as the age of onset of anxiety disorder for cases 
and the baseline assessment age for controls for this analysis. We chose a 
priori to not control for depressive disorders. As in previous work by our 
group (Moylan et al., 2013b), we considered that given the highly comorbid 
nature of anxiety and depressive disorders, controlling for depressive 
disorders would unacceptably increase the risk of a type 2 error.  We further 
undertook analyses testing associations between anxiety disorders / panic 
disorder-only diagnoses and exposure to differential rates of daily smoking (0, 
1-9 daily, 10-19 daily, 20+ daily). 
 
RESULTS 
Characteristics of the participants in the whole sample as assessed at baseline 
are presented in Table 1. Overall, approximately 13.2% of study participants 
had experienced an anxiety disorder during their lifetime, as assessed with the 
SCID-I/NP. Average age of anxiety disorder onset was 25.2 years (SD 17.1). 
Approximately 38% of the sample reported having a history of regular 
smoking. 
Grouped Anxiety Disorders  
After exclusion of cases with a self-reported age of onset of anxiety disorder 
prior to age 15 (n=51), and exclusion of a single case and control due to 
inability of ascribing temporal ordering of smoking and anxiety onset, a total 
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of 93 cases and 948 controls were available for analysis. Characteristics of 
participants included in the analyses are displayed in Table 1. Those with 
anxiety disorders were younger but were not different on other measured 
demographic variables, including smoking exposure.  
 
Table 1: Characteristics of participants with and without lifetime 
anxiety disorder 
 
 Anxiety Disorder No Anxiety 
Disorder 
 
 (n=93) (n=948) P 
Age, years: median (IQR) 25.0 (19.0-45.0) 44.4 (28.8-57.7) <0.001 
Smoking prior anxiety disorder 
onset, n(%) 
28 (30.11%) 354 (37.34%) 0.17 
Socioeconomic status   0.99 
Quintile 1 (low) 13 (14.77%) 137 (15.34%) 0.91 
Quintile 2  22 (25.00%) 183 (20.49%)  
Quintile 3  19 (21.59%) 212 (23.74%)  
Quintile 4  16 (18.18%) 173 (19.37%)  
Quintile 5 18 (20.45%) 188 (21.05%)  
Alcohol Use, n (%) 15 (16.3%) 164 (17.43%) 0.786 
Physically active, n (%) 76 (81.72%) 731 (77.93%) 0.398 
Cardiovascular disease, n (%) 26 (27.97%) 251 (27.53%) 0.930 
Respiratory disease, n (%) 30 (32.26%) 261 (27.53%) 0.332 
 
 
Is exposure to regular smoking associated with later anxiety 
disorder onset? 
 
The odds ratios for developing an anxiety disorder after exposure to regular 
smoking derived from logistic regression analyses, both unadjusted and 
adjusted for potential confounding variables, were calculated. Analysis of 
possible confounding suggested that only age affected the observed 
association. No association between regular smoking and an increased 
likelihood of being diagnosed with an anxiety disorder was observed 
(unadjusted OR = 0.71 (0.44-1.13); adjusted OR = 0.69 (0.42-1.10)), 
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Reported dose of smoking 
Due to missing data, two respondents from each group were excluded in 
analyses involving smoking dose. Smoking frequencies for cases and controls 
are displayed in Table 2. Results from analyses of smoking dose on the 
likelihood of being diagnosed with an anxiety disorder are displayed in Table 
3. Results suggest that, after adjustment for age, smoking between 1-9 
cigarettes daily was associated with a reduced likelihood of experiencing an 
anxiety disorder than non-smoking. 
Table 2: Participants reported smoking dose with and without 
lifetime anxiety disorders 
 Anxiety 
Disorder 
No Anxiety 
Disorder 
 
 (n=92) (n=947) P 
Smokers, n(%) 27 (29.35%) 350 (36.96%) 0.147 
Smoking dose   0.322 
Non smokers 65 (70.7%) 597 (63.0%)  
1-9 cigarettes per 
day 
6 (6.5%) 120 (12.7%)  
10-19 cigarettes 
per day  
13 (14.1%) 137 (14.5%)  
20+ cigarettes 
per day  
8 (8.7%) 93 (9.8%)  
 
Table 3: Adjusted and unadjusted odds ratios of smoking dose 
(number of cigarettes per day) and the risk for anxiety disorders* 
  
Cigarettes per 
day 
Unadjusted OR 
(95% CI) 
Adjusted OR 
(95% CI) 
1-9 cigarettes 
per day 
0.46 (0.19-1.08),  0.40 (0.17-0.95),  
10-19 cigarettes 
per day  
0.87 (0.47-1.63),  0.84 (0.45-1.60),  
20+ cigarettes 
per day  
0.79 (0.37-1.70),  0.88 (0.40-1.91),  
*Reference group is non-smokers. 
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Panic disorder 
We compared the likelihood of panic disorder associated with previous 
exposure to regular smoking. Overall, 58 individuals reported a history of 
panic disorder, with 10 cases excluded as self-reported age of onset was <15 
years. Characteristics for individuals included in the analysis are detailed in 
Table 4. The panic disorder group was younger than the non-anxiety disorder 
group, although exposure to regular smoking did not differ between groups. 
 
Table 4: Characteristics of participants with panic disorder and 
without lifetime anxiety disorders 
 Panic Disorder No Anxiety 
Disorder 
 
 (n=48) (n=948) P 
Age, years; median (IQR)  39.5 (21.5-50.0) 41.4 (28.8-57.7) 0.014 
Smokers exposure, n(%) 13 (27.08%)  354 (37.34%)  0.15 
Socioeconomic status   0.79 
Quintile 1 (low) 7 (15.56%) 137 (15.34%) 0.93 
Quintile 2  8 (17.78%) 183 (20.49%)  
Quintile 3  12 (26.67%) 212 (23.74%)  
Quintile 4  7 (15.56%) 173 (19.37%)  
Quintile 5 11 (24.44%) 188 (21.05%)  
Alcohol Use, n (%) 8 (16.67%) 164 (17.43%) 0.892 
Physically active, n (%) 39 (81.25%) 731 (77.93%) 0.588 
Cardiovascular disease, n (%) 17 (35.42%) 261 (27.5%) 0.235 
Respiratory disease, n (%) 17 (35.42%) 261 (27.5%) 0.235 
 
Is exposure to regular smoking associated with later panic disorder 
diagnosis? 
The odds ratios for developing panic disorder after exposure to regular 
smoking derived from logistic regression analyses, both unadjusted and 
adjusted for potential confounding variables, were calculated as per the 
grouped anxiety disorders. In common with the grouped anxiety disorder 
results, there was no association between regular cigarette smoking and the 
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likelihood of being diagnosed with panic disorder unadjusted or adjusted for 
age (unadjusted OR =0.63 (0.33-1.21); adjusted OR =0.62 (0.32-1.18). 
 
Reported dose of smoking 
Smoking doses for each group (panic disorder vs. no anxiety disorder) were 
calculated as for the grouped anxiety disorders analysis. No association was 
found between average number of cigarettes per day and having panic 
disorder, although very low cell numbers were available in the panic disorder 
group. Due to these low numbers, analysis comparing the odds of exhibiting 
an average smoking dose depending on having panic disorder or no anxiety 
disorder was not pursued. 
 
DISCUSSION 
In contrast to our hypothesis, our study did not demonstrate that exposure to 
regular cigarette smoking was associated with an increased risk of developing 
an anxiety disorder or panic disorder specifically. Overall, no association 
between anxiety disorder status (either grouped anxiety disorders or panic 
disorder only) and regular cigarette smoking was found. The data did not 
support a dose-dependent relationship as hypothesised, although in a subgroup 
of participants with lower dose of smoking, a reduced likelihood of anxiety 
disorder was observed. 
 
As outlined in the introduction, we initially hypothesised that exposure to 
cigarette smoking in this cohort would be associated with an increased 
likelihood of developing an anxiety disorder and panic disorder. This 
hypothesis was informed by results from previous population based 
epidemiological studies where smoking exposure has been more consistently 
associated with increased rates of anxiety symptoms and disorders rather than 
the reverse association (anxietysmoking) (Moylan et al., 2012), coupled 
with an increasing understanding of the potential biological mechanisms 
through which this effect may be mediated (Moylan et al., 2013c). Numerous 
studies have previously demonstrated an association between regular smoking 
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and subsequent increased risk of developing an anxiety disorder. For example, 
Johnson et al. (2000) demonstrated that in a sample of 688 adolescents drawn 
from New York State and followed for approximately 10 years, those who 
smoked >1 pack of cigarettes per day at baseline (mean age 14 years) 
demonstrated increased odds of exhibiting an anxiety disorder (OR 10.78, 
95% CI 1.48 to 78.55), panic disorder (OR 15.58 (2.31 to 105.14) and 
generalized anxiety disorder (OR 5.53, 95% CI 1.84 to 16.66) in adulthood, 
when compared to those who smoked <1 pack a day. In addition, data drawn 
from the Oregon Adolescent Depression Project demonstrated daily smoking 
in adolescence (14-18 years) was associated with an increased rate of panic 
disorder (OR 5.1, 95% CI 2.4-10.5) diagnosis at age 24 after controlling for 
other anxiety disorders and parental risk factors when compared to non-
smokers (Goodwin et al., 2005a). Further, analysis of 1007 young adults (21-
30 years) from the Detroit Epidemiologic Study demonstrated an association 
between prior daily smoking (smoking daily for >1month) and subsequent 
risk of developing panic disorder, adjusted for gender and major depressive 
disorder (HR 13.13, 95% CI 4.41 to 39.10) (Breslau and Klein, 1999). Similar 
to our study design, Breslau et al. (2004) utilised the National Comorbidity 
Survey in the USA to demonstrate that self-reported pre-existing daily 
smoking was associated with increased odds of subsequently developing panic 
disorder (OR 2.6, 95% CI 1.2 to 5.4). Interestingly, in this analysis, an 
increase in standardised pack years of smoking was associated with increased 
odds of generalised anxiety disorder, but decreased odds of panic disorder, 
although the authors reflect that these patterns do not appear to support dose-
dependent relationships overall (Breslau et al., 2004). These findings are also 
supported by recent evidence drawn from a meta-analysis that smoking 
cessation is associated with reduced rates of anxiety (Taylor et al., 2014). 
 
Our failure to find an association between anxiety disorder status and prior 
exposure to regular smoking was therefore unexpected. The only association 
discovered through our analysis was one where, after adjustment for age, a 
low dose of smoking (1-9 cigarettes daily) was associated with a reduced 
likelihood of later grouped anxiety disorder. This finding is in contrast to 
previous literature that has demonstrated higher rates of smoking (e.g. >20 
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cigarettes per day) as being associated with higher rates of anxiety disorders 
(Johnson et al., 2000), and is based upon quite low cell numbers for 
individuals with anxiety disorders reporting smoking 1-9 cigarettes per day 
(n=6). Therefore, this finding and the findings in general should be interpreted 
with caution and in light of the study limitations. These factors are discussed 
below. 
Selection Bias and Cohort Factors 
Our analysis was nested within the wider GOS, and it is therefore possible 
that factors related to this cohort may have influenced the observations. The 
cohort only included women over the age of 20 years and relied primarily on 
retrospective recall of events (see below Recall bias).  
 
Women are known to exhibit higher rates of anxiety disorders than men, a 
finding that has been replicated in multiple population based studies (McLean 
et al., 2011; Bruce et al., 2005; Regier et al., 1990; Kessler et al., 1994). 
There is cross-sectional evidence to suggest that the relationship between 
cigarette smoking and anxiety disorders is stronger in adolescence than 
adulthood (Wu et al., 2010). Sex, however, does not appear to be associated 
with differences in the age of onset of specific anxiety disorders (McLean et 
al., 2011). In our cohort, the prevalence of lifetime grouped anxiety disorder 
(13.2%), and current anxiety disorders (7.6%) was lower than that observed in 
female respondents to the National Survey of Mental Health and Wellbeing 
2007  (32%: Lifetime prevalence, 18%: 12-month prevalence) (Slade et al., 
2009). Although it is likely some of these differences relate to cohort 
differences, it is possible that the lower rate of anxiety disorders may at least 
partially have resulted from non-response bias, where individuals with anxiety 
based issues may have been less likely to respond and/or continue 
participation in the study over time. There is some evidence that those with 
increased levels of anxiety are less likely to respond to invitations to 
participate in academic studies (Selmer et al., 2003). Given the GOS is a 
study that initially focussed predominantly on investigating bone health 
amongst women, and that psychiatric assessment was performed on women a 
decade after the initial recruitment, it is possible women with anxiety 
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disorders were under-represented in the initial sample and displayed increased 
attrition in comparison to those without anxiety disorders. The loss of 
potential “cases” would have implications for the observed interrelationship 
between anxiety disorders and an environmental risk factor like smoking 
(with estimates in our sample consistent with population estimates 
(Commonwealth Government of Australia, 2013)), and also for the degree of 
statistical power afforded the analyses. 
 
Recall Bias 
The GOS cohort relied upon retrospective recall of both onset of regular 
smoking and anxiety disorder. It is possible that participants may have 
inaccurately recalled the onset of either factor. Retrospective recall of 
smoking has been demonstrated to have reasonable accuracy when compared 
with contemporaneous assessment (Kenkel et al., 2003), although some 
authors have suggested that reliance on age of onset data provided through 
self-report may not be appropriate where this factor is significant in the 
research question (Johnson and Mott, 2001). Given the key nature of age of 
onset of smoking in our analysis, this may therefore have biased the 
observations, particularly if individuals inflated their age of onset of smoking 
to occur after the onset of their anxiety disorder (which would have rendered 
potential “cases” to be classified spuriously as “controls”). Given it is illegal 
to purchase and consume cigarettes in Australia below the age of 18 years, 
age inflation of this kind is entirely possible.  
 
Classification of the age of onset of anxiety disorders can be equally fraught.  
As outlined by Jones (2013), many adult psychiatric disorders often begin 
with “non-specific symptoms” that may evolve into a diagnostic syndrome 
over time. It is a matter of judgement as to whether these early features were a 
part of the eventual disorder or not, leading to what Jones describes as 
“enormous scope for error or bias in the recall or memory of events” (Jones, 
2013, Simon and VonKorff, 1995). Although some psychiatric disorders, such 
as the psychotic disorders, are considered to be extremely rare prior to puberty 
(Hafner et al., 1994), anxiety disorders exhibit a high degree of continuity 
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between childhood/adolescence and adulthood (Harrington et al., 1990). Data 
from a recent review of the literature suggest that some anxiety disorders (e.g. 
the phobias and separation anxiety) have a very early median age of onset (7-
14 years, Interquartile range 8-11), however for other anxiety disorders (e.g. 
generalised anxiety disorder, panic disorder, posttraumatic stress disorder) the 
median age of onset if much later (24-50 years, Interquartile range 31-41) 
(Kessler et al., 2007). In this regard, it is worth noting that in our sample, over 
35% of those with grouped anxiety disorder and 17% of those reporting panic 
disorder reported their ages of onset as occurring before the of 15 years age.  
 
Recall accuracy of age of onset can be complicated for individuals who may 
attribute their onset age as being when they first experienced symptoms, when 
they first were diagnosed, when they first received treatment, or some other 
combination of situations.  If the attribution was influenced by the receipt of 
treatment, it is worth considering that analysis of the National Comorbidity 
Survey – Replication demonstrated that those with anxiety disorders waited 
between 9 and 23 years to seek treatment after symptom onset (Wang et al., 
2005).  
 
Therefore, for many people the onset of smoking (often occurring in 
adolescence) and anxiety disorders will occur, or at least appear to occur, 
simultaneously. In fact, longitudinal analysis of the interaction between 
depression and smoking suggests these factors follow a bidirectional 
developmental pattern, with both factors affecting each other, through early 
life up to the age of 30 (Tjora et al., 2014). These issues with recall coupled 
with difficulty in ascribing a definite “onset” of anxiety disorder may have led 
to individuals being misclassified as cases or controls in this analysis, 
potentially affecting the associations observed.   
Grouping anxiety disorders and comorbidity with other psychiatric 
disorders 
Since the introduction of discrete anxiety disorder diagnostic constructs in the 
DSM-III, there has been extensive debate as to what extent anxiety and its 
disorders should be considered “discrete” constructs.  Early exploration of 
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symptom profiles of the then DSM-III anxiety disorder states suggested 
greater similarities between some disorders (e.g. panic disorder and 
generalized anxiety disorder) than others (e.g. obsessive-compulsive disorder) 
(Cameron et al., 1986).  However, there are a number of factors suggesting 
that distinction amongst the disorders, and high rates of comorbidity with 
other related disorders (e.g. major depression), should at least give pause to 
consider whether combining disorders into a “grouped anxiety disorder” 
category is appropriate. It has been demonstrated that some anxiety disorders 
demonstrate great similarities to other non-anxiety disorders.  For example, 
work from Mineka et al. (1998) suggested that generalised anxiety disorder 
and depression are “indistinguishable” genetically, whereas depression and 
panic disorder are only moderately related (Watson, 2005). This genetic 
relationship is reflected also in rates of comorbidity, with higher rates of 
depressive and generalised anxiety disorder demonstrated than for other 
anxiety disorders (Watson, 2005). The high levels of comorbidity between 
depressive and anxiety disorders was the reason we chose a priori to not 
control for depressive disorders, as we felt this would introduce a substantial 
risk of type 2 error. 
Use of categorical versus dimensional scales for anxiety disorder 
measurement 
Another factor that needs to be considered in analysis of our results is the use 
of categorical (i.e. DSM-IV-TR) diagnostic endpoints in the GOS.  Although 
there are a number of advantages to categorical classification of mental 
disorders, including the ease of interpretation and communication, there 
remains the issue of a need to “define clear-cut thresholds between presence 
and absence of disorders” (Bjelland et al., 2009). Due to this clearly defined 
threshold, individuals may be classified as not exhibiting a disordered state 
even though they are experiencing significant symptoms (Preisig et al., 2001; 
Angst et al., 1997; Haller et al., 2014) which exert functional morbidity. For 
these reasons, authors have argued that use of dimensional scales for 
evaluation of anxiety disorders is more fruitful than categorical approaches 
(Shear et al., 2007). In this regard, the categorical endpoint may have affected 
our observed results. For example, individuals with a diagnosed anxiety 
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disorders (and therefore higher levels of anxiety symptoms) may be more 
likely to engage with health services than those with sub-threshold symptoms. 
In this regard, individuals with higher levels of symptoms may therefore be 
more likely to seek out medical treatment for anxiety and less likely, overall, 
to utilise smoking as a coping mechanism. In addition, higher symptom rates 
(that correlate with increased likelihood of anxiety disorder diagnosis) may 
interact with other factors to change the likelihood of smoking. For example, 
anxiety is correlated with diagnoses of respiratory illnesses such as asthma 
(Meuret et al., 2006), a physical diagnosis that would bias against the onset of 
regular smoking. In our study, individuals with anxiety disorders were more 
likely to report a history of respiratory disease, which depending on time of 
onset, may have influenced both the real and reported smoking history. Such 
an effect would bias towards an inverse relationship between cigarette 
smoking and anxiety disorders. Indeed, this is what we noted in the subgroup 
of participants with low rates of smoking. 
Variability of smoking throughout the study period 
Another factor that could have introduced bias in our results was a reliance on 
“regular smoking” as the primary exposure variable. As is demonstrated by 
the changing rate of smoking in the Australian population over the last few 
decades (Commonwealth Government of Australia, 2013), it is likely that 
there would be significant variability in the consistency of exposure over time.  
In data taken from a survey of smokers aged 14 years and older in Australia, 
more than three quarters of individuals reported trying to change their 
smoking behaviour in the 12 months before the survey. This included 
reducing the overall quantity of cigarettes consumed per day (38%), 
attempting to give up smoking for greater than one month (29%), and failed 
attempts at quitting (29%) (Australian Institute of Health and Welfare, 2011). 
Given this, it is entirely possible that even in individuals who classified 
themselves as regular smokers, there would be significant periods of time 
where their exposure to smoking varied. This could have had unpredictable 
effects on our ability to observe an association.  
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Residual confounding of smoking/anxiety and other poor health 
related outcomes 
A further limitation relates to potential residual confounding that may have 
influenced our observed associations. For example, variability in genetic 
profiles may predispose individuals to exhibit increased levels of anxiety in 
response to smoking, or vice versa (Nunes et al., 2014). Similarly, both 
anxiety and smoking are related to a series of biological (e.g. other medical 
conditions), psychological (other mental disorders) and social factors (e.g. 
family interactions, social sphere, occupational success etc.) that may have 
influenced the associations observed.  
Issues with power 
A lack of statistical power may also have affected the ability to observe an 
association between cigarette smoking and subsequent development of 
anxiety disorders, although analysis of similar literature suggests this may not 
have been a substantial issue. Although some studies that have demonstrated 
an association between cigarette smoking and anxiety disorders benefited 
from access to larger cohorts sizes (e.g. 1500-5000 participants) (Goodwin et 
al., 2005b; Swendsen et al., 2010), other studies displaying associations 
utilised cohorts of similar size (600-1000 participants) and with similar case 
rates of anxiety disorders to the GOS cohort (Breslau and Klein, 1999; 
Johnson et al., 2000).  Therefore, given a similar effect size, we would have 
expected to have sufficient power to observe an association if one was 
present.  
Methodological issues and the previous literature 
The identified issues with our study design, particularly those involving 
accurate assessment of age of onset of smoking and anxiety disorders, are not 
as relevant in the previous literature. For example, most of the previously 
mentioned studies did not rely on recall of these factors due to prospective 
designs (Johnson et al., 2000, Goodwin et al., 2005, Breslau and Klein, 1999), 
and some of these studies assessed adolescents at younger ages which is a 
large advantage over our cohort where everyone was aged greater than 20 
years at assessment.  Similar methods in regards that required recall were 
required in the study of the National Comorbidity Survey by Breslau et al. 
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(2004), although their included sample extended to age 15 years and was 
substantially larger (n=4414) which would have afforded greater power to 
observe effects.  
 
CONCLUSION 
In conclusion, this nested case-control investigation utilising a large sample 
did not confirm an association between exposure to regular smoking and 
subsequent onset anxiety disorders or panic disorder specifically. Although it 
is possible that our findings are an accurate representation of the true 
relationships, multiple limitations with the available data suggest these 
findings should be viewed with caution. There was no convincing evidence of 
a dose-dependent relationship. This study highlights some of the difficulties in 
investigating associations between cigarette smoking and anxiety disorders in 
data reliant on participant recall. 
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Abstract
Cigarette smoking is increased in people with trait anxiety and anxiety disorders, however no longitudinal data exist
illuminating whether smoking in adolescence can influence the developmental trajectory of anxiety symptoms from early
vulnerability in infancy to adult anxiety expression. Using The Tracing Opportunities and Problems in Childhood and
Adolescence (TOPP) Study, a community-based cohort of children and adolescents from Norway who were observed from
the age of 18months to age 18–19years, we explored the relationship between adolescent smoking, early vulnerability for
anxiety in infancy (e.g. shyness, internalizing behaviors, emotional temperaments) and reported early adult
anxiety. Structural equation modeling demonstrated that adolescent active smoking was positively associated with
increased early adulthood anxiety (b= 0.17, p,0.05), after controlling for maternal education (proxy for socioeconomic
status). Adolescent anxiety did not predict early adult smoking. Adolescent active smoking was a significant effect modifier
in the relationship between some infant vulnerability factors and later anxiety; smoking during adolescence moderated the
relationship between infant internalizing behaviors (total sample: active smokers: b= 0.85,p,0.01, non-active smokers: ns)
and highly emotional temperament (total sample: active smokers: b= 0.55,p,0.01,non-active smokers: ns), but not shyness,
and anxiety in early adulthood. The results support a model where smoking acts as an exogenous risk factor in the
development of anxiety, and smoking may alter the developmental trajectory of anxiety from infant vulnerability to early
adult anxiety symptom expression. Although alternative non-mutually exclusive models may explain these findings, the
results suggest that adolescent smoking may be a risk factor for adult anxiety, potentially by influencing anxiety
developmental trajectories. Given the known adverse health effects of cigarette smoking and significant health burden
imposed by anxiety disorders, this study supports the importance of smoking prevention and cessation programs targeting
children and adolescence.
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Introduction
Multiple population based epidemiological studies, utilizing
cross-sectional and prospective designs, have demonstrated higher
rates of cigarette smoking in individuals with anxiety disorders [1–
3] and increased anxiety symptoms [4](see review, Moylan et al [5]).
These increased rates of smoking are quite startling. For example,
data from the US National Comorbidity Study revealed rates of
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current smoking rates between 38–46% in those with an anxiety
disorder compared to 22.5% in those with no mental disorder [1].
Rates of smoking amongst those with anxiety disorders in New
Zealand were estimated at approximately 30% (compared to 20%
in those without a mental disorder) in a nationally representative
study, with those individuals consuming approximately 16% of all
cigarettes in New Zealand [3]. Despite significant investigation
[4,6–13] a complete understanding of this association remains
elusive. Such understanding is important, as it could inform
interventions aimed at reducing the morbidity associated with this
association. Three non-mutually exclusive models could explain
this association [5].
First, the observed association could be explained by shared
vulnerability, where biological and/or environmental factors
increase the likelihood of smoking and of developing increased
anxiety [14,15]. As an example, lower socioeconomic status, which
is associated with multiple disease risk factors and mental disorder
expression, is associated with both increased smoking [16,17] and
anxiety [18]. Second, anxiety may increase smoking-related
behaviors [4,19–23]. Evidence suggests individuals with increased
anxiety do display increased smoking behaviors [4,19–23], with
various factors, including an increased vulnerability to start
smoking in response to peer pressure [4,16] and use of cigarettes
for anxiety-relief, proposed as possible explanations. Finally,
smoking may predispose to increased anxiety levels through a
variety of mechanisms [20,21,24–27]. For example, smoking
adversely impacts respiratory health and autonomic control;
effects that potentially increase vulnerability for developing anxiety
[13,28–31]. Furthermore, some literature suggests a direct effect of
cigarette smoke and nicotine on normal neurodevelopment
[32,33], which may increase the chance of developing anxiety in
later life. In support, rats exposed to nicotine in early life exhibit
more anxiety-like states in adulthood than those exposed at a later
age [34].
It is possible that models proposed to explain the adverse effects
of cigarette smoke exposure on development of numerous medical
disorders may be relevant to anxiety development. Exposure to
cigarette smoke in childhood and adolescence is known to increase
adult disease expression and severity of multiple physical illnesses
[35], including aortic atherosclerosis [36] and asthma [37,38],
particularly in those with a pre-existing disease vulnerability (e.g.
family history). In these disorders, cigarette smoke may act as an
exogenous risk factor that compounds pre-existing vulnerability to
intensify disease development and severity. A similar pathogenic
model could be relevant for mental disorders: commencing
smoking at an earlier age, particularly during key stages of
neurodevelopment such as adolescence, may exacerbate an
underlying vulnerability for anxiety. In this model, exposure
cigarette smoke could alter the developmental trajectory of anxiety
through effects on underlying neurobiology [39] and leave
individuals more susceptible to increased anxiety in the long term.
These effects could result from direct effects of cigarette smoke
components (e.g. nicotine and free radicals) leading to disturbance
in the function and regulation of neurotransmitter systems (e.g. the
cholinergic system) and/or by direct cellular damage secondary to
increased oxidative and nitrosative stress. This model is supported
by recent observations that early onset smoking is associated with
shorter time to onset of anxiety disorders [40].
Some early childhood behaviors are predictive of increased
adult anxiety, including internalizing behaviors, shyness and a
highly emotional temperament [41–43]. These behaviors may be
conceptualized as early markers of an underlying risk for increased
adult anxiety. Through testing whether or not exposure to
cigarette smoke moderates the developmental trajectory of anxiety
from these early observed anxiety behaviors to adult anxiety
expression, we have the opportunity to test whether a neurode-
velopmental model could apply to anxiety development. Such
insights could provide a basis for future endeavors in further
understanding anxiety pathogenesis, and how cigarette smoke
influences this process.
This study uses a large longitudinal cohort, the Tracing
Opportunities and Problems in Childhood and Adolescence (TOPP) Study,
to assess the prospective relationship between adolescent smoking
and adult anxiety symptoms. The study tests two hypotheses: that
adolescent smoking is associated with increased early adult anxiety
symptoms, and that adolescent smoking moderates the relation-
ship between infant vulnerability for anxiety and early adult
anxiety.
Methods
Participants and Study Procedures
We used data from the TOPP Study [44], a prospective
community-based observational study of children and adolescents
from eastern Norway. In 1993, 929 families attending 18-month
vaccination visits from 19 health care areas in eastern Norway
completed the initial survey. The 19 health care areas were
representative of the diversity of Norwegian social environments.
The sample was predominantly middle class ethic Norwegian
families, 28% of whom resided in large cities, 55% in densely
populated areas and 17% rurally. Mothers were on average 30
years of age (SD=4.7; Range: 19–46years) at baseline assessment.
Data collected from child health clinics demonstrated no
association between maternal age, employment status, education,
marital status of number of children and likelihood of study
participation. The participating families were subsequently invited
to undertake further questionnaires when their children were 2–3
years, 4–5 years, 8–9 years, 12–13 years, 14–15 years, 16–17 years
and 18–19 years. The parents provided all information until the
age of 8–9 years, after which information was collected from
parents and children. All participants provided informed consent
and the study procedures were approved by the Norwegian Ethical
Committee.
At baseline, age 18months, information was available from 913
mothers on their infants (49% male), with 456 (50%) adolescent
respondents at age 14–15 and 441 (48%) adolescent respondents at
ages 18–19 years. Multiple baseline variables were tested to assess
their association with study attrition at early adulthood follow up
(age 18–19 yrs). After controlling for multiple-significance testing
via Bonferroni correction, study attrition was only significantly
related to maternal education (increased education associated with
decreased drop-out) and gender (girls with less likelihood of drop-
out). Hence gender and maternal education measured at baseline
were included and controlled for in the models.
Basic descriptive statistics for independent and dependent
variables are displayed in Table 1. Baseline maternal education,
utilized as a proxy for socioeconomic status, was assessed at
baseline using eight categories ranging from ‘‘seven years of
primary school or less’’ to ‘‘university level with four or more
years’’. During the period of schooling for some parents, Norway
had some alternative schooling options available on a limited basis
that represented items 7–8years schooling and 10 years schooling.
These are the equivalent of primary schooling and hence we have
collapsed these items down into a single category ‘‘Primary
Schooling Only’’. Maternal report of infant vulnerability factors
for anxiety was also taken from the baseline questionnaire, and
included levels of emotionality, shyness and internalizing behav-
iors. Shyness and emotionality were assessed by the Emotionality,
Adolescent Smoking and Adult Anxiety
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Activity and Sociability Temperament Survey (EAS) [45] where
each temperament trait was measured by five items rated on a 5-
point scale (1 = not typical to 5= very typical). Shyness refers to the
tendency to display inhibited and awkward behaviors in new social
situations, and emotionality refers to the tendency to become easily
and intensely aroused. Due to ambiguity in translation, one item
from emotionality scale (‘‘The child tends to be somewhat
emotional’’) and the shyness scale (‘‘ The child makes friends
easily’’) was deleted, as has been undertaken in other studies using
this dataset [43]. Factor analytic investigation of the EAS has been
undertaken in this data set, demonstrating good reliability
(Emotionality: Cronbach a=0.66; Shyness: Cronbach a=0.75)
and construct validity [46,47]. Internalizing behaviors were
assessed using two items (‘‘Has many different worries, broods
over things’’, ‘‘Is often frightened by loud noises and unexpected
things’’) from the Behaviour Checklist [48], and one additional item
pertaining to sadness (‘‘Seems often, or for long periods, to be
unhappy’’). The items for each dimension were combined into a
mean index.
Smoking (child self-report) was assessed at ages 12–13 to 18–19
years. For ages 12–13 and 14–15, respondents endorsed a four-
option categorical scale (‘‘never smoked’’, ‘‘have tried smoking’’,
‘‘sometimes smoke’’ and ‘‘daily smoker’’); for ages 16–17 and 18–
19 a five-option categorical scale (‘‘never smoked’’, ‘‘have tried
smoking’’, ‘‘former smoker, now quit’’, ‘‘sometimes smoke’’ and
‘‘daily smoker’’) was used. Due to the limitation of quite small
numbers of smokers in some categories, we decided to reclassify
smokers into a dichotomous variable – ‘‘active smoking’’ versus
‘‘non-active smoking’’ – by collapsing categories 1–2 and 3–4 at
ages 12–13 and 14–15, and categories 1–3 and 4–5 at ages 16–17
and 18–19. As only 1 respondent identified as an active smoker at
age 12–13, our analysis focused on smoking at age 14–15.
Self-report anxiety was measured at ages 12–13 and 14–15
using items from the Generalized Anxiety Disorder Scale, a
subscale of the Coolidge personality and neuropsychological
inventory for children [49]. The scale measured twelve items
drawn from DSM-IV [50] criteria for generalized anxiety
disorder, separation anxiety disorder and social phobia on a four
point continuous scale for anxiety symptoms experienced in the
last two months. At ages 16–17 & 18–19, self-report anxiety was
measured using 14 items relevant to anxiety in the Depression
Anxiety Stress Scales – 42 (DASS42 [51]). DASS42 questions
utilize a 0–3 scale, and we averaged these scores and added 1 to
gain a score between 1–4 for each respondent. Increased anxiety
scores equated to increased anxiety symptoms. This scale has
shown good reliability, convergent and discriminant validity in
non-clinical samples [52]. Additional information on validity and
reliability of scales is available elsewhere [43,46,53].
To assist the reader, the results and discussion are presented
such that age 18 months is defined as ‘‘infancy’’, age 14–15 is
defined as ‘‘adolescence’’ and age 18–19 is defined as ‘‘early
adulthood’’.
Data Analytic Procedures
Statistical analyses were undertaken using SPSS version 17 and
Mplus version 6.0 [54]. One smoker was an outlier in terms of
Table 1. Descriptive statistics of included independent and dependent variables.
Baseline Variables Frequency (%) Anxiety Mean Scores Frequency (%)
Maternal Education Anxiety - Age 14–15 yrs
#7 years Schooling 7 (0.8%) 1–1.50 337 (73.9%)
Primary Schooling Only 85 (9.3%) 1.51–2.0 81 (17.8%)
1–2 years High Schooling 245 (26.9%) 2.01–2.5 29 (6.4%)
3 years High Schooling 231 (25.4%) 2.51–3.0 7 (1.5%)
#4 years College/University 208 (22.9%) 3.01–3.5 2 (0.4%)
$4 years College/University 134 (14.7%) 3.51–4.0 0 (0.0%)
Shyness (mean score) Anxiety - Age 16–17 yrs
1–2.00 339 (37.9%) 1–1.50 294 (79.0%)
2.01–3.00 444 (48.6%) 1.51–2.0 57 (15.3%)
3.01–4.00 116 (12.7%) 2.01–2.5 14 (3.8%)
4.01–5.00 15 (1.6%) 2.51–3.0 3 (0.8%)
3.01–3.5 3 (0.8%)
Emotionality (mean score) 3.51–4.0 1 (0.2%)
1–2.00 207 (22.7%)
2.01–3.00 489 (53.6%) Anxiety - Age 18–19 yrs
3.01–4.00 185 (20.3%) 1–1.50 351 (79.6%)
4.01–5.00 32 (3.5%) 1.51–2.0 56 (12.7%)
2.01–2.5 20 (4.5%)
Internalizing (mean score) 2.51–3.0 11 (2.5%)
0–0.49 749 (81.9%) 3.01–3.5 2 (0.5%)
0.50–0.99 124 (13.6%) 3.51–4.0 1 (0.2%)
1.0–1.49 41 (4.5%)
1.50–1.99 1 (0.1%)
doi:10.1371/journal.pone.0063252.t001
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anxiety score, and was recoded to level with the next highest
anxiety score among the smokers. This procedure is in line with
recommendations by Tabachnick & Fidell [55], who recommend
recoding an outlier to a less extreme value.
A structural model was constructed in Mplus to examine how
anxiety and smoking at age 14–15 were associated with smoking
and anxiety at age 18–19. The WLSMV estimator was used due to
the categorical nature of the smoking variable. The WLSMV
estimator allows pairwise rather than listwise deletion and
performs well under the MRAX missing data assumption (where
missingness is associated with independent variables in the model)
[56]. Maternal educational level was included in the models as a
proxy for socioeconomic status [57]. We chose a priori to not
control for depression. Due to the significant overlap between the
self-reported anxiety and depressive symptoms, controlling for
depression would have unacceptably increased the risk of a type 2
error. Given the low number of boys who reported active smoking
at age 14–15 (n= 5), we only created models incorporating the
total sample and girls only.
The moderating effect of smoking on the associations between
childhood risk markers (temperamental emotionality, internalizing
problems, and temperamental shyness) and anxiety at age 18–19
was then examined by running two-group analyses in Mplus. In
these analyses the Robust Maximum Likelihood estimator was
used, allowing use of all available information and accounting for
the non-normal distribution of the measures. The associations
between childhood risk markers and anxiety at age 18–19 were
constrained to be equal among smokers and non-smokers and then
allowed to be estimated freely in the two groups in a second step of
these analyses. The fit of the unconstrained and constrained
models were then compared to test for statistically significant
differences. The smoking group was small in these analyses, and to
reduce the ratio of estimated parameters/number of observations,
the mean and variance of the maternal education variable was
identified for the smokers first and then entered into the models.
We used adjusted chi-square difference values in difference
testing of nested models as suggested by Satorra and Bentler [58].
However, in the model examining the moderating effect of
smoking on the association between early internalizing problems
and later anxiety, the adjusted chi-square difference turned out
negative, and should thus not be interpreted [59]. The ML-
estimator and regular chi-square difference was thus used in these
analyses. An alternative to this methodology would have been to
use the MLMV estimator and the diff-test option [59], but that
would have required listwise deletion and hence a reduction in the
already small active smoking group.
Results
Between ages 14–15 years (‘‘adolescence’’) 21 (4.7%) adoles-
cents (5 boys and 16 girls) self-reported active smoking. The mean
anxiety score for the early adulthood group was 1?30 (SD 0.41).
Between ages 18–19 (‘‘early adulthood’’), 85 (24.2%) adults (36
boys and 49 girls) reported active smoking and mean DASS
anxiety score for the entire sample was 1.30 (SD 0.42). Active
smoking during adolescence was correlated with active smoking in
early adulthood (r = 0.3, p,0.001). In addition, anxiety scores
during adolescence were correlated with anxiety scores during
early adulthood (r = 0.4, p,0.001). Baseline information, smoking
and anxiety scores across time points and correlations are
displayed in Tables 1, 2, 3.
Prospective relationship between adolescent smoking
and early adult anxiety symptoms
Structural Equation Modeling found no relationship between
adolescent anxiety and early adult active smoking. However, a
prospective relationship was found in the total sample between
active smoking in adolescence and early adult anxiety symptoms
(b=0.17, p,0.05). In the model utilizing data from girls only, a
prospective relationship between adolescent active smoking and
early adult anxiety symptoms was also found (b=0.20, p,0.05).
Both models showed perfect fit, as expected when all paths are
allowed to be estimated freely (chi 2 = .000, RMSEA= .000, 90%
C.I. RMSEA= .000–.000, TLI 1.00, CFI = 1.00). In both the total
sample model and girls only model, level of self-reported anxiety at
age 14–15 years was not associated with active smoking at age 18–
19 years.. See Figure 1 for both models.
Smoking as a moderator of the relationship between
vulnerability factors in infancy and later anxiety
We tested the moderating effect of adolescent active smoking on
the relationship between maternally reported temperament,
shyness and internalizing behaviors in infancy and early adult
anxiety symptom scores. Initial correlations demonstrated no
relationship between infant emotionality (temperament) (r = 0.1,
p = 0.83), shyness (r = 0.08, p = 0.12) or internalizing behaviors
(r = 0.05, p = 0.28) and early adult anxiety symptoms scores in the
total sample. However, freeing equality constraints across smoking
groups on the association between infant emotionality and early
adult anxiety, significantly improved model fit (Corrected delta
chi2 = 23.03, df = 1, p,0.01), showing that the association
between early vulnerability markers and later anxiety was
significantly different among smokers and non-smokers (age 14–
15 years). A significant positive association was discovered between
infant emotionality and early adult anxiety symptoms scores for
active smokers (b=0.55, p,0.01), that was not present for non-
active smokers (b=20.01, p.0.05) (see Figure 2). This uncon-
strained model demonstrated excellent fit (chi2 = .027, df = 2,
RMSEA= .000, 90% C.I. RMSEA= .000–.000, CFI= 1.00,
TLI= 1.71). For girls only, freeing the equality constraint across
smoking groups lead to a significant improvement of model fit
(Corrected delta chi2 = 27.01, df = 1, p,0.01), indicating that
active and non-active smokers were significantly different in
reference to the infant emotionality – early adult anxiety
association. A positive association was observed between infant
emotionality and early adult anxiety symptoms scores for active
smokers (b=0.52, p,0.01) that was not present for non-active
smokers (b=0.01, p.0.05). Again, the unconstrained model
demonstrated excellent fit (chi2 = .040, df = 2, RMSEA= .000,
90% C.I. RMSEA= .000–.000, CFI= 1.00, TLI= 4.17).
Similarly, freeing the equality constraint across smoking groups
on the association between infant internalizing behaviors and early
adult anxiety symptoms lead to significantly improved model fit
(delta Chi2 = 14.05, p,0.01, df = 1). In the total sample, this
association was significant for active smokers during adolescence
(b=0.85, p,0.01), but was not present for non-active smokers
(b=0.07, p.0.05) (see Figure 3). The fit of the unconstrained
model was excellent (chi2 = .02, df = 2, RMSEA= .000, 90% C.I.
RMSEA= .000–.000, CFI= 1.00, TLI = 1.56). Similar results
were found for the girls only model, with model fit improving
significantly when freeing the equality constraint across smoking
groups (delta Chi2 = 11.78, p,0.01, df = 1). The association
between infant internalizing symptoms and early adult anxiety
was significant for active smokers (b=0.80, p,0.01), but not for
non-active smokers (b=0.11, p.0.05) during adolescence. Fit of
Adolescent Smoking and Adult Anxiety
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the unconstrained model was excellent (chi2 = .03, df = 2,
RMSEA= .000, 90% C.I. RMSEA= .000–.000, CFI = 1.00,
TLI = 1.49).
No significant interaction was observed between infant shyness
and early adult anxiety symptoms in reference to active smoking
(b=0.08, p.0.05) versus non-active smoking (b=0.14, p.0.05)
(see Figure 4). The constrained model showed excellent fit
(chi2 = .06, df = 3, RMSEA= .000, 90% C.I. RMSEA= .000–
.000, CFI= 1.00, TLI = 1.65.) There was thus no need for a
formal test to conclude that freeing the equality constraint across
smoking groups would not improve model fit significantly. This
was the case for the girls only model as well (active smoking
(b=0.10, p.0.05), non-active smoking (b=0.15, p.0.05))
(chi2 = .06, df = 3, RMSEA= .000, 90% C.I. RMSEA= .000–
.000, CFI= 1.00, TLI = 1.00), indicating that smoking did not
moderate the shyness-later anxiety relationship. No correlation
existed between infant emotionality, internalizing behaviors or
shyness and smoking during adolescence.
Discussion
To our knowledge this is the first study to empirically test the
hypothesis that adolescent smoking moderates the relationship
between early vulnerability for anxiety and early adult anxiety
scores. We found support for this hypothesis in our data. In
addition, we demonstrated a prospective relationship between
active smoking during adolescence and increased early adult
anxiety symptoms, controlling for socioeconomic status.
In our study, both internalizing behaviors and emotionality
expressed in infancy were positively associated with early adult
anxiety symptoms, but only in those who were active smokers in
adolescence. These results suggested that smoking during adoles-
cence conferred a very large effect on the relationship between
internalizing behaviors and early adult anxiety symptoms, as well
as a moderate to large effect on the relationship between increased
emotionality and early adult anxiety symptoms. In contrast, no
differences were observed between adolescent smokers and non-
smokers in the relationship between infant shyness and early adult
anxiety.
There are several potential explanations for the observed
moderating effect of active smoking on these relationships. First, it
is possible that active smoking during adolescence in this study
captured the influence of another factor, or group of factors, that
moderate the relationship between these vulnerability behaviors
and adult anxiety scores. In this study we controlled for
socioeconomic status by utilizing maternal education as a proxy
measure, however a number of other potential moderating and
confounding factors, including individual (e.g. cognitive style) and
social factors (e.g. parental and peer smoking behaviors [60–62]),
were not available to be included in the models. It will be
important for further studies to assess whether such factors affect
Table 2. Baseline smoking and anxiety scores and correlations.
Anxiety
(14–15)
Anxiety
(16–17)
Anxiety
(18–19)
Active Smoking
(14–15)
Active Smoking
(16–17)
Active Smoking
(18–19)
Mean (SD)/Frequency Yes (%) Total;
Female
0.33 (0.38); 0.38
(0.39)
0.30 (0.39); 0.40
(0.44)
0.30 (0.42); 0.37
(0.49)
21 (4.7%); 16 (76%) 45 (4.6%); 30 (67%) 85 (24.2%); 49 (58%)
Anxiety 14–15 x r = 0.314** r = 0.405** r = 0.087 r = 0.035 r = 0.059
Anxiety 16–17 r = 0.314** x r = 0.586** r = 0.042 r = 0.283** r = 0.153*
Anxiety 18–19 r = 0.405** r = 0.586** x r = 0.165** r = 0.167** r = 0.097
Active Smoking 14–15 r = 0.087 r = 0.042 r = 0.165** x r = 0.297** r = 0.296**
Active Smoking 16–17 r = 0.035 r = 0.283** r = 0.167** r = 0.297** x r = 0.413**
Active Smoking 18–19 r = 0.059 r = 0.153* r = 0.097 r = 0.296** r = 0.413** x
Maternal Education (baseline) r =2.08 r =2.09 r = .00 r =2.07 r =2.05 r =2.11
Emotionality (baseline) r =20.101 r = 0.121 r =20.075 r =20.109 r = 0.058 r =20.105
Internalizing Behaviors (baseline) r = 0.065 r =20.035 r =20.079 r = 0.064 r = 0.001 r =20.068
Shyness (baseline) r = .12* r = .17** r = .08 r = .01 r =2.02 r =2.06
Baseline = 18 months of age,
*p,0.05,
**p,0.01.
doi:10.1371/journal.pone.0063252.t002
Table 3. Frequency of smoking reported at different age
categories.
Smoking Rates by Category Frequency (%)
Smoking Age 14–15
Never Smoked 336 (74.7%)
Have Tried Smoking 93 (20.7%)
Sometimes Smoke 13 (3.1%)
Daily Smoking 7 (1.6%)
Smoking Age 16–17
Never Smoked 199 (53.6%)
Have Tried Smoking 119 (32.1%)
Former Smoker, Now Quit 8 (2.2%)
Sometimes Smoke 31 (8.4%)
Daily Smoking 14 (3.8%)
Smoking Age 18–19
Never Smoked 130 (37%)
Have Tried Smoking 120 (34.2%)
Former Smoker, Now Quit 16 (4.6%)
Sometimes Smoke 58 (16.5%)
Daily Smoking 27 (7.7%
doi:10.1371/journal.pone.0063252.t003
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the relationship between anxiety vulnerability and later anxiety
symptoms.
In addition, it is possible that active smoking during adolescence
could represent an expected behavior in individuals with an
underlying vulnerability for anxiety as part of a developing
‘‘anxiety phenotype’’. Such a phenotype could progress from
infant anxiety vulnerability, through increasing periods of anxiety
symptoms, depressive symptoms and psychological distress in late
childhood and adolescence that predispose to increased adolescent
smoking onset, and finally to increased adult anxiety. Individuals
who do not start smoking may overcome this vulnerability
phenotype in some way, altering their anxiety trajectory.
Numerous investigations have demonstrated ‘‘anxiety sensitivity’’,
the exhibition of fear in response to anxiety-related sensations
[63,64], as being significant in influencing the association between
smoking and anxiety symptoms, potentially via increasing anxiety
reactions to smoking cues (e.g. nicotine withdrawal) [65,66].
Another possible explanation is that active smoking is a true risk
factor that modulates the translation of infant anxiety vulnerability
into early adult anxiety. Numerous potential mechanisms for how
cigarette smoking may influence anxiety expression have been
postulated. First, much investigation has explored how the effects
of smoking on the respiratory and autonomic systems may
exacerbate anxiety, particularly panic-type sympto [67]. These
outcomes may involve the disease-inducing effects of smoking,
negative health perception, and/or acute physiological effects
[13,29,31]. The primary addictive ingredient in cigarettes,
nicotine, is known to increase most measures of physiological
arousal, despite often being associated with subjective calming
effects [68], and this increased arousal may promote increased
anxiety symptoms. Second, an evolving literature suggests
exposure to cigarette smoke can adversely affect neurodevelop-
ment. The exposure to cigarette smoke in utero has been shown to
alter gene expression in areas critical to mood and anxiety control
[69], and to modify the expression of infant externalizing
behaviors [70] and other behaviors throughout the life course
[71]. Adolescence is a critical time for neurodevelopment,
characterized by pronounced changes to specific cortical func-
tioning [72], myelination [73] and synaptic connectivity [39,74].
Components of cigarette smoke including nicotine [39,75,76],
metals and free radicals [77] can exert deleterious effects on these
processes, potentially altering developmental trajectories and
leaving individuals more susceptible to increased anxiety symp-
toms in early adulthood. Although it is unlikely that the above
pathways solely explain the large moderating effects demonstrated
in the results, our data suggests that further pursuit of this area as
one component of an explanatory model for the relationship
between anxiety development and cigarette smoking may be
warranted.
In contrast to findings for internalizing behaviors and highly
emotional temperament, no difference was found between active
and non-active smokers in the relationship between infant shyness
Figure 1. Structural model of associations between active smoking and anxiety scores in adolescence (age 14–15) and early
adulthood (age 18–19). Caption: Adolescent active smoking at age 14–15 years in the total sample and for girls only was associated with
increased anxiety symptoms scores at age 18–19 years (b coefficients displayed for total sample first, then for girls only). * p,0.05, ** p,0.01. The
model is adjusted for maternal educational level. Only significant paths are shown. All paths were estimated in the model (df = 0). Model fit perfect
(x 2 = 0.00, RMSEA=0.000, TLI and CFI = 1.00). The path from Adolescent active smoking to early adult active smoking is a probit regression
coefficient. When translated into probabilities, the results show that at a mean level of maternal education and adolescent anxiety, active smoking
during adolescence has 65% risk of being active smokers in early adulthood, while non-active smokers during adolescence has a 36% risk of active-
smoking in early adulthood.
doi:10.1371/journal.pone.0063252.g001
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Figure 2. Association between childhood emotionality at 18 months and early adult anxiety scores (18–19 years) by adolescent
smoking status. Caption: Adolescent active smokers who demonstrated higher emotionality scores during infancy (18months) displayed
significantly elevated anxiety in early adulthood that was not present for non-adolescent active smokers.
doi:10.1371/journal.pone.0063252.g002
Figure 3. Association between childhood internalizing behavior scores at 18 months and early adult anxiety scores (18–19 years)
by adolescent smoking status. Caption: Adolescent active smokers who demonstrated higher internalizing behaviors during infancy (18months)
displayed significantly elevated anxiety in early adulthood that was not present for non-adolescent active smokers.
doi:10.1371/journal.pone.0063252.g003
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and early adult anxiety. Temperamental shyness is linked to
behavioral inhibition, while emotionality is often linked to
approach and pro-active behavior [78,79]. In line with this,
findings demonstrate that shyness is more strongly related to later
social anxiety than other forms of anxiety (see Coplan & Rubin
[78] for a review). Since our measure of anxiety did not include
specific items on social anxiety it’s possible that we may have failed
to observe a specific relationship in this domain of symptoms in
early adulthood. It will be important for future research to
examine how smoking moderates the relationship between early
vulnerability factors and specific sub-groups of adult anxiety.
Our modeling failed to demonstrate a prospective relationship
between increased anxiety symptoms scores at age 14–15 and
active smoking age 18–19 years. Data are conflicting [4,22,26,80]
on whether anxiety leads to increased smoking behavior [81].
Moderating factors, including peer smoking, family smoking and
socioeconomic status, appear important in smoking initiation [16],
and further investigation of adolescent smoking initiation in
populations with a pre-existing vulnerability to anxiety would be
informative.
This study has many strengths but also some limitations. The
main strength is the longitudinal follow-up of a large cohort of
participants over 18 years. The initial sample of over 900 children
was assessed at eight time periods, incorporating self-report data
from mothers and children, providing a unique opportunity to
model change throughout child development to adulthood. The
limitation of missing data that is common in longitudinal studies
was managed utilizing the WLSMV estimator in Mplus. Another
consideration is the representativeness of the study population.
Maternal education was utilized in this study to control for
socioeconomic status, as this measure has been strongly linked to
health behaviors and conscious lifestyle choices in the Norwegian
population [82], although its use is not without contention [83].
However, attrition resulted in the study population becoming
progressively skewed, such that the mean level of maternal
education increased over time. Given the inverse relationship
between socioeconomic status, maternal education and anxiety
symptoms, it is possible that both smoking and anxiety symptoms
were underrepresented in the sample. Replication of this study in a
sample with better coverage of low-SES families would be useful.
We chose a priori to not control for depression in our study, as
we believed such analysis would have unacceptably increased the
risk of type 2 error. In children and adolescents, anxiety and
depressive symptoms are highly comorbid; occurring both
sequentially and concurrently [84]. Taking into account the
longitudinal nature of our study, controlling for depression would
have masked potentially significant individual effects in children
who changed between states of anxiety and depression over time.
However, to investigate specificity of these results to anxiety, we
ran a sensitivity analysis replicating the model with a depression
scale and did not find significant effects (data not shown). We
therefore conclude that even if shared anxiety/depressive/negative
affect symptomatology is responsible for the observed effects, then
it is the anxiety component that appears to be more important.
Further, the self-report measure of smoking grouped smokers
into frequency groups, as opposed to more definitive criteria such
as quantity of cigarettes smoked. It is possible that different
reporters would have defined their smoking behavior differently
(e.g. occasional vs. daily), potentially affecting the accuracy of
smoking rates. We decided to group the relatively small number of
participants who identified themselves as ‘‘former smokers, now
quit’’ into the non-active smokers category as we felt this most
Figure 4. Association between childhood shyness at 18 months and early adult anxiety scores (18–19 years) by adolescent smoking
status. Caption: No relationship, both for adolescent active smokers and non-active smokers, was discovered between reported infant shyness at
18 months and early adult anxiety scores.
doi:10.1371/journal.pone.0063252.g004
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accurately represented their current position. However, we
acknowledge that this small group (as former smokers) may have
suffered neurodevelopmental effects during their time of smoking
that may have altered their anxiety expression, making them
similar to active smokers. Although incorrect grouping of these
participants may have influenced the results, we feel this effect
would be small (due to the small number of participants in this
category) and would lead to smaller, not larger, differences
between smoking groups. In addition, it is possible that reporters
may have been reluctant to report regular smoking in adolescence,
lowering reported smoking rates. Our smoking rates were lower
than rates of daily smoking reported in a study of Norwegian 15-
year-olds in 2005 (8.5% in boys and 9.5% in girls [85]), which may
be due to differences in our population (e.g. higher socioeconomic
status), under-reporting or a combination of both, with this
relatively low sample influencing our ability to undertake more
detailed analysis (e.g. of boys only). Nevertheless, under reporting
would have acted to attenuate observed relationships, resulting in
a more conservative set of findings. Additionally, we were unable
to report on rates of nicotine dependence in our study. Individual
smokers who are nicotine dependent demonstrate increased levels
of anxiety and depression compared to non-dependent smokers
[27], and consideration of this will be important in future
investigations. In respect to anxiety symptom measures, a different
anxiety measurement scale was utilized at age 14–15 and age 18–
19. It is possible that this change in symptom scale affected the
accuracy in tracking the development of anxiety symptoms over
time. However, the fact that anxiety symptoms correlated strongly
between time points suggests this is unlikely to have been a
significant issue. Finally, our sample did not provide information
on other potentially important variables that may influence the
relationships between adolescent smoking and anxiety, including
parental smoking, parental nicotine dependence, parental anxiety,
use of anti-depressant or anti-anxiety medications and more
detailed measures of socioeconomic circumstances. Consideration
of these factors in future investigations would be prudent.
In conclusion, this study aimed to explore whether smoking may
act as an exogenous risk factor that can alter the developmental
trajectory of anxiety from infant vulnerability to early adult
anxiety symptoms. We discovered a prospective relationship
between adolescent active smoking and early adult anxiety, and
strong moderating effects of adolescent smoking on the trajectory
of some, but not all, measures of anxiety vulnerability in infancy
and later adult anxiety symptoms. Although a number of
alternative models which themselves are not mutually exclusive
may explain these findings, the possibility that smoking is able to
exert an adverse effect on the developmental trajectory of anxiety
is not discounted by these findings and is worthy of further
investigation. Further investigation aimed at confirming this
model, coupled with efforts to understand the impact of smoking
on adolescent neurodevelopment, may afford an enhanced
understanding of how cigarette exposure contributes to anxiety
pathogenesis from a developmental perspective. These insights
could eventually inform new treatment opportunities (e.g. agents
that protect against adverse neurobiological effects) and public
health strategies. Although much remains unclear, given the
known adverse health effects of cigarette smoking, in conjunction
with the significant health burden imposed by anxiety disorders
[86,87], this study does support the importance of smoking
prevention and cessation programs targeting children and
adolescence. Smoking should be considered as one of the
potentially plastic environmental risk factors for common mental
disorders, and needs to be incorporated into prevention and
promotion efforts [88]. These efforts may exert positive effects not
just on characteristics of physical health but also on anxiety.
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Abstract
Background: Maternal smoking during pregnancy (MSDP) is associated with multiple adverse childhood outcomes
including externalizing behaviors. However, the association between MSDP and internalizing (anxiety and
depressive) behaviors in offspring has received less investigation. We aimed to assess the association between
MSDP and childhood internalizing (anxiety and depressive) behaviors in a very large, well-characterized cohort
study.
Methods: We assessed the association between MSDP and internalizing behaviors in offspring utilizing information
drawn from 90,040 mother-child pairs enrolled in the Norwegian Mother and Child Cohort Study. Mothers reported
smoking information, including status and frequency of smoking, twice during pregnancy. Mothers also reported
their child’s internalizing behaviors at 18 months, 36 months, and 5 years. Associations between MSDP and
childhood internalizing behaviors, including dose-response and timing of smoking in pregnancy, were assessed at
each time point.
Results: MSDP was associated with increased internalizing behaviors when offspring were aged 18 months
(B = 0.11, P <0.001) and 36 months (B = 0.06, P <0.01), adjusting for numerous potential confounders. Higher rates of
smoking (e.g., >20 cigarettes per day) were associated with higher levels of internalizing behaviors. Maternal
smoking during early pregnancy appeared to be the critical period for exposure.
Conclusions: We found evidence supporting a potential role for MSDP in increasing internalizing (anxiety and
depressive) behaviors in offspring. We also found evidence supportive of a possible causal relationship, including
dose-dependency and support for a predominant role of early pregnancy exposure. Further investigation utilizing
genetically informed designs are warranted to assess this association.
Keywords: Anxiety, Depression, Cigarette smoking, Pregnancy, Obstetrics, Psychiatry
Background
Maternal smoking during pregnancy (MSDP) is associated
with numerous adverse outcomes in children. These occur
in physical, cognitive, and behavioral domains, including
stillbirth [1], lowered birth weight [2], childhood asthma
[3], obesity [4], intelligence [5], hyperactivity, impulsivity,
and conduct problems [6-10]. Hypotheses explaining
these associations include direct causation (e.g., ci-
garette components directly damaging developing fetal
structures and physiological systems) and shared vul-
nerability [11-13] (e.g., genetic and/or environmental
factors increasing rates of MSDP and childhood out-
comes). In the realm of childhood behavioral outcomes,
consistent findings from multiple prospective observa-
tional studies [14], controlling for plausible confounders,
support an argument for a direct causal relationship (e.g.,
via physiological effects) rather than one solely under-
pinned by shared vulnerability. This is complimented by
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animal and human research [15] demonstrating that
MSDP can disrupt neurodevelopment via effects on ma-
turing neurotransmitter systems and brain architecture in
regions associated with stress and mood regulation (e.g.,
the hippocampus [16] and somatosensory cortex [17]).
Despite these findings, however, debate continues re-
garding whether these associations represent causal rela-
tionships [18-20]. As noted by several authors [19,21],
MSDP is associated with numerous social and environ-
mental factors (e.g., teenage motherhood, lower maternal
education [11], increased single motherhood [22]) that
influence childhood outcomes. In addition, genes that
influence the likelihood of MSDP [23] may also affect
childhood outcomes through maternal-child genetic inher-
itance. For this reason, studies utilizing quasi-experimental
designs [19] (e.g., siblings with discordant exposures [24],
children from in vitro fertilization [25]), predominantly
investigating MSDP-childhood externalizing behavior as-
sociations, have been undertaken in an attempt to control
for unmeasured genetic and environmental confounders.
These studies have generally demonstrated attenuation
of previously observed MSDP-childhood externalizing
behavior associations [11,21,26], though exceptions exist
[27]. Although these approaches have advantages over
traditional observational methods [19] and should be pur-
sued further [19,28], they are not without problems [29].
For example, most studies utilizing discordant sibling and
in vitro fertilization analysis have fewer participants,
reducing power to detect true associations. Additionally,
discordant samples are a highly selected group [29], with
factors that underpin maternal behavioral change also
potentially impacting on childhood outcomes. Further,
siblings share on average only 50% of alleles, and therefore
differential effects, even ones protective of adverse behav-
ioral outcomes, could be influenced by variations in the
other 50% of the inherited alleles. It is therefore unlikely
that any single study design will be completely capable of
determining causal inference, and a range of approaches
will be required. In contrast to the effort expended in
exploring the MSDP-childhood externalizing behavior
association, fewer studies have explored the association
between MSDP and childhood internalizing (anxiety and
depressive) behaviors. Those that have investigated this
association report both positive and null results [30-34].
Limitations of these studies, such as small sample sizes,
limited controls for potential confounders, and variable
reporting of smoking, amongst other issues, may have
contributed to these inconsistencies.
Anxiety and depressive disorders represent a signifi-
cant contribution to the global burden of disease [35]. In
contrast to many potential risk factors associated with
childhood outcomes (e.g., genetics), MSDP is potentially
preventable. For this reason, a greater understanding of
the MSDP-childhood internalizing behavior association
is very relevant for public health. We therefore aimed to
build on previous observational studies to investigate the
MSDP-childhood internalizing behavior association in a
very large and well-characterized prospective study. We
tested hypotheses that i) there would be a dose-response
effect, such that higher cigarette consumption would be
associated with higher internalizing behaviors, and ii)
that early pregnancy, as a phase of rapid neurodevelop-
ment, would be a sensitive period. If such an association
existed in a large observational study, further investiga-
tion via a genetically informed design would have signifi-
cant merit.
Methods
Study design and participants
The Norwegian Mother and Child Cohort Study (MoBa)
is a prospective population-based study that aimed to re-
cruit all women who gave birth in Norway between 1999
and 2009 [36]. The sampling frame consisted of women
who attended for routine ultrasound examination at
approximately 17 weeks of gestation. Participation rates
were 38.7% of those invited. For this study, information
was available on 107,379 children (51.2% boys) who were
born to 89,962 participating mothers. Only one child
was included when the mother had twins or triplets to
reduce problems with dependency between observations.
The twin/triplet registered first in the data files was
included in the analyses. Of these respondents, we were
able to utilize information from 90,040 mother-child
pairs where smoking information was available. Mothers
completed detailed questionnaires on their health and
social status at gestational weeks 17 (questionnaire 1) and
30 (questionnaire 3), and questionnaires on the health and
development of their children at multiple time points after
birth, including at ages 18 months (questionnaire 5),
36 months (questionnaire 6), and 5 years (questionnaire 7).
Of those who agreed to participate in MoBa, the response
rates were 94.9% for questionnaire 1 (early pregnancy),
91.0% for questionnaire 3 (late pregnancy), 72.5% for ques-
tionnaire 5 (18 month follow-up), 58.5% for questionnaire
6 (36 month follow-up), and 53.0% for questionnaire 7
(5 year follow-up). All participants provided written infor-
med consent, and ethics approval was obtained from
The Regional Committee for Medical Research Ethics in
South-Eastern Norway.
Exposure: maternal smoking
Mothers self-categorized their current and past smoking
status (daily, occasional, or non-smoking) and also re-
ported the number of cigarettes they smoked per day or
week, at gestational weeks 17 (‘early pregnancy’) and 30
(‘late pregnancy’). We subsequently dichotomized MSDP
(smoking/non-smoking). Mothers who reported smoking
any cigarettes per day or week were considered smokers
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even if they self-categorized as non-smokers. Mothers
who provided smoking data from early and late preg-
nancy were categorized into four groups: smoking only
in early pregnancy, smoking only in late pregnancy, smok-
ing throughout pregnancy, and no smoking in pregnancy.
We calculated a smoking frequency for all women in early
pregnancy by using self-reported daily cigarette consump-
tion or, where not available, dividing self-reported weekly
cigarette consumption by seven. These data were used to
categorize early pregnancy smokers into four groups: no
smoking in early pregnancy, 1 to 9 cigarettes per day,
10 to 19 cigarettes per day, and 20+ cigarettes per day.
For the final analysis, we also incorporated data
from questionnaire 1 to create a dichotomous variable
(yes/no) coding whether women had smoked in previ-
ous pregnancies.
Outcome: childhood anxiety and depressive
(internalizing) behaviors
Mothers reported their child’s internalizing behaviors by
answering questions taken from a condensed 25 ques-
tion version of The Childhood Behavior Checklist
(CBCL) [37] at ages 18 months, 36 months, and 5 years.
At 18 months, internalizing behaviors were assessed
using five items from the internalizing scale of CBCL.
Mothers rated on a 1 to 3 scale (1: ‘Not true’, 2: ‘Somewhat
or sometimes true’, 3: ‘Very true or often true’) the extent
to which their child’s behavior was consistent with the
following statements over the previous 2 months:
1. “Clings to adults or too dependent”
2. “Gets too upset when separated from parents”
3. “Too fearful or anxious”
4. “Disturbed by any change in routine”
5. “Does not eat well”
The first three items are from the anxious/depressed
subscale of the internalizing scale, the fourth from the
emotionally reactive subscale, and the fifth from the
somatic complaints subscale. A mean score of the five
items was computed to represent overall internalizing
behaviors.
At 36 months, internalizing behaviors were assessed
using nine items from the CBCL, including the five
items used at 18 months plus four additional items:
1. “Constipated doesn’t move bowels”
2. “Stomach aches or cramps (without medical cause)”
3. “Vomiting, throwing up (without medical cause)”
4. “Sudden changes in moods or feelings”
The first three items are from the somatic complaints
subscale and the fourth from the emotionally reactive
subscale. Again, each item was rated 1 to 3, with a mean
score of the nine items computed to represent overall
internalizing behaviors.
At 5 years, internalizing behaviors were assessed using
11 items from the CBCL, including the five items used
at 18 months plus six additional items:
1. “Feelings are easily hurt”
2. “Nervous, high-strung, or tense”
3. “Self-conscious or easily embarrassed”
4. “Unhappy, sad, or depressed”
5. “Stomach aches or cramps (without medical cause)”
6. “Vomiting/throwing up (without medical cause)”
The first four items were from the anxious/depressed
subscale, and last two from the somatic complaints
subscale. Each item was rated 1 to 3 (1: ‘Never/rarely’, 2:
‘Sometimes’, 3: ‘Often/typical’) and a mean score of the
11 items was computed to represent overall internalizing
behaviors. Mean inter-item correlations were used as
estimates of internal consistency. Clark and Watson [38]
argue that the mean inter-item correlation is a useful
index of internal consistency for such scales, and recom-
mend that this should be in the range 0.15 to 0.20 for
broad constructs. Correlations measured 0.14, 0.13, and
0.16 at 18 months, 36 months, and 5 years, respectively,
which were very close to this optimal range. Factor
analysis suggested that scale items were best explained by
one factor at each time point (results available on request).
The CBCL possesses good predictive validity in the
Norwegian population [39], with the Norwegian trans-
lation performed by Nøvik [39,40] used in this study.
Covariates
We statistically controlled for a series of potential con-
founding variables, including paternal smoking, maternal
education, maternal age, maternal depressive and anxiety
symptoms, maternal alcohol consumption, parity, gesta-
tional age at birth, and smoking in previous pregnancies.
Information on these covariates was obtained from ques-
tionnaire 1.
Paternal smoking status was assessed from the fathers’
questionnaire undertaken during pregnancy and dichot-
omized. Where fathers had not participated, their smok-
ing status was obtained from the mother’s report of their
smoking status. Maternal education, utilized as a proxy
for socioeconomic status, was assessed by self-report on
a 5-point scale (1: ≤9 years of schooling; 2: 1 to 2 years
of high school; 3: technical high school or junior col-
lege education; 4: 1 to 4 years in college or university;
5: >4 years in college or university). Maternal age in early
pregnancy was calculated from information provided by
the medical birth register. Maternal depressive and anxiety
symptoms were assessed in early pregnancy by self-report
of the Hopkins Symptom Checklist 5 (HSCL-5). This scale
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is a short version of the Hopkins Symptom Checklist 25
(HSCL-25), consisting of five items (“Feeling fearful”,
“Nervousness or shakiness inside”, “Feeling hopeless about
the future”, “Feeling blue”, and “Worrying too much about
things”) rated on a 4-point scale (from not bothered to
very bothered). The HSCL-5 correlates strongly with the
HSCL-25 [41,42]. Cronbach’s alpha in the current sample
was 0.80. Maternal alcohol consumption was assessed on
a 7-point scale ranging from never to approximately 6 to
7 times a week. Information on parity, child’s gender, and
gestational age at birth was obtained from the Norwegian
birth register. Mothers provided information on previous
pregnancies in questionnaire 1, including the number of
previous pregnancies and individual pregnancy details
including birth status, breastfeeding status, weight gain
during pregnancy, and a dichotomous tick box for
“Smoked during pregnancy”.
We performed correlations of all potential confounding
factors to assess their relationship between exposures
(MSDP characteristics) and outcomes (internalizing beha-
viors). Due to rules regarding the publication of covariate
effects derived from MoBa data we are unable to report
correlation data in its entirety. However, of our potential
confounding factors, only child gender did not display
associations between exposure and outcome and hence
was not included in adjusted models.
Statistical analyses
All statistical analyses were performed in SPSS version 20.
Only subjects without missing data points were included
in each individual analysis. The internalizing scale was
log-transformed due to a non-normal distribution (right
or positively skewed). A right skewed distribution meant
that most respondents reported low levels of internalizing
problems – as one would expect in a community sample.
The log-transformed scale was then standardized for ease
of interpretation. Standardizing allowed comparison of
results across analyses using internalizing behavior at dif-
ferent time points as outcomes. ANOVA was performed
to compare level of internalizing symptoms among chil-
dren of mothers who did not smoke to the level of such
symptoms among children of the different groups of
smokers (e.g., early in pregnancy, late in pregnancy, and
throughout pregnancy). The ANOVAs were performed
using generalized estimating equations (GEE) with the
“sandwich estimator” because of violations of the assump-
tions of linear models about homogeneity of variance and
independence between observations. This estimator pro-
vides robust standard errors, especially when N and the
number of independent observations are large [43]. We
used an unstructured correlation matrix, as this does not
put any a priori restrictions on the modelling of these cor-
relations, while an independent correlation matrix treats
related observations (e.g., siblings) as not more correlated
than other observations. Both of these are possible models
for siblings’ data and were checked. The one with the best
fit to the data was selected – the independent correlation
matrix. We interpreted that correlations between siblings’
data were not found to be a major concern in our ana-
lyses. GEE was still preferred over usual ANOVA as GEE
allows using models with unequal variances in different
groups.
Basic descriptive statistics and Pearson correlations of
study variables were performed. We used ANOVA
models to examine mean differences between MSDP
status and childhood internalizing behaviors at 18 months,
36 months, and 5 years. Model A was unadjusted,
Model B was adjusted for paternal smoking, maternal
alcohol consumption, maternal depressive and anxiety
symptoms, maternal age, maternal education level, par-
ity, and gestational age at birth, and Model C further
adjusted for retrospective reporting of smoking in previ-
ous pregnancies. For each model and subsequent ana-
lysis, only participants reporting all required data were
included.
We hypothesized that the impact of smoking on
internalizing behaviors would be largest in early preg-
nancy, as this is a time of rapid neurodevelopment [44].
Therefore, we tested the association between timing of
MSDP (early only, late only, throughout, or no smoking)
on internalizing behaviors at 18 months, 36 months, and
5 years. We then compared the effect size of smoking
only in early pregnancy and smoking only in late preg-
nancy with the effect size of smoking throughout preg-
nancy at each time point. We hypothesized that if the
effect size of smoking in a particular stage of pregnancy
(e.g., early or late) was significantly weaker than the
effect size of smoking throughout pregnancy, then this
would suggest exposure to MSDP at this stage con-
tributed less to internalizing behavior expression than
exposure in the alternative stage of pregnancy. We
undertook significance testing between comparing the
effects of early pregnancy smoking and late pregnancy
smoking with smoking throughout pregnancy by using
the standard error (SE) of the difference as advised by
Cohen et al. [45]. This procedure involves calculating
the SE of the difference between effect sizes (SEdiff = sqrt
(SEB1
2 + SEB2
2 )) and then dividing the difference be-
tween effects by this SEdiff to obtain z-scores for the
differences.
Further, we tested whether a dose-response relation-
ship existed between daily maternal cigarette consump-
tion in early pregnancy and internalizing behaviors in
children at 18 months, 36 months, and 5 years. Linear
models comparing three categories of smoking frequency
(20+ per day, 10 to 19 per day, 1 to 9 per day) were
compared to non-smokers and adjusted for Model B
covariates.
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Finally, we undertook a subsample analysis of mother-
child pairs where information was available regarding
smoking in previous pregnancies (n = 65,439) to test
MSDP-childhood internalizing behavior associations at
ages 18 months, 36 months, and 5 years adjusting for
Model B covariates plus smoking in previous pregnan-
cies (Model C).
As discussed in the introduction, MSDP and child-
hood behavioral outcomes are associated with various
genetic and environmental factors that are challenging
to measure in observational studies. If uncontrolled,
these factors may contribute to spurious associations be-
ing observed between MSDP and childhood behaviors.
MSDP could influence childhood internalizing behavior
expression in two ways. First, MSDP could influence
internalizing behavior expression through direct effects
on the developing fetus. Second, MSDP and internaliz-
ing behaviors could be indirectly linked through a series
of shared genetic and environmental factors unrelated to
the direct smoking effects. In contrast to MSDP, smok-
ing in a past pregnancy can only be associated with a
current child’s internalizing behaviors through effects
mediated by shared genetic and environmental factors
(as no direct smoking effects are possible). Therefore,
given a portion of these indirect factors (e.g., maternal
genetics, maternal education level) will be consistent be-
tween past and current pregnancies, controlling for this
variable is likely to capture some of the indirect effects
influencing the MSDP-internalizing behavior association.
Although limitations exist for this approach, by con-
trolling for as many indirect effects as possible, we aimed
to approximate the direct impact of MSDP (e.g., by dis-
ruption of normal neurodevelopment) on the current
child’s internalizing behaviors.
Results
Descriptive statistics
The sample sizes available for the different analyses are
shown in Figure 1. Mean maternal age at birth was 29.8
(standard deviation (SD), 4.6) years and mean gestational
age at birth was 39.3 (SD, 2.26) weeks. Smoking informa-
tion was reported in 90,040 pregnancies, with maternal
smoking in early pregnancy present in 8,418 pregnancies
(9.3%). Mean maternal depression and anxiety in early
pregnancy on the HSCL-5 was 1.26 (SD, 0.40). Informa-
tion on internalizing behaviors was available for 69,946
children at 18 months, 57,143 children at 36 months, and
19,778 children at 5 years. Mean internalizing behaviors
were 1.27 (SD, 0.25) at 18 months, 1.25 (SD, 0.22) at
36 months, and 1.16 (0.19, SD) at 5 years. Descriptive
statistics of exposures, outcomes, and covariates are in-
cluded in Table 1. Missing information on questionnaires
lead to exclusion of 5,274 mother-child pairs at 18 months,
407 mother-child pairs at 36 months, and 95 mother-child
pairs at 5 years. Compared to eligible participants, chil-
dren excluded due to missing data or being lost to follow-
up had mothers who were more likely to be younger, less
well educated, had higher rates of depression, higher par-
ity, and were smokers in early pregnancy (results available
on request).
Linear associations
Linear associations were noted between increased ma-
ternal alcohol consumption, maternal depressive and
anxiety symptoms, parity and paternal smoking, and in-
creased maternal smoking in early and late pregnancy.
Increasing maternal age, maternal education, and gesta-
tional age at birth were correlated with decreased mater-
nal smoking in early and late pregnancy. Child gender
was not associated with maternal smoking. Internalizing
behaviors at 18 months, 36 months, and 5 years were
strongly positively correlated. Linear associations were
noted between increased internalizing behaviors at all-
time points and increased paternal smoking, maternal
depressive and anxiety symptoms, and child gender
(boys). Increasing maternal age, maternal education, ges-
tational age, and parity were associated with decreased
internalizing behaviors at all-time points. Linear associa-
tions of relatively small effect size were observed between
MDSP and internalizing symptoms at all time points
(Table 2).
Associations between MSDP, timing of MSDP, and
childhood internalizing symptoms
Maternal smoking in early pregnancy and throughout the
entire pregnancy was associated with increased internaliz-
ing behaviors in children at 18 months, 36 months, and
5 years unadjusted for confounding variables (Model A,
Table 3). Maternal smoking in late pregnancy only was
associated with increased internalizing behaviors at
18 months but not at later time points. In our analysis of
timing of smoking during pregnancy, we found insuffi-
cient evidence to conclude any differences between
mothers who smoked only in early pregnancy and those
who smoked throughout pregnancy on children’s internal-
izing behaviors observed at 18 months (P ≥0.05). However,
the observed effect size of association of smoking only in
late pregnancy was smaller than the observed effect size of
association of smoking throughout pregnancy (P <0.01),
possibly indicating maternal smoking in early pregnancy
underpins this effect. No significant differences in associa-
tions were observed in children at 36 months and 5 years.
After adjusting for Model B covariates, maternal smoking
in early pregnancy remained associated with increased
internalizing behaviors at 18 months and 36 months, but
not 5 years. As observed for Model A, the relative magni-
tude of the association between maternal smoking and
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subsequent internalizing behaviors after adjustment
reduced as children aged (Figure 2).
Dose-response relationship between MSDP and childhood
internalizing symptoms
A dose-response relationship was observed between fre-
quency of maternal smoking in early pregnancy and
childhood internalizing behaviors at 18 months, adjusting
for Model B covariates (Figure 3). Smoking 20+ cigarettes
daily conferred a much larger effect (B = 0.56, SE = 0.19,
P <0.01) than smoking 10 to 19 cigarettes (B = 0.14,
SE = 0.04, P <0.001) or 1 to 9 cigarettes (B = 0.10, SE =
0.20, P <0.001), when compared to not smoking. These
results suggest that children of mothers who smoked
20+ cigarettes during pregnancy displayed an average
of 0.56 SD higher levels of internalizing symptoms at
age 18 months than children of non-smoking mothers, on
the log-transformed scale. Similar disparities in observed
associations with different daily smoking rates were
present at 36 months and 5 years, but failed to reach
significance.
Associations between MSDP and childhood internalizing
symptoms, controlling for smoking in past pregnancies
In a subsample of women who provided information
about previous pregnancies (n = 65,439), smoking in
previous pregnancies was associated with increased
current childhood internalizing behaviors at 18 months
(B = 0.04, P <0.05) and 36 months (B = 0.10, P <0.01),
but not at 5 years. Adjusting for Model B covariates
plus smoking in previous pregnancies (Model C) showed
that maternal smoking in early pregnancy was associated
with increased internalizing behaviors in children at
18 months, but not at 36 months and 5 years, when com-
pared to non-smokers.
Figure 1 Study profile. Figure 1 details the data available for each individual analysis performed in the study. Data from a total of 107,379
mother-child pairs was available in the Norwegian Mother and Child Cohort Study at the time of this study, of which 90,040 provided information
about maternal smoking during pregnancy. For each model described, the number of mother-child pairs excluded due to missing internalizing
symptom information is listed first, followed by the total number of mother-child pairs available for the specific analysis at each time point. Model
A represents the unadjusted model. Model B represents the main confounder model adjusted for covariates paternal smoking, maternal alcohol
consumption, maternal depressive and anxiety symptoms, maternal age, maternal education level, parity, and gestational age at birth. Dose-response
analysis includes controls for Model B covariates. Model C represents the main confounder model in a subsample of mothers who provided information
on smoking in past pregnancies. Analyses in Model C include Model B covariates plus adjustment for smoking in previous pregnancies.
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Discussion
In this large, well-characterized prospective study, MSDP
was associated with increased internalizing behaviors in
children, adjusting for a broad range of possible con-
founders. A dose-dependent effect of MSDP was evident.
There was a larger adverse impact of smoking in early
pregnancy than in late pregnancy. Finally, smoking in
previous pregnancies was associated with increased inter-
nalizing behaviors in subsequently born children at age
18 months, suggesting this variable may capture some
portion of residual confounding (e.g., genetic risk, envir-
onmental influences) not included in models. Controlling
for this variable did not, however, eliminate the observed
association.
Our data builds significantly on previous observational
literature that has demonstrated inconsistent results. For
example, analysis of 2,758 mother-child pairs from the
RAINE study revealed that children displayed higher
internalizing behaviors between ages 2 and 14 if their
mother failed to quit smoking by week 18 of pregnancy
(OR 1.55, P = 0.006), also after controlling for a range of
potential confounders [34]. Children of women who quit
prior to gestational week 18, irrespective of their pre-
vious smoking levels, did not display different levels of
internalizing behaviors than children of non-smoking
mothers. These results contrast with outcomes from two
large cohorts, where adjustment for confounders elimi-
nated the association. In assessment of The Generation
R study (n = 4,680), effects of MSDP on childhood inter-
nalizing behaviors at 18 months were completely con-
founded by adjustment for parental educational level,
family income, national origin, parental psychopath-
ology, and child gender [46]. In the Avon Longitudinal
study (n = 4,394), MSDP was not associated with in-
creased internalizing behaviors in children aged 4 years,
after controlling for a range of potential confounders in-
cluding socioeconomic status, parental psychopathology,
and alcohol consumption [32].
The inconsistency in published studies may reflect
power issues, varying ages of assessment, and differences
in included confounders or populations assessed. For
example, the overall risk of behavioral problems in the
Generation R Study sample was lower than that of the
normal Dutch population, potentially limiting capacity
to find small associations [46]. Our study found the largest
impact of MSDP appeared in children aged 18 months,
with magnitude of associations diminishing over time.
This observation may reflect an evolution from a greater
impact of genetic and intrauterine factors immediately
after birth, towards an increasing impact of prevailing psy-
chosocial factors on internalizing behavior expression as
children grow up. These data are concordant with studies
demonstrating positive associations between MSDP and
internalizing behaviors when assessing younger (e.g., 1 to
3 years) [33,34] but not older (e.g., age >4) [9,32,47]
children, although exceptions exist [30,46,48].
Most toxins display a dose-dependent relationship.
Our finding of the greatest impact on internalizing be-
haviors occurring in mothers who smoked 20+ cigarettes
per day is therefore concordant with expected patterns.
Our data additionally demonstrated the largest effect on
Table 1 Descriptive statistics of exposures, outcomes, and
included covariates
Mean (SD)
Maternal age (years) 29.8 (4.6)
Gestational age at birth (weeks) 39.34 (2.26)
Maternal depression and anxiety
in early pregnancy (range 1 to 4)
1.26 (0.40)
Maternal education N (% total)
≤9 years education 2,782 (2.6%)
1 to 2 years high schooling 4,944 (4.6%)
3 years schooling 26,854 (25.0%)
1 to 4 college/university 39,388 (36.7%)
>4 years college/university 22,579 (21.0%)
Missing 10,832 (10.1%)
Maternal alcohol consumption N (% total)
Never 74,702 (69.6%)
<1 episode per month 8,615 (8.0%)
1 to 3 episodes per month 1,995 (1.9%)
<1 episode per week 429 (0.4%)
2 to 3 episodes per week 61 (0.1%)
4 to 5 episodes per week 7 (0.0%)
6 to 7 episodes per week 15 (0.0%)
Missing data 21,555 (20.1%)
Maternal parity N (% total)
0 47,515 (44.2%)
1 38,188 (35.6%)
2 16,443 (15.3%)
3 3,610 (3.4%)
4+ 1,132 (1.1%)
Missing data 492 (0.5%)
Paternal smoking (early pregnancy) N (% total)
Yes 25,039 (23.3%)
No 76,079 (70.9%)
Missing data 6,261 (5.8%)
Internalizing symptoms (range 1 to 3) Mean (SD)
18 months (n = 69,946) 1.27 (0.25)
36 months (n = 57,143) 1.25 (0.22)
5 years (n = 19,778) 1.16 (0.19)
Internalizing symptoms are drawn from maternal report from a condensed
version of the CBCL. Maternal depression and anxiety symptoms are drawn
from the HSCL-5.
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childhood internalizing behaviors in those who smoked
during early rather than late pregnancy. These findings
are consistent with animal models that demonstrate pre-
natal nicotine exposure is associated with long term in-
creases in anxiety behaviors [49]. It is hypothesized that
increased anxiety behaviors observed in animals exposed
to MSDP may at least partially relate to nicotine and
other cigarette smoke components directly interfering
with normal neurodevelopmental processes in utero
[16,50]. Germane to first trimester effects of MSDP, nic-
otinic acetylcholine receptors are expressed very early
(prior to neurulation) in gestation and serve a critical
role in facilitating key aspects of neurodevelopment,
including neurogenesis, planned apoptosis, and axonal
and synaptic growth [16]. Abnormal activation of these re-
ceptors via exogenous nicotine has been demonstrated to
interfere with these key neurodevelopmental processes,
including in brain regions associated with mood and anx-
iety control [17,51]. These changes appear to be associated
with later behavioral problems in animal models, includ-
ing increased anxiety states [52], but it is not yet known if
this applies to humans [53].
Despite this, whether our results represent a causal
relationship is not yet determined. Causal assumptions
from observational data are vulnerable to unmeasured
confounding [18,26,28]. Although our observed associa-
tions sustained even after statistically (not experimen-
tally) controlling for numerous important confounders,
including maternal mental health, alcohol consumption,
demographics, socioeconomic status, and paternal smok-
ing, it remains possible that the dose-dependent MSDP-
internalizing behavior association may still have resulted
from unmeasured and uncontrolled genetic and environ-
mental confounding (e.g., parental genetic factors) [19,21].
Table 2 Correlations between maternal smoking, smoking in previous pregnancies, and internalizing behaviors in
children at 18 months, 36 months, and 5 years
Maternal smoking
early pregnancy
(dichotomized)
Maternal smoking
early pregnancy
(cigarettes per day)
Maternal
smoking late
pregnancy
(dichotomized)
Maternal
smoking
in previous
pregnancy
Internalizing
behaviors
(18 months)
Internalizing
behaviors
(36 months)
Internalizing
behaviors
(5 years)
Maternal smoking
early pregnancy
(dichotomized)
1
Maternal smoking
early pregnancy
(cigarettes per day)
n/a 1
Maternal smoking
late pregnancy
(dichotomized)
0.840** 0.822** 1
Maternal smoking in
previous pregnancy
0.534** 0.519** 0.519** 1
Internalizing behaviors
(18 months)
0.065** 0.065** 0.057** 0.067** 1
Internalizing behaviors
(36 months)
0.051** 0.050** 0.043** 0.073** 0.354** 1
Internalizing behaviors
(5 years)
0.031** 0.039** 0.029** 0.051** 0.272** 0.404** 1
Internalizing behaviors have been log transformed and standardized. Correlations are Pearson Coefficients. **P <0.001.
Table 3 Associations between timing of maternal smoking and internalizing behaviors in children at 18 months,
36 months, and 5 years
Dependent variable
Internalizing behaviors
(18 months; n = 62,119)
Internalizing behaviors
(36 months; n = 50,223)
Internalizing behaviors
(5 years; n = 19,155)
Maternal non-smokers Reference Reference Reference
Maternal smoking in early pregnancy only B = 0.20 (SE, 0.04), P <0.001 B = 0.17 (SE, 0.04), P <0.001 B = 0.15 (SE, 0.07), P = 0.03
Maternal smoking in late pregnancy B = 0.11 (SE, 0.05), P = 0.04 B = 0.10 (SE, 0.06), P = 0.09 B = 0.21 (SE, 0.11), P = 0.06
Maternal smoking throughout pregnancy B = 0.19 (SE, 0.02), P <0.001 B = 0.19 (SE, 0.02), P <0.001 B = 0.11 (SE, 0.04), P <0.01
Maternal non-smokers are the reference group, i.e., each of the three smoking groups is compared to this group in the analyses. Internalizing behaviors have been
log transformed and standardized. B coefficients should be interpreted as units of standard deviation difference between each smoking group and non-smokers
in the log-transformed scale for internalizing behaviors.
SE, Standard error.
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As genetic or adequate same-sibling data were not
available in MoBA, we were unable to undertake a
quasi-experimental design that could attempt to control
for these genetic and environmental factors. Therefore,
we attempted to address potential residual confounding
by controlling the observed association for smoking in
past pregnancies. We hypothesized that smoking in past
pregnancies would act as a proxy that captures some
residual genetic and environmental confounding as i)
there was an observed positive association between
smoking in a previous pregnancy and the current child’s
internalizing behaviors after controlling for other in-
cluded covariates, ii) genetic factors predisposing the
mother to MSDP should be consistent across both preg-
nancies, and iii) many of the environmental factors
influencing the likelihood of MSDP not captured through
the measured confounding variables should be consistent
across past and current pregnancies. Although this ap-
proach does not completely control for residual genetic
and environmental confounding (e.g., parental genetic
influences, changes to environmental circumstances be-
tween pregnancies), we believe this approach brings us
one step closer to the true relationship. Including this
variable into analysis, we found that the strength of associ-
ation between MSDP in the current pregnancy and child-
hood internalizing behaviors at age 18 months decreased,
but remained significant. Future studies utilizing afore-
mentioned quasi-experimental designs in a large popula-
tion would be of great benefit in further assessing the role
of residual confounding.
Limitations and directions for future research
Although this study has numerous strengths, including lon-
gitudinal follow-up of a very large and well-characterized
cohort, the results should be interpreted in light of some
limitations. The inability to confirm a causal association is
common to all observational studies. In addition, our
study was limited by maternal self-report of internalizing
behaviors and smoking. Although previous investigations
demonstrate that self-report of smoking correlates highly
with measured cotinine levels in pregnancy [54], the lack
of multiple informants for assessment of childhood in-
ternalizing symptoms (e.g., paternal, teacher, or clinician
reports) to correlate the maternal reports is a limitation.
We were unable to control for numerous paternal factors
in addition to postnatal factors, including child-rearing
Figure 2 Associations between maternal smoking and internalizing behaviors in children at 18 months, 36 months, and 5 years
adjusting for Model A, Model B, and Model C covariates. This figure displays the individual B coefficients for associations between maternal
smoking during pregnancy and internalizing behaviors at different time points for Models A, B, and C. Associations were discovered at all time points
for Model A (unadjusted), and at 18 months and 36 months for Model B (main confounder model). After controlling for smoking in past pregnancies
only associations at age 18 months remained significant. The effect sizes decreased as children grew older. Non-smoking mother-child pairs are the
reference group. Internalizing behaviors have been log transformed and standardized. B coefficients should be interpreted as units of standard
deviation difference in corrected internalizing behaviors between smokers and non-smokers. * Model A: Unadjusted model. † Model B: Main
confounder model adjusted for paternal smoking, maternal alcohol consumption, maternal depressive and anxiety symptoms, maternal age, maternal
education level, parity, and gestational age at birth. ‡ Model C: Main confounder model in subsample of mothers, Model B plus adjustment for
smoking in previous pregnancies. For Model A, ratio of smokers to non-smokers was 4,663/57,456, 3,728/46,495 and 1,167/17,988 for analysis at
time points 18 months, 36 months, and 5 years, respectively. For Model B, the ratio of smokers to non-smokers was 3,829/46,986, 3,072/38,268, and
960/14,800 for analysis at time points 18 months, 36 months, and 5 years, respectively. For Model C, the ratio of smokers to non-smokers was 2,717/
30,052, 2,157/24,229, and 663/9,620 for analysis at time points 18 months, 36 months, and 5 years, respectively.
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proficiency, rates of breastfeeding [55], and exposure to
environmental cigarette smoke that may have influenced
expression of childhood internalizing behaviors. There
was loss to follow-up throughout the study that may have
distorted the findings, with children lost to attrition
mainly having younger and less educated mothers, with
higher rates of depression and anxiety symptoms, higher
parity, and increased rates of smoking in early pregnancy.
Monte Carlo simulations have shown that even though es-
timates of mean levels are sensitive to selective attrition,
estimates of associations between variables are generally
robust against selective attrition and that this is true even
when non-response is related to unmeasured variables
[56]. Although the MoBa study is a very large cohort and
therefore confers substantial power to detect effects,
for some analyses, such as those involving later ages of
follow-up (e.g., 36 months and 5 years) and the dose
dependence analysis (with relatively few mothers reporting
certain behaviors, e.g., smoking >20 cigarettes per day),
reduced availability of data may have reduced power to
detect associations. MoBa utilized condensed versions of
the CBCL scale to assess internalizing behaviors, which is
a limitation, although factor analysis of the scales sug-
gested that scale items were best explained by a single
factor at each time point (results available on request). In
addition, reporting of smoking in past pregnancies in
Model C was retrospective, introducing the possibility of
reporting bias. The MoBa cohort has a relatively low
response rate that may represent a potential issue for
generalizability to the Norwegian population, although the
sample size remains substantial. In a comparison per-
formed between data acquired in MoBa between 2000 and
2006 and data from the Norwegian Medical Birth Registry,
maternal participants in MoBa were more likely to be
older, less likely to be single, have lower parity, have lower
rates of previous stillbirths, and less likely to suffer mater-
nal asthma [57]. In addition, MoBa participants were more
likely to be non-smokers, more likely to use folic acid, and
less likely to suffer from gestational diabetes and placental
abruption [57]. Although it is difficult to predict in what
way these factors could bias our observations, we believe
it is likely these factors (e.g., lower smoking rates) would
be more likely to underestimate rather than overestimate
associations.
Conclusions
Overall, utilizing a very large mother-child cohort, our
findings build significantly on the previous literature in
demonstrating a population-wide association between
MSDP and increased internalizing behaviors in children.
Our study demonstrated a dose-dependent relationship
and that the magnitude of observed association is great-
est when mothers smoked in early pregnancy. The ob-
served association sustained even after using smoking in
past pregnancies as a proxy to control for some likely
residual genetic and environmental confounding under-
pinning this relationship. These results suggest further
studies, potentially utilizing quasi-experimental designs
Figure 3 Associations between different daily maternal cigarette consumption and internalizing behaviors in children at 18 months,
36 months, and 5 years. This figure displays the individual B coefficients for associations between different daily rates of maternal smoking during
prgnancy and internalizing behaviors at different time points adjusted for Model B covariates. Associations were discovered for all rates of smoking
at 18 months. Non-smoking mother-child pairs are the reference group. Internalizing behaviors have been log transformed and standardized. B
coefficients should be interpreted as units of standard deviation difference in corrected internalizing behaviors between smokers and non-smokers. All
analyses adjusted for Model B covariates paternal smoking, maternal alcohol consumption, maternal depressive and anxiety symptoms, maternal age,
maternal education level, parity, and gestational age at birth. Reported n’s are numbers of smokers at each time point in that smoking category. N’s for
maternal non-smokers were 46,986, 38,268, and 14,800 at time points 18 months, 36 months, and 5 years, respectively.
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exploring the contribution of unmeasured genetic
and environmental confounds as undertaken in other
MSDP-childhood outcomes literature [19], are justi-
fied to further investigate the relationship between
MSDP and internalizing behaviors in children. Consistent
findings across differing study designs, in concert with the
known deleterious impact of MSDP on other elements of
childhood health [1,3,11], would provide further support
for public health interventions aimed at reducing smoking
in women of child-bearing age.
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1 CHAPTER ELEVEN: FINAL 
DISCUSSION 
The primary goal of this research study was to develop a greater 
understanding of whether cigarette smoking can be considered a plausible risk 
factor for the development of increased anxiety symptoms and disorders. To 
achieve this, the research study aimed to answer five research questions 
detailed in Chapter 3. These questions informed the basis for the five research 
projects undertaken that were subsequently detailed. As the included 
published papers and chapters have already incorporated a comprehensive 
discussion of the context, methodology, results and limitations of each 
individual study within the text, the final discussion will not re-examine these 
issues in detail. Rather, in the final discussion I will briefly summarise the 
results of the individual studies, consider some consistent limitations that exist 
across the research study, draw a conclusion and highlight areas identified by 
the study as deserving future investigation.  
SUMMARY OF RESULTS FROM THE RESEARCH STUDY 
Despite the limitations of this type of research, this series of research projects 
provides extensive support for the concept that cigarette smoking can be 
considered a plausible risk factor for the development of anxiety symptoms 
and disorders.   
 
As detailed in Chapter 5: Paper 1 (Moylan, Jacka, Pasco, & Berk, 2012), 
comprehensive systematic review of the existing population-based 
epidemiological literature most consistently supported a relationship between 
prior cigarette smoking and a subsequent increased risk of developing anxiety 
disorders, particularly PD and GAD. Interestingly, studies that utilised 
samples exploring exposure to cigarette smoking in adolescence, as opposed 
to in adulthood, displayed the most consistent associations. This finding is 
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interesting because it suggested that adolescence, a period of significant 
neurodevelopment (Spear, 2003), may represent a vulnerable time for 
exposure to cigarette smoke. 
 
Following this thought process, Chapter 6: Paper 2 (Moylan et al., 2013c) 
detailed a comprehensive integration of the animal and human literature that 
has explored the biological mechanisms through which cigarette smoking may 
increase the expression of anxiety symptoms and disorders.  The results 
demonstrated numerous mechanisms through which components of cigarette 
smoke can influence key biological pathways thought to underpin anxiety 
control. These include effects on biological structures and pathways involved 
in modulating release of key anxiety-regulating neurotransmitters such as 5-
HT, NA, DA, GABA, Glutamate and ACh (e.g. via interaction with 
nAChR’s), through promoting inflammatory and CMI cytokine responses, 
through induction of increased levels of O&NS, through altering neurotrophin 
expression and subsequent neurogenesis, through impairing mitochondrial 
function, and through inducing epigenetic changes to key genes involved in 
all of these processes. These effects were summarised in Chapter 6 – Figure 1. 
In addition, the comprehensive integration of this far-reaching literature 
supported the contention that cigarette smoke exposure during key stages of 
neurodevelopment (e.g. in utero, early childhood and adolescence) can alter 
anxiety trajectories by influencing the functioning and development of these 
aforementioned biological processes and pathways. Multiple lines of evidence 
also supported the contention that cigarette exposure during key periods of 
neurodevelopment can increase levels of anxiety in animal models, and that 
this effect can extend into adolescence and adulthood.  
 
Based in the context of this literature, the research study continued its 
exploration of this relationship by focusing on further developing an 
understanding of the epidemiological relationships between cigarette smoking 
and anxiety symptom and disorder development. This was undertaken with a 
view to examining the relationship contingent on exposures at three different 
stages in life: adulthood, childhood and adolescence, and in utero.  
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In Chapter 8: Paper 3, an investigation of a population-based cohort of adult 
women failed to demonstrate a relationship between anxiety disorder 
diagnosis and prior exposure to self-reported regular cigarette smoking. This 
finding was in contrast to our expected hypothesis and some, but not all, of 
the extant literature on this topic that was examined in Chapter 5: Paper 1 
(Moylan et al., 2012). Discussion of these findings (included in the Paper 
text) suggested a range of possible methodological issues that may have 
affected the results.  However, given the context of the evolving hypothesis of 
this research study that there may be periods of heightened vulnerability for 
exposure (e.g. during periods of neurodevelopment), this result may not be 
have been unexpected. 
 
Therefore in Chapter 9: Paper 4 (Moylan et al., 2013b) & Chapter 10: Paper 5 
(Moylan et al., 2015) the research study aimed to test the hypothesis that 
exposure during periods of neurodevelopment and disease onset vulnerability 
would be most associated with increased anxiety symptoms.  
 
In Chapter 9: Paper 4 (Moylan et al., 2013b) the hypothesis that adolescence 
is a period of vulnerability for cigarette smoke exposure on subsequent 
development of anxiety was tested through use of a large prospective cohort. 
The results elucidated two important outcomes. First, the results demonstrated 
a prospective relationship between adolescent cigarette smoking at age 14 
years and increased levels of anxiety symptoms in early adulthood. This 
relationship suggests that intervention to reduce smoking in adolescence may 
reduce early adult anxiety symptoms. Second, a large interaction effect was 
discovered, such that those individuals with high levels of anxiety symptoms 
in early childhood (age 18 months) displayed substantially higher levels of 
early adult anxiety symptoms if they smoked during adolescence, compared to 
non-smoker peers. Interestingly, those individuals with higher levels of early 
childhood anxiety who did not smoke in adolescence displayed no higher 
anxiety in early adulthood than individuals with normal levels of early 
childhood anxiety.  Although requiring further investigation, these results 
suggest a model where smoking in adolescence may disproportionately 
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influence expression of high anxiety in individuals with pre-existing anxiety 
vulnerability. 
 
Finally, in Chapter 10: Paper 5 (Moylan et al., 2015) the results drawn from 
an investigation of a very large cohort of mother-child pairs demonstrated a 
dose-dependent association between maternal smoking during pregnancy and 
early childhood (age 18 months and 36 months) anxiety and depressive 
symptoms. The results also supported early pregnancy (prior to week 17 of 
gestation) as the most important period for exposure. The observed results at 
age 18 months were not nullified by efforts to control for residual 
confounding. These results align with the understanding of how cigarette 
smoke exposure can exert effects during gestation on developing 
neurobiological pathways associated with anxiety control as articulated in 
Chapter 6: Paper 2 (Moylan et al., 2013c).  
SYNTHESIS OF THE RESULTS 
So what can we draw from this research study overall? It must first be 
acknowledged that by no means do the results derived from this research 
study confirm cigarette smoking as a causal risk factor for the development of 
anxiety symptoms and disorders.  This was not the intention. Rather, the 
intention of the research study was to determine if, on balance, smoking could 
be considered a plausible risk factor for the development of anxiety, and if so, 
to articulate areas of knowledge deficit that could be targeted in future 
research endeavours. 
 
Anxiety symptoms and disorders are complicated phenomena. The 
contributions to aetiology are numerous and inter-connected. The human 
anxiety response is a physiological as well as a potentially psychopathological 
phenomenon, one that has stayed a core component of our biology throughout 
our evolution. Anxiety and the biological systems that underpin it serve a core 
function: that of alerting us to, and providing motivation to protect ourselves 
from, potential future threats. It is with this background that elevated levels of 
anxiety symptoms, or anxiety disorders as constructs, should be considered. 
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Whether or not a certain level of anxiety becomes pathological (i.e. when the 
anxiety exerts negative effects on an individual’s level of functioning) 
depends not only on the level of anxiety, but also on the context and level of 
threat present, and on the psychological and socio-cultural resources available 
to the particular individual at that time.  
 
To understand and contextualise risk factors that contribute toward a 
“pathological anxiety” state must therefore be seen in this context. In common 
with other psychiatric disorders (e.g. depression, schizophrenia) that are better 
described as syndromes rather than discrete entities (Kendell & Jablensky, 
2003), anxiety symptoms and disorders are likely to develop as a consequence 
of multiple interconnecting factors, that if present at the right time in a 
vulnerable individual, lead to “disorder” expression. The pathways and 
combinations of inter-connecting factors likely differ for each individual, and 
reflect their own individual vulnerability. Therefore, in the search to identify 
these related factors, we must accept that the effect of any individual risk 
factor in isolation is likely to be small and complex. In population-based 
research studies, this may represent a small but potentially verifiable increase 
in self-reported anxiety symptom levels in those exposed. Whether or not a 
person who is exposed to an individual risk factor will be aware of and report 
its effect, however, depends not only on the magnitude of increase in anxiety 
severity but also on the myriad of other protective and/or risk factors present 
for that person. A short list of factors that are associated with increased levels 
of anxiety symptoms and disorders include genetics (Hovatta & Barlow, 
2008), certain personality styles (Brandes & Bienvenu, 2006), negative early 
life experiences (e.g. abuse, inconsistent or invalidating parenting, poor 
attachment) (Newman et al., 2013) and multiple environmental and lifestyle 
risk factors including exercise (Moylan et al., 2013a), diet (Jacka et al., 
2013a; 2013b; Sarris et al., 2012), alcohol (Cosci et al., 2007; Kushner, 
Abrams, & Borchardt, 2000) and other drug use (Cheung et al., 2010; Kedzior 
& Laeber, 2014). In addition, increased anxiety is highly comorbid with 
multiple medical illnesses including cardiac disease, migraines, 
gastrointestinal problems, chronic pain, respiratory disease and cancer (Härter, 
Conway, & Merikangas, 2003; Roy-Byrne et al., 2008).  Therefore, it will 
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remain an ongoing challenge to identify the role of any single risk factor on an 
individual experiencing a complex outcome such as pathological anxiety. 
 
However, identification of a risk factor can result in two potentially important 
outcomes. First, an identified and known risk factor can predict an effect over 
populations of exposure, which can then inform the need for population-based 
primary and secondary prevention approaches (Jacka, Mykletun, & Berk, 
2012).  Although the deleterious effects of smoking on physical health has 
already provided substantial motivation for population-based and targeted 
prevention efforts (Bala, Strzeszynski, & Cahill, 2008; Haustein, 2003), 
cigarette smoking remains common in the community, and in some settings 
(e.g. developing and middle income countries) individuals are commencing 
smoking earlier and smoking more frequently (Giovino et al., 2012). Second, 
and perhaps more importantly, identification of a risk factor can help elucidate 
the underlying pathogenesis of the disorder itself. In the area addressed in this 
research study, the confirmation of cigarette smoking as a true risk factor for 
the development of increased anxiety symptoms and disorders could provide a 
significant basis for a greater understanding of the pathological processes 
underpinning anxiety pathogenesis. For example, the knowledge gained from 
investigation of how cigarette smoke exposure interacts with developing 
neurocircuitry may provide important insights into how these processes 
become disrupted. Such work could provide leads, not only into a greater 
understanding of how the pathology within these brain processes may lead to 
increased anxiety states, but also into the development of novel therapeutics. 
  
Establishing causal relationships 
Sir Austin Bradford Hill famously articulated nine factors (Strength, 
Consistency, Specificity, Temporality, Biological Gradient, Plausibility, 
Coherence, Experiment and Analogy) (Hill, 1965) that should be considered 
when interpreting whether a causal relationship may exist in observed 
associations.  As outlined in the Introduction and Literature Review (Chapters 
1 & 2), a relationship between cigarette smoking and anxiety symptoms and 
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anxiety disorders could be underpinned by three non-mutually exclusive 
relationships: smoking increasing anxiety, anxiety increasing smoking, or 
shared factors increasing both. This research study, through the five individual 
studies undertaken, addresses many of the factors articulated by Hill (1965) in 
seeking to understand whether cigarette smoking is a plausible causal risk 
factor for the development of increased anxiety symptoms and disorders.  
 
Consistency 
Consistency suggests that a causal relationship is more likely if the association 
is observed consistently over multiple different investigations in different 
populations. The present research study informed Consistency through the 
systematic review and de novo epidemiological investigations. The systematic 
review of extant literature (Moylan et al., 2012) demonstrated that the most 
consistent direction of causation displayed in the literature was from prior 
cigarette smoking to subsequently increased anxiety disorders, particularly in 
adolescents. This was consistent with our de novo investigations, which 
demonstrated effects of prior adolescent cigarette smoking (Moylan et al., 
2013b) and early life exposures (Moylan et al., 2015) leading to subsequently 
higher anxiety levels measured at later time points. 
 
Temporality 
Temporality suggests that for an exposure to be causal in producing an 
outcome, the exposure must occur prior to the change in outcome. The present 
research study established temporality through the use of prospective 
observational studies, which were able to determine that onset of smoking 
occurred prior to anxiety changes. In addition, review of the extant literature 
most consistently supports a cigarette smoking  anxiety symptoms and 
disorders pathway, as opposed to the reverse association (anxiety  cigarette 
smoking) (Moylan et al., 2012). It should be noted however, that it is possible 
the association between cigarette smoking and anxiety symptoms and 
disorders is bidirectional and/or a function of shared vulnerability factors. 
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A Biological Gradient 
Biological gradient suggests that greater magnitude of an exposure should 
lead to a greater magnitude of change in an outcome. The present research 
study was only afforded the opportunity to investigate a biological gradient 
within the investigation of maternal smoking during pregnancy (Moylan et al., 
2015) due to issues with statistical power and available data. However, in this 
study we demonstrated that higher rates of cigarette smoking during 
pregnancy were associated with higher rates of childhood anxiety and 
depressive symptoms in early childhood (Moylan et al., 2015). This finding is 
consistent with a ‘dose-dependent’ effect (biological gradient). 
 
Plausibility 
Hill (1965) suggested that having a plausible mechanism to connect an 
exposure to an outcome is helpful in establishing causality. Through this 
research study numerous pathways (detailed in Chapter 6: Paper 2) through 
which cigarette smoking could increase anxiety were articulated (Moylan et 
al., 2013c). This work established a basis for Plausibility. 
 
Coherence 
Coherence refers to consistency between laboratory and epidemiological 
findings. Through the combined strategy of articulating biological 
mechanisms and de novo epidemiological investigations, this research study 
articulated multiple areas of coherence in regards to the association between 
cigarette smoking and anxiety symptoms and disorders. A particular example 
is the coherence in the laboratory and epidemiological literature surrounding 
the key issue of vulnerability in regards to the timing of exposure (i.e. during 
periods of neurodevelopment). 
 
Therefore, this research study provides substantial support for many factors 
that are considered to underpin a potentially causal relationship. However, it 
should be noted that this research study was not able to establish some of 
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Hill’s other factors (Hill, 1965). For example, in regards to Strength of 
association, the effects found in the research study were not generally large. 
Although this may be considered a limitation, as previously discussed, it is 
unlikely that any individual risk factor such as cigarette smoking will exert 
large effects on a complex outcome such as anxiety. Hill himself suggested 
that, despite the information a large strength of association may convey, “We 
must not be too ready to dismiss a cause-and-effect hypothesis merely on the 
grounds that the observed association appears to be slight” (Hill, 1965). 
Similarly with Specificity, given that cigarette smoking exists within a milieu 
of other environmental factors, interacting with complex individual 
characteristics, it is not reasonable to suggest the conditions would be present 
to meet this factor. However, Hill once again cautions against the importance 
of not over-emphasising this characteristic (Hill, 1965), stating “multi-
causation is generally more likely than single causation” (Hill, 1965). Finally, 
for obvious reasons related to the known deleterious health effects of cigarette 
smoking, it is simply unethical to explore the present association through 
Experiment. 
 
Taking all of the above into account, this research study has provided 
considerable new information to the field and suggests the plausibility of 
cigarette smoking as a modifiable risk factor for development of increased 
anxiety symptoms and disorders. The results however do need to be 
considered in the context of the study limitations. 
 
LIMITATIONS 
Limitations of the individual study designs have been discussed within the 
relevant chapters. However, it is important to consider a series of limitations 
that exist across the whole study. 
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Confounding 
A major difficulty in the interpretation of observational studies is the potential 
for effects from residual and unmeasured confounding (Fewell, Davey Smith, 
& Sterne, 2007).  A series of factors are known to be associated with cigarette 
smoking behaviours and anxiety symptoms and disorders. If these factors are 
present in certain combinations, they could bias observed associations. Some 
of these factors, including age and socioeconomic status, are consistently 
controlled for throughout our statistical analyses. However, other factors 
could not be considered as consistently. An example is physical activity 
levels. 
 
Numerous studies have demonstrated an inverse association between smoking 
behaviour and physical activity levels (Conway & Cronan, 1992; Nagaya et 
al., 2007; Winnail et al., 1995). In addition, multiple studies have 
demonstrated the positive effects of physical activity on anxiety symptoms 
(Jonsdottir et al., 2010; Strohle et al., 2007; Wedekind et al., 2010). Although 
this study controlled for a measure of physical activity in the exploration of 
the association between cigarette smoking and anxiety symptoms and 
disorders in adult women, it was not possible to do the same in our 
exploration of gestational (Moylan et al., 2015) and child and adolescent 
relationships (Moylan et al., 2013b). In addition, most studies included in the 
systematic review (Moylan et al., 2012) did not control for physical activity 
levels. Given that exercise is related to both cigarette smoking levels and 
anxiety symptom and disorder expression, its non-inclusion in some 
investigations serves an example of how bias may have been introduced into 
the observed associations through inadequate consideration of potential 
confounding. 
 
However, the issues with confounding are more complicated that simple 
inclusion or exclusion of these variables in analytic models. For example, in a 
recent review of the literature led by this author, our research team 
demonstrated that physical activity may at least in part exert anxiolytic effects 
through modulating levels of O&NS (Moylan et al., 2013a). Therefore, the 
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level of improvement in anxiety symptoms secondary to a change in physical 
activity level may in part depend on factors within the individual that also 
influence control of O&NS. For instance, if the individual in question has a 
poor diet and smokes cigarettes (both factors associated with higher levels of 
O&NS (Moylan et al., 2014)) then the potential effect of an exercise 
intervention on anxiety levels may be reduced. This interaction between 
different confounding variables complicates interpretation of observed 
associations. 
 
Further, another interesting outcome from our research exploring the 
interaction between physical activity levels and anxiety symptoms was the 
observation that different forms of physical activity (e.g. resistance versus 
aerobic training) may be associated with different magnitudes of effect on 
anxiety symptom levels (Herring et al., 2012).  Therefore, how a confounding 
variable is classified is also important. For example, if physical activity is 
categorised, as it was in our investigation of adult women, there is likely to be 
variability within these categories that may introduce bias to the observed 
associations.   
 
Confounding by genetics 
A further possible contribution to residual and unmeasured confounding that 
occurred across all of our studies is the potential effects of genetics. 
Psychiatric genetics and the effects of epigenetics is a rapidly evolving field 
that has the potential to provide great insights into psychiatric disorder 
pathogenesis (Diwadkar et al., 2014; Kendler, 2013). As identified in the 
Introduction & Literature Review, genetically informed studies have already 
been utilised to identify factors that may link exposures like cigarette smoking 
and anxiety symptoms and anxiety disorders. For example, a genome-wide 
linkage study has identified certain chromosomal loci that correlate with both 
increased anxiety disorder states and cigarette smoking (Gelernter et al., 
2004). Similarly, a recent investigation demonstrated that certain 
polymorphisms of two glutathione-S-transferase enzymes (GSTM1 and 
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GSTT1 genes) were associated with anxious smokers (Odebrecht Vargas 
Nunes et al., 2014).  It is therefore possible that results drawn from the 
investigations of observational studies may be at least in part influenced by 
factors related to genetics that were not included in the analytic models. This 
possibility has been extensively discussed in Chapter 10: Paper 5 (Moylan et 
al., 2015) 
Measurement error  
A further limitation of our overall research study was the measurement of our 
exposure, cigarette smoking. Given the population health burden attributable 
to cigarette smoking, accuracy in smoking measurement is imperative. 
Multiple studies have explored the association between self-reported levels of 
cigarette smoking and biological markers of nicotine exposure (e.g. cotinine) 
(Caraballo, Giovino, & Pechacek, 2004; Caraballo et al., 2001; Wagenknecht  
et al., 1992). A review of this literature supported trends toward 
underreporting when estimates are reliant on self-report (Gorber et al., 2009). 
The findings suggest that, although in most adult populations there appears to 
be reasonable consistency between self-reported levels of cigarette smoking 
and biomarkers of cigarette smoke exposure, there are certain groups, such as 
adolescents, who display higher rates of misclassification. This 
misclassification includes both over and under reporting, and may result from 
factors such as social stigma or concerns about the consequences of providing 
accurate levels of consumption (e.g. worry about their parents being 
informed) (Caraballo Giovino, & Pechacek, 2004; Wagenknecht et al., 1992).  
In addition, and highly relevant to our study, underreporting of smoking 
during pregnancy is common (Boyd et al., 1998).  
 
The reliance on self-reported cigarette smoking levels therefore may lead to 
biased associations being observed. However, given that the trends in studies 
comparing self-report to biological markers of cigarette smoking suggest if 
anything a bias toward underreporting, this misclassification would bias 
against an association between smoking and increased levels of anxiety 
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symptoms. Therefore, as a result of this effect the observed associations 
across our studies may actually be conservative estimates. 
 
Publication Bias & limitations of the extant literature 
A further difficulty that effects the conclusions drawn across the entire study 
is that of publication bias.  Investigations of publication bias have 
demonstrated the tendency for studies with significant outcomes, particularly 
laboratory or epidemiological investigations, to have a higher likelihood of 
being published than studies without significant outcomes (Dwan et al., 2013; 
Easterbrook et al., 1991). There is no doubt that these factors would have 
influenced the literature available for both the systematic review (Moylan et 
al., 2012) of observational studies and the review of biological literature 
(Moylan et al., 2013c), and should be considered in the interpretation of the 
available results. 
 
This limitation connects with another difficulty encountered within this 
research study: that of a simple lack of biological literature available that 
details the effects of cigarette smoke on pathways that underpin anxiety 
symptoms and disorders. The available literature, as discussed in Chapter 6: 
Paper 2 (Moylan et al., 2013c), is heterogeneous and limited in certain areas. 
There is a distinct lack of studies that have triangulated the effects of 
smoking, biological pathways, and behavioural outcomes consistent with 
anxiety. There is a significant need for this to be addressed in the future. 
Further investigations of these pathways, ideally with studies involving multi-
modal designs (see “Directions for future research”), are needed. Such work 
would provide great advances to the field. 
DIRECTIONS FOR FUTURE RESEARCH 
In light of these limitations and those discussed within the individual study 
chapters, a number of questions that can be addressed in future research have 
been identified. 
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First, the research literature would benefit from further investigation of the 
association between cigarette smoke exposure and development of anxiety 
symptoms and disorders utilising genetically-informed epidemiological study 
designs, particularly examining exposures during periods of rapid 
neurodevelopment.  There is a need for greater clarity regarding early life 
exposures, especially second hand smoke exposure in early childhood, on the 
longitudinal development of anxiety symptoms. Some studies have suggested 
that these exposures may be deleterious to mental health trajectories (Bandiera 
et al., 2011), however, these need replication in different settings. Further 
exploration of these effects using genetically informed study designs would be 
of great benefit to the field. Studies could in addition utilise modern 
technology (e.g. mobile apps) to capture the onset, use and emotional and 
behavioural aspects of anxiety and smoking behaviours, and their 
interrelationship, with greater accuracy. Such information would be of 
substantial benefit in improving the understanding of this interrelationship, 
particularly during childhood and adolescence. 
 
Second, further exploration of this relationship using newer techniques that 
utilise genetic variants as explanatory variables for certain exposures will be 
of assistance. For example, a recent investigation performed in the very large 
HUNT survey utilised a Mendelian randomization technique to investigate the 
causal relationship between cigarette smoking and anxiety and depression in 
Norway. By assessing the associations between the rs1051730 single 
nucleotide polymorphism, a genetic variant found to be related to smoking 
behaviour, and anxiety and depression symptoms, they concluded that 
smoking was not causal in anxiety and depression development (Bjorngaard et 
al., 2013; Gage et al., 2013). As this area utilising genetic predictors is an 
evolving field, it is important that further evaluation of this work is 
undertaken before definitive conclusions are reached. Integration of these 
techniques, particularly in areas where samples incorporate other facets of 
smoking behaviour and exposures and in cohorts of adolescents where early 
adult anxiety measures can be utilised, will likely afford highly valuable new 
information. 
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Third, the field will benefit greatly from continuation of the already 
established large cohort studies set up to follow individuals throughout the 
entire developmental period, from gestation through to adulthood. The 
obvious difficulty with such an endeavour is the substantial cost associated 
with running long-term prospective studies of this nature. Opportunities do 
exist to undertake such work within the ongoing Norwegian Mother and Child 
Cohort Study (MoBa); this is currently planned to continue through multiple 
future rounds of follow up assessments. It is hoped this study will continue to 
provide substantial knowledge to the field of environmental exposures and 
mental health outcomes. 
 
Finally, the field would benefit greatly from multi-modal studies that 
investigate the impact of cigarette smoke exposure on areas of the central 
nervous system involved in anxiety control at different stages of development. 
Such multi-modal studies have been used with significant success in 
improving the understanding of the role of the immune system in depression 
pathogenesis (Baune et al., 2010). For example, studies could utilise animal 
models to assess the impact of different levels of cigarette smoke exposure on 
psychological/behavioural outcomes during development, whilst 
contemporaneously monitoring serum and immunogenic biomarkers and 
changes in brain structure and function through neuroimaging.  Such studies 
could also control for certain genetic variants, and also consider the 
potentially different roles of nicotine and other cigarette smoke components, 
such as tars, metals and free radicals.  
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2 CHAPTER TWELVE: CONCLUSION 
In summary, this study supports cigarette smoking as a plausible exogenous 
risk factor for the development of increased anxiety symptoms and anxiety 
disorders. The findings support a model where components of cigarette 
smoke, including nicotine, interact with the development and function of 
neurobiological pathways that are important in the regulation of anxiety.  The 
timing of exposure to smoking appears important, with exposure during 
periods of rapid neurodevelopment such as the gestational period, childhood 
and adolescence, displaying the most consistent associations with increased 
anxiety levels later in life.  In addition, the findings suggest those with a prior 
vulnerability to anxiety, when compared to those without anxiety 
vulnerability, appear to demonstrate larger deviations in anxiety symptoms 
when exposed to early life cigarette smoking.   
 
This research study lays a foundation that can be utilised for substantial new 
investigation into this field. Such future investigations have the potential to 
inform and support the continued public health efforts aimed at reducing 
cigarette smoking, particularly in younger people. In addition, this foundation 
could serve as a basis for the scientific community to develop a greater 
understanding of the pathogenic processes that help transform anxiety from 
physiological to pathophysiological. Such efforts will provide insights that 
inform both the prevention and treatment of pathological anxiety symptoms 
and disorders.  
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